Epigenetic and pharmacological regulation of gene exprssion involved in senescence and tumor progression by Lodygin, Dmitri
Dissertation der Fakultät für Biologie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
Epigenetic and pharmacological  
regulation of gene expression  
involved in senescence and tumor progression 
 
 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
 
 
Dmitri Lodygin 
 
aus 
Arkhangelsk 
 
 
 
 
 
 
 
Dissertation eingereicht am:  11.05.2005 
 
 
 
 
 
Erklärung 
Hiermit erkläre ich, dass ich die vorliegende Dissertation selbständig und ohne 
unerlaubte Hilfe angefertigt habe. Sämtliche Experimente sind von mir selbst 
durchgeführt, außer wenn explizit auf dritte verwiesen wird. Ich habe weder 
anderweitig versucht, eine Dissertation oder Teile einer Dissertation einzureichen 
bzw. einer Prüfungskommission vorzulegen, noch eine Doktorprüfung durchzuführen. 
 
München, den 6. Mai 2005 
Dmitri Lodygin 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung:  24.10.2005 
 
Erstgutachter: Prof. Dr. Dirk Eick   
Zweitgutachter: Prof. Dr. Thomas Cremer 
 
Betreuer: Dr. Heiko Hermeking 
 1
CONTENTS 
1. Introduction  4
1.1 Cellular senescence as a tumor suppressor mechanism 4
1.2 14-3-3σ in tumor suppression  9
1.3 Epigenetics and cancer 12
1.4 Prostate cancer 16
 
2. Aim of the study 20
 
3. Materials  21
3.1 Chemicals 21
3.2 Enzymes and commercial kits 21
3.3 Antibodies 22
3.3.1 Primary antibodies 22
3.3.1 Secondary antibodies 23
3.4 DNA constructs 23
3.5 Other materials 23
3.6 Equipment 24
 
4. Methods  25
4.1 Cell culture and treatments  25
4.2 Patient material  25
4.3 Laser-assisted tissue microdissection  26
4.4 RT-PCR analysis  26
4.5 Bisulfite treatment of genomic DNA  26
4.6 Genomic bisulfite sequencing  27
4.7 Methylation-specific PCR  27
4.8 cDNA microarray analysis of gene expression 27
4.9 Oligonucleotide microarray analysis of gene expression 28
4.10 Quantitative real-time PCR  28
4.11 Proliferation assays 29
4.12 BrdU incorporation assay 29
4.13 Measurement of DNA content and apoptosis by flow cytometry  29
 2
4.14 Senescence-associated ß-galactosidase staining 30
4.15 cGMP assay 30
4.16 Northern blot hybridization 30
4.17 Luciferase assay  30
4.18 Western blot analysis  31
4.19 Immunofluorescent staining  31
4.20 Immunohistochemistry 32
4.21 Microscopy 32
4.22 Generation and analysis of knock–down and transgenic cell lines 33
 
5. Results  34
5.1 Expression profiling of replicative and premature senescence 34
5.1.1 Microarray analysis of senescence-specific gene expression  34
5.1.2 Induction of senescence by LY83583 36
5.1.3 Microarray analysis of LY83583-regulated genes 38
5.1.4 Rapid induction of p21  by LY83583 WAF1/CIP1/SDI 39
5.1.5 Effect of LY83583 on cancer cell proliferation 42
 5.1.6 Requirement of p21, but not p53, for inhibition of proliferation by 
LY83583  43
 5.1.7 Conversion of LY83583-induced arrest to apoptosis in pRb-negative 
cells 45
5.2 Analysis of 14-3-3σ expression in hyperproliferative skin diseases  48
5.2.1 Immunohistochemical analysis of hyperproliferative skin diseases  48
5.2.2 Analysis of 14-3-3σ  CpG methylation in BCC and normal epidermis 50
5.3 Identification of genes epigenetically silenced in prostate cancer by 
pharmacological unmasking 55
5.3.1 Epigenetic analysis of PCa cell lines 55
5.3.2 The methylation pattern of candidate promoters 59
5.3.3 Validation of candidate genes for epigenetic silencing 61
5.3.4 Analysis of DNA methylation in primary PCa samples 64
5.3.5 Analysis of 14-3-3σ and SFRP1 protein expression in PCa 69
5.3.6 Functional analysis of 14-3-3σ  71
5.3.7 Functional analysis of DKK3 and SFRP1 73
 3
 
6. Discussion  75
6.1 Induction of cellular senescence by LY83583 75
6.2 Epigenetic inactivation of 14-3-3σ in basal cell carcinoma 77
6.3 Functional epigenomic analysis of prostate carcinoma cell lines 79
6.4 Frequent epigenetic silencing of 14-3-3σ in prostate cancer 80
6.5 CpG methylation and down-regulation of SFRP1 and DKK3 in prostate 
cancer 82
6.6 Hypermethylation of p57, COX2, GSTM1 and GPX3 genes in prostate 
cancer 83
 
7. Summary 87
 
8. References  89
 
9. Abbreviations  109
 
10. Supplement 110
Supplemental Table 1 110
Supplemental Table 2 113
Supplemental Table 3 114
 
Acknowledgement 115
 
Curriculum Vitae 117
 
 4
1. Introduction 
1.1 Cellular senescence as a tumor-suppressor mechanism 
Development of a multicellular organism and tissue regeneration require an 
enormous proliferative potential of a single cell. For example, this property is 
essential to form human body consisting of about 1014 cells from one-cell embryo and 
to compensate for the daily physiological loss of millions of cells in adult organism. 
However, uncontrolled proliferation may result in a number of pathological states 
including the formation of malignant tumors. One of the biological mechanisms 
restraining proliferation is cellular senescence. This phenomenon was first described 
by Hayflick and Moorhead in 1961 (Hayflick and Moorhead, 1961). Primary cells in 
culture initially undergo a period of proliferation, during which the telomeres of their 
chromosomes become significantly shorter. Shortening of the telomeres arises from 
the inability of DNA polymerase to replicate the unprimed lagging strand at the very 
end of linear DNA molecule. Therefore, in the absence of a compensatory 
mechanism the terminal fragments of chromosomes 50-100 nucleotides in length are 
lost during each cycle of replication. Eventually, cellular proliferation decelerates and 
the cells enter a permanent cell-cycle arrest known as replicative senescence. A 
senescent cell shows morphological changes, such as a flattened cytoplasm and 
increased granularity. At the biochemical level, senescence is accompanied by 
changes in metabolism and the induction of senescence-associated ß-galactosidase 
activity (Dimri et al., 1995). In addition, alterations to chromatin structure (Narita et al., 
2003) and gene expression patterns are seen.  
Initiation of the senescence program activates various cell-cycle inhibitors and 
requires the functions of p53, the CDKN1A gene product WAF1 (Noda et al., 1994; el 
Deiry et al., 1993), the CDKN2A gene product of the INK4A genomic locus (also 
known as p16), and the retinoblastoma protein (Alcorta et al., 1996; Dannenberg et 
al., 2000; Kamijo et al., 1997; Sage et al., 2003; Stein et al., 1999). The involvement 
of these tumor suppressors implies that one of the main functions of the senescence 
program is to suppress tumorigenesis — a hypothesis that has been confirmed in 
animal models. For example, mutant mice carrying cells that are incapable of 
entering senescence develop cancer at an early age (Donehower et al., 1992; Kamijo 
et al., 1999; Krimpenfort et al., 2001; Serrano et al., 1996; Sharpless et al., 2001). 
Conversely, the induction of premature senescence in murine mammary epithelial 
cells suppresses tumor development (Boulanger and Smith, 2001).     
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 Figure 1 Proliferation dynamics of primary human cells explanted in culture  
(a) Cultured primary human fibroblasts proliferate exponentially for 70-90 population doublings (3 
doublings are equivalent to 1 passage) and then enter irreversible growth arrest (M1). This state 
termed replicative senescence features complete insensitivity to mitogenic stimuli, retained basal level 
of metabolic activity and no apoptosis. Ectopic expression of the catalytic subunit of human 
telomerase (hTERT) in presenescent cells is sufficient to evade senescence and immortalize human 
fibroblasts. Fibroblasts transduced by viral oncogenic proteins (for example, SV40 large T antigen) or 
with a homozygous deletion of p21 gene undergo crisis (M2). This is a state distinct from senescence 
in the way that the high rate of apoptosis takes over the ongoing replication. (b) Primary cells of 
epithelial origin (for example, mammary gland epithelium, prostate epithelium or keratinocytes) 
cultured under standard conditions reach the first growth plateau (M0) after a few passages (typically 
6 to 8). The onset of this stage, also called selection, is associated with induction of the CDK inhibitor 
p16. Small fraction of cells, which has lost the p16/pRB check-point is able to surmount the M0 barrier 
and resume active proliferation. The second growth plateau, designated as crisis (M1) is characterized 
by increased genomic instability due to dysfunction of shortened telomeres. An escape from crisis 
requires re-expression of telomerase or activation of alternative mechanism of telomere lengthening 
(ALT). Culturing of primary cells on a feeder layer of irradiated fibroblasts abrogates M0 arrest and 
eliminates the need to inactivate p16 for immortalization of primary human epithelial cells.     
 
Primary human skin fibroblasts represent one of the most extensively studied 
systems for replicative senescence. These cells undergo irreversible growth arrest 
(also designated as mortality stage 1, M1) after 70-90 population doublings in culture 
(Figure 1a). Replicative senescence in this cell type is triggered by erosion of 
telomeres. The ectopic expression of hTERT in presenescent primary human 
fibroblasts allows cells to evade replicative senescence and to become immortal 
without additional genomic alterations. The functional mechanism for the 
immortalization of skin fibroblasts is the maintenance of telomere length, not the 
expression of telomerase. Using a cre-excisable telomerase, it has been shown that 
the transient expression of hTERT for only seven cell divisions resulted in a 50 
division extension of lifespan (Steinert et al., 2000). This increase could be entirely 
 6
explained by elongation of the shortest telomeres by 2.5 kbp and telomere shortening 
of 50 bp per division rate in these fibroblasts.  
p53
p21
CDKs
ARF p16
14-3-3σ
INK4A
locus
Apoptosis
Senescence
(SAHF, SA-β-gal)
DNA damage
response
?
Oncogene
activation
Oxidative
stress
Telomere
disfunction
Ionizing radiation,
genotoxic drugs
MAPK
E2F
?
Suboptimal 
culture
conditions
HDM2
pRB
p107p130
inhibition
activation
? unknown mediator
RAS
Figure 2 Pathways involved in cellular senescence 
A variety of stress conditions posing a threat of oncogenic transformation to the cell can induce 
terminal proliferation arrest with characteristic features of senescence - cellular enlargement and 
flattening, formation of heterochromatin foci (SAHF) and accumulation of acidic ß-galactosidase (SA-
ß-gal). Replication-dependent shortening of telomeres, ionizing radiation, genotoxic chemicals and 
oxidative stress initiate a DNA damage response resulting in the activation of the tumor suppressor 
protein p53 and induction of its transcriptional targets p21 and 14-3-3σ. p21 inhibits CDKs (particularly, 
CDK2-cyclin A and -cyclin E complexes) and promotes hypophosphorylation of the pocket proteins 
pRB, p107 and p130. Overexpression of oncogenes and inadequate culture conditions induce the 
CDK inhibitor p16, which inhibits CDK2 and CDK6 resulting in pRB dependent growth arrest. 
Inappropriate oncogene activation also induces the ARF protein, the alternative product of the INK4A 
locus which results in the accumulation of p53 via inhibition of its HDM2-dependent degradation.      
 
Telomere shortening beyond a certain limit results in the activation of the DNA 
damage response and operates via the p53 – p21 – pRB pathway (Figure 2). The 
pRB protein represents a classical example of a tumor suppressor gene, inactivated 
in variety of familial and sporadic human cancers. The functional activity of pRB 
(retinoblastoma protein) is regulated by phosphorylation by cyclin-dependent kinases. 
Hypophosphorylated pRB binds to and inhibits the E2F family transcription factors, 
which mediate cell cycle progression. Inhibitors of cyclin-dependent kinases (e.g. p21, 
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p16, p27 and p57) prevent phosphorylation of pRB and therefore lead to inhibiton of 
E2F resulting in cell cycle arrest.  
Besides pRB, two other members of the pocket protein family, p107 and p130 
are involved in the control of senescence. Germ line inactivation of pRb alone is not 
sufficient to overcome senescence in cultured mouse embryo fibroblasts (MEFs) 
(Dannenberg et al., 2000). However, simultaneous knock-out of the pRb, p107 and 
p130 genes (Dannenberg et al., 2000; Sage et al., 2000) renders MEFs completely 
insensitive to senescence-inducing signals, demonstrating functional redundancy 
between pocket proteins. Still, the relative impact of pRB on tumor prevention may be 
more significant than that of the other pocket proteins as mutations of p130 and p107 
occur rarely, if ever in human cancer, whereas pRB mutations are common (Classon 
and Harlow, 2002). Consistently, acute ablation of Rb in senescent cells is sufficient 
for reversal of the cellular senescence program (Sage et al., 2003). The role of pRB 
in the control of senescence turned out to be more complex than simply antagonizing 
E2F-driven transition from G1 to S phase of cell cycle. Recently, onset of 
senescence has been shown to correlate with the establishment of a specific form of 
heterochromatin present in discrete nuclear foci, known as senescence-associated 
heterochromatic foci (SAHF), the formation of which is directed in part by 
hypophosphorylated pRB (Narita et al., 2003). These data suggest that senescence 
results from the stable repression of promoters associated with growth control genes.  
Inactivation of cell-cycle check-points by the expression of viral oncoproteins, 
such as SV40 large T antigen or HPV E7, or by targeted disruption of p21 gene in 
primary human fibroblasts abrogates the onset of typical replicative senescence 
(Figure 1a). However, cell growth eventually reaches a plateau designated as crisis 
(mortality stage 2, M2). In contrast to the senescent phenotype, such cells display 
ongoing replication (e.g. high index of BrdU incorporation), but also a high rate of 
apoptosis, presumably initiated due to eroded telomeres in the absence of 
telomerase activity. The fact, that human fibroblasts never become immortal 
spontaneously, underlines a very tight control of proliferation by the telomere-length 
check-point.  
Several features of senescence in primary epithelial cells differ from those in 
primary fibroblasts. The time period between explanting into culture and cessation of 
proliferation is significantly shorter for primary epithelial cells than for fibroblasts. 
Typically after 6-8 passages primary human epithelial cells reach the growth plateau 
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(stage M0, Figure 1b) which is characterized by a very slow proliferation rate, 
morphological features of senescence (e.g. positive for SA-ß-Gal) and subsequent 
emergence of outgrowing clones capable of surmounting this first barrier (Figure 1b). 
After additional rounds of proliferation these “selected” at M0 stage cells undergo the 
next growth arrest called crisis, or M1 stage. In the absence of the p53 - and p16 - 
pRB–mediated checkpoints, cultured cells with dysfunctional telomeres continue to 
proliferate, entering a period of slow growth that is characterized by genomic 
instability. Clones emerging from crisis invariably reactivate telomerase or establish 
the alternative lengthening of telomeres (ALT) mechanism (reviewed in Sharpless 
and DePinho, 2004). During crisis, the unprotected telomere ends in proliferating 
cells can be illegitimately fused through DNA repair mechanisms, ultimately leading 
to the generation of complex non-reciprocal translocations, a hallmark feature of 
adult solid tumors.  
The onset of the M0 stage is dependent on p16 induction and 
hypophosphorylation of pRB and precedes the shortening of telomeres beyond a 
critical limit required for the activation of the DNA damage pathway. Immortalization 
of primary epithelial cells requires both hTERT expression and p16 inactivation. 
However, the culturing of primary human epithelial cells on a feeder layer of 
mesenchymal cells prolongs the life span in culture significantly and abrogates the 
need to inactivate p16 for immortalization (Ramirez et al., 2001). This indicates that 
inadequate culture conditions may trigger the p16-dependent growth arrest ex vivo 
(Figure 2). Whereas the in vivo relevance of a “culture-shock”-induced and p16-
mediated arrest has not explicitly been shown yet, the important role of p16 in tumor 
suppression is clearly demonstrated by its frequent inactivation in several human 
cancers, especially characteristic for malignant melanoma (Sharpless and Chin, 
2003). Moreover, gradual accumulation of p16 in aging tissue was shown to be the 
most consistent marker of cellular senescence in vivo (Krishnamurthy et al., 2004).   
          Several stress conditions evoke a terminal proliferation arrest before telomeres 
become short enough to elicit the DNA damage signal (Figure 2). This state shares 
many features with replicative senescence and is refered to as premature 
senescence (reviewed in Serrano and Blasco, 2001). For example, DNA damage 
response induced by ionizing radiation or oxidative stress results in accumulation of 
p53 and growth arrest. Another trigger of premature senescence is an activation of 
oncogenes, such as Ras or E2F. Although this pathway is particularly relevant to the 
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prevention of malignant transformation, the understanding of its molecular 
mechanisms remains incomplete. In mouse cells senescence induced by Ras 
requires primarily the function of the Arf protein, which is the alternative product of 
the INK4a genomic locus. Induction of the Arf leads to the inhibition of Mdm2 and 
thereby accumulation of p53 (reviewed in Voorhoeve and Agami, 2004). In human 
cells initiation of growth arrest after overexpression of an oncogene (e.g. 
constitutively active RAS mutant) is characterized by a more prominent role of 
p16INK4a than ARF (Voorhoeve and Agami, 2003). 
Expression profiling of senescent cells revealed the existence of a specific 
transcriptional program (Ly et al., 2000; Shelton et al., 1999; Zhang et al., 2003). An 
important issue is whether the senescence program can be activated in tumor cells, 
which already underwent malignant transformation, and therefore might be exploited 
for therapeutic purposes. Despite the fact that many key regulators such as p53 or 
p16 are often inactivated in cancer cells, under some circumstances the senescence-
like growth arrest can be induced in tumor cells (reviewed in Kahlem et al., 2004). 
Moreover, tumor cell senescence is detectable following DNA-damaging treatment in 
vivo and significantly increases overall survival of the host (Schmitt et al., 2002; te 
Poele et al., 2002). Further characterization of the senescence-associated 
transcriptional program may help to identify novel mediators of this important 
biological phenomenon and potential targets for therapeutic intervention.   
 
 
1.2 14-3-3σ in cancer suppression  
The tumor suppressor protein p53 is a nodal point in the network of DNA 
damage induced signaling pathways. The p53 mediates inhibition of cell proliferation, 
presumably to allow time for repair or to permanently arrest damaged cells 
(Vogelstein et al., 2000). The net effect of p53 activation, which is typically 
proliferation arrest or apoptosis, is determined by the subset of transcriptional targets 
activated in a certain cell type and signaling context. Together with p21WAF1, 14-3-3σ 
belongs to a subset of p53 targets which mediate cell-cycle arrest, whereas other 
p53 target genes mediate programmed cell death (Figure 2).   
14-3-3σ, or stratifin (SFN), belongs to the 14-3-3 family comprising six other 
members in mammals (designated β, ε, γ, η, τ, ζ), characterized by high degree of 
homology (reviewed in Yaffe, 2002). 14-3-3 proteins form homo- and heterodimers 
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and bind to protein ligands that have been phosphorylated on serine/threonine 
residues in a consensus binding motif. The binding can regulate other proteins by 
cytoplasmic sequestration, masking of interaction domains and export or import 
sequences, prevention of degradation, modulation of enzymatic activity and 
transactivation, and facilitation of protein modifications (reviewed in Hermeking, 
2003). Recently the crystal structure of 14-3-3σ bound to an optimal phosphopeptide 
ligand was solved, providing an explanation for specific properties of the sigma 
isotype with regard to other 14-3-3 proteins (Wilker et al., 2005). In contrast to other 
14-3-3 isoforms, the σ protein preferentially forms homodimers and its ligand 
specificity is determined by a second binding site unique for 14-3-3σ, rather than by 
the phosphopeptide binding cleft conserved in all 14-3-3 family members (Wilker et 
al., 2005). Putative determinants of ligand binding and dimerization specificity were 
revealed by comparison of the crystal structure of 14-3-3σ to the structure of the τ 
and ζ isoforms (Benzinger et al., 2005). 
14-3-3σ is the only isoform of 14-3-3 proteins, which is induced after DNA 
damage (Figure 3). Induction of 14-3-3σ mRNA by DNA damage was identified in a 
SAGE (serial analysis of gene expression) based screen for genes induced after γ-
irradiation in colorectal cancer cells expressing wild type p53 (Hermeking et al., 
1997). In this study p53 was found to directly activate the transcription of 14-3-3σ via 
p53-responsive element in the promoter of the gene. ∆Np63α, an isoform of the p53 
homolog p63, which lacks a transactivation domain, was shown to bind to the p53-
responsive element in the 14-3-3σ promoter, but, in contrast to p53, represses 
transcription of 14-3-3σ (Westfall et al., 2003). BRCA1 was shown to affect G2/M 
progression by inducing expression of 14-3-3σ (Aprelikova et al., 2001).  
The ectopic expression of 14-3-3σ in colorectal cancer cells and primary 
prostate epithelial cells leads to the initiation of a G2 arrest (Hermeking et al., 1997). 
A similar effect was observed in breast carcinoma cell line (Ferguson et al., 2000). 
The negative effect of induced 14-3-3σ expression on cell-cycle progression is 
mediated by its binding to CDC2/cyclin B1. Cytoplasmic 14-3-3σ prevents nuclear 
localization of the CDC2/cyclin B complex, which is required for progression through 
mitosis (Chan et al., 1999). Disruption of the 14-3-3σ gene by homologous 
recombination in colon cancer cells results in impaired G2/M checkpoint after DNA 
damage: γ-irradiated 14-3-3σ-knockout cells are unable to maintain a G2 arrest and 
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eventually undergo mitotic catastrophe (Chan et al., 1999; Chan et al., 2000). 
Moreover, 14-3-3σ-deficient cells show increased genomic instability, characterized 
by loss of telomeric repeat sequences, chromosome end-to-end fusions and 
nonreciprocal translocations (Dhar et al., 2000). Altogether these facts strongly argue 
for an important role of 14-3-3σ  in the maintenance of genomic integrity.  
  
14-3-3σ
BRCA1
p63
p53
DNA 
damage
CpG methylation
CDC2
cyclin
B mitosis
BAD
EFP
Ub
EFP
14-3-3σ
X
ppp p
CDC2
cyclin
B 
Ub
UbUb
Figure 3 Regulation and function of 14-3-3σ 
After DNA damage p53 binds to the promoter and induces transcription of the 14-3-3σ gene. BRCA1 
acts as a co-activator in the induction of 14-3-3σ transcription by p53. In the cytoplasm 14-3-3σ forms 
homodimers and binds to a variety of ligands phosphorylated at the serine/threonine residues in a 
consensus binding motif (p). The nuclear translocation of cyclin B/CDC2 complexes required for the 
initiation of mitosis is inhibited by 14-3-3σ binding. The BH3-domain protein BAD phosphorylated by 
AKT associates with 14-3-3σ and loses its ability to antagonize the function of the anti-apoptotic BCL2-
like proteins. A dominant negative form of p63 (e.g ∆Np63α) represses 14-3-3σ expression. CpG 
methylation contributes to epigenetic silencing of 14-3-3σ in neoplasia and, presumably, in normal 
cells of mesenchymal origin. A RING-finger-dependent E3 ubiquitin (Ub) ligase (EFP) targets 14-3-3σ 
for protesomal degradation.  X = unknown binding partner. 
 
A hallmark of tumor suppressive factors is their frequent inactivation in primary 
cancer cells. SAGE analysis revealed down-regulation of sigma in breast cancer cells 
(Nacht et al., 1999). A subsequent search for mutations in the 14-3-3σ locus did not 
reveal any genetic alterations which could explain its down-regulation. Instead the 
epigenetic silencing by CpG methylation turned out to be responsible for the loss or 
reduction of 14-3-3σ expression in more than 90 % of primary breast cancers 
(Ferguson et al., 2000).  Hypermethylation of the 14-3-3σ locus occurs rather early, 
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as it was detected in 38% of atypical hyperplasia (Umbricht et al., 2001). Moreover, 
hypermethylation of 14-3-3σ was detected in adjacent histologically normal breast 
epithelium, while this was never observed in individuals without evidence of breast 
cancer. The treatment of breast cancer cells with an inhibitor of DNA 
methyltransferases, 5-aza-2’-deoxycytidine (5Aza-2’dC), results in induction of the 
14-3-3σ mRNA indicating a causative role of hypermethylation in the loss of 14-3-3σ 
expression (Ferguson et al., 2000). Consistent with a function of 14-3-3σ  in 
preventing the acquisition of chromosomal abnormalities as revealed by somatic 
knock-out in colon cancer cell line, breast cancer cells with hypermethylation of 14-3-
3σ display increased genomic instability (Ferguson et al., 2000). 
Among epithelial tissues, the epidermis is characterized by the highest level of 
14-3-3σ expression. Differentiation and exit from the stem cell compartment in 
keratinocytes is accompanied by an increase of 14-3-3σ expression (Pellegrini et al., 
2001). Experimental inactivation of 14-3-3σ in primary human keratinocytes by an 
anti-sense approach was shown to be sufficient for their immortalization, suggesting 
that 14-3-3σ is involved in control of the cellular senescence (Dellambra et al., 2000). 
Taken together these data indicate that 14-3-3σ may function to restrain aberrant 
proliferation in the epidermis. However, 14-3-3σ expression in skin tumors and non-
neoplastic skin diseases has not yet been analyzed systematically.  
 
 
1.3 Epigenetics and cancer 
In the process of neoplastic transformation changes in the function of critical 
genes which allow cells to overgrow their neighboring cells are selected for. The 
altered genes which are causally involved in carcinogenesis can be broadly divided 
in two major classes: oncogenes and tumor-suppressor genes. Whereas oncogenes 
gain an increased function via activating point mutations or gene amplification, tumor 
suppressor genes lose their function in cancer cells. Tumor suppressor genes may 
be subdivided into caretakers and gatekeepers (Kinzler and Vogelstein, 1997). 
Caretaker genes encode proteins which function in the preservation of genomic 
integrity, whereas gatekeepers keep cells in a defined state of differentiation.   
The inactivation of tumor suppressor genes is mediated by two mechanisms: 
genetic inactivation by DNA mutations and epigenetic silencing. In some cases 
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genetic and epigenetic events complement each other. In general bi-allelic gene 
inactivation resulting in complete loss of function is characteristic for tumor 
suppressor genes.  
The term epigenetic refers to information which is transmitted from the 
parental genome to the next generation of cells and is not encoded by the primary 
DNA sequence. Epigenetic mechanisms are essential for the regulation of gene 
expression and genome integrity in normal cells (Bird, 2002; Jaenisch and Bird, 2003; 
Li, 2002). The maintenance of epigenetic information is mediated by polycomb group 
proteins and cytosine methylation within CpG-dinucleotides, also referred to as DNA 
methylation. 
 Patterns of DNA methylation and chromatin structure are profoundly altered in 
neoplasia and include genome-wide losses of and regional gains in DNA methylation. 
Global hypomethylation compromises stability of the genome and in turn may 
promote secondary genetic alterations (Eden et al., 2003; Gaudet et al., 2003), 
whereas the local hypermethylation of promoter regions is associated with 
transcriptional silencing and possible loss of tumor suppressor gene expression.  
Epigenetic inactivation of tumor suppressor genes contributes significantly to 
tumor development (Feinberg and Tycko, 2004; Jones and Baylin, 2002). The genes 
aberrantly methylated in human cancer fall into several functional categories 
intimately involved in cellular processes relevant to carcinogenesis such as DNA 
repair (MGMT, MLH1, BRCA1), cell cycle control (CDK inhibitors - p15, p16, p27), 
apoptosis (APAF1, CASP8), invasion (CDH1, TIMP3), angiogenesis (THBS1, VHL) 
and others. Nearly 50% of the genes that cause familial forms of cancer when 
mutated in the germ line are known to undergo methylation-associated silencing in 
various sporadic forms of cancer (Jones and Baylin, 2002). Although some 
methylation changes seem to be common to many kinds of cancer, tissue-specific 
differences exist. For example, the p15INK4B promoter is frequently methylated in 
lymphoid, but not in solid cancers (Herman et al., 1997), and glutathione S-
transferase π 1 (GSTP1) is methylated in prostate, breast and hepatic cancers, but 
rarely in others (Lin et al., 2001). 
The molecular mechanisms of epigenetic silencing during tumor formation are 
only partially understood. In normal cells the pattern of CpG methylation is 
established by two types of methyltransferases catalyzing the addition of a methyl-
group at the C-5 position of cytosine: DNMT1 serves as a maintenance 
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methyltransferase, whereas DNMT3A and DNMT3B mediate de novo DNA 
methylation. All three DNMTs are modestly over-expressed at the mRNA and/or 
protein level in many types of tumor cells (De Marzo et al., 1999b; Robertson et al., 
2000). Ectopic expression of DNMT1 cooperates with oncogenes in the 
transformation of primary cells supporting the idea that aberrant expression of DNA 
methyl-transferases may contribute to abnormal promoter methylation in cancer cells 
(Bakin and Curran, 1999). 
Factors directing the activity of DNMTs to specific genomic sites under normal 
and pathological conditions remain largely unknown. Covalent modifications of core 
histones may serve as plausible marks for the establishment of DNA methylation. 
The methylation of histone H3 lysine 9 was shown to be a prerequisite for DNA 
methylation in Neurospora crassa and Arabidopsis thaliana (Jackson et al., 2002; 
Tamaru and Selker, 2001). Although this requirement does not seem to be 
conserved in mammalian cells, the concept that histone methylation provides a signal 
which somehow can be interpreted by DNA methylation machinery is supported by 
experimental data. For example, the histone methyltransferase Suv39H1 directs DNA 
methylation to satellite repeats at pericentric heterochromatin (Lehnertz et al., 2003). 
The p16INK4A gene has been shown to undergo re-activation after reversal of DNA 
methylation after experimental removal of DNMT activity in colorectal cancer cells 
(Bachman et al., 2003). Subsequent re-silencing of p16INK4A occurred after prolonged 
passage of these cells. Methylation of histone H3-K9 was detected in association 
with re-silencing of this tumor suppressor gene in the absence of DNA methylation 
(Bachman et al., 2003). Therefore, the methylation of histones may precede 
methylation of DNA during epigenetic silencing of tumor suppressor genes. In plants 
and some animals double stranded RNAs were implicated in the guidance of de novo 
methylation (Bender, 2001; Matzke et al., 2001). Also, RNAi-mediated transcriptional 
silencing has been associated with promoter methylation in human cells (Kawasaki 
and Taira, 2004; Morris et al., 2004). In addition, transcription factors which interact 
with DNA in a sequence-specific manner may direct CpG methylation to specific 
promoters. In line with this hypothesis, it was recently shown that Myc protein recruits 
DNMT3A methyltransferase to the p21WAF1 promoter and represses its expression 
through CpG methylation (Brenner et al., 2005). However, so far it is unclear whether 
any of these mechanisms plays a role in establishing the aberrant methylation 
patterns seen in human malignancies.  
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Methylated CpG-dinucleotides are bound by the methyl-CpG-binding domain 
(MBD) containing proteins MBD1, MBD2, MBD3, MBD4 and MeCP2. The protein 
Kaiso binds to methylated CpG groups via its zinc-finger motif. With the exception of 
MBD4, which operates in mismatch repair, these proteins were shown to recruit 
chromatin remodeling factors (e.g. Mi2/NuRD complex) and histone deacetylases 
(HDAC) to the respective promoters and thereby establish transcriptionally inactive 
chromatin (Figure 4). How and at which stage the CpG methylation of tumor 
suppressor genes is established during tumor progression is still unclear. Stochastic, 
age-associated accumulation of aberrantly methylated CpG-sites may be involved in 
this process.  
DNMTs
De novo
CpG
methylation
Deacetylation
of histone tailes
HP1
HMT
Histone
methylation
Inactive chromatinActive chromatin
MBD proteins, 
co-repressors
and HDACs
- acetylated H3
- methylated H3 at Lys9
- CpG methylation
Figure 4 The relationship between DNA methylation and chromatin structure 
The carbon atom at the 5’ position of cytosines within a CpG-dinucleotide context can be methylated 
by DNA methyltransferases (DNMTs). Clusters of methylated CpGs are recognized and bound by 
specific proteins sharing a methyl-CpG binding domain (MBD). In turn, MBD proteins recruit 
transcriptional co-repressors, chromatin remodeling complexes and histone deacetylases (HDACs). 
Deacetylation of histone tails (N-terminal parts of histone H3 and H4) results in alteration of 
nucleosomal structure and decrease in transcriptional activity of the chromatin. Subsequent 
methylation of histone tails by histone methyltransferases (HMTs) (particularly, lysine 9 of H3 and 
lysine 20 of H4) and recruitment of auxiliary proteins, such as heterochromatin binding protein 1 (HP1), 
enhance the formation of transcriptionally incompetent heterochromatin.  
 
Experimental reversion of DNA methylation leads to re-expression of silenced 
genes in tumor cells, which may have consequences at the cellular level: e.g. 
restored sensitivity to apoptotic stimuli after reactivation of caspase 8 (Hopkins-
Donaldson et al., 2003) and APAF1 (Soengas et al., 2001) or inhibition of cell-
proliferation after re-expression of the CDK-inhibitor p16 (Rhee et al., 2002). 
Consistent with a role of hypermethylation-mediated gene repression in tumor 
formation, inactivation of DNMT1 or MBD2 suppresses intestinal tumorigenesis in 
Apc min mice (Eads et al., 2002; Sansom et al., 2003). 
Although CpG methylation patterns can be erased during DNA replication in 
the absence of DNMT activity, aberrant epigenetic marks persist through multiple 
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generations of cells and are as stable as genetic alterations. For example most 
cancer cell lines maintain the pattern of aberrant DNA methylation characteristic for 
primary tumors of the same tissue origin (Paz et al., 2003). Moreover, aberrant 
methylation of CpG-islands, also called epimutation, can be transmitted through the 
germ line, as recently shown for the MLH1 gene (Suter et al., 2004).   
The estimated number of CpG-islands abnormally methylated in a particular 
type of cancer is about 600 (Costello et al., 2000), which is significantly greater than 
the number of genes experimentally shown to undergo epigenetic inactivation in any 
one cancer type. Therefore, genome-wide rather than candidate gene approach is 
desirable for the efficient identification of novel targets for epigenetic inactivation in 
human cancer. As one kind of approach the comprehensive analysis of the genes 
expression after treatment of tumor cell lines with inhibitors of DNA 
methylatransferases (5Aza-2’dC) and HDACs (TSA) was recently used to identify 
genes specifically silenced in tumors of the colon and oesophagus (Suzuki et al., 
2002; Yamashita et al., 2002). The key component of this strategy is a microarray 
technique exploited for the analysis of genome-wide transcriptional changes. The 
major advantage of this approach is the functional link between demethylation and 
re-expression of a particular gene, which other approaches, such as restriction 
landmark genomic scanning, differential methylation hybridization or methylation-
specific RDA do not provide (Jones and Baylin, 2002). 
 
 
1.4 Prostate Cancer 
Prostate cancer (PCa) is the most commonly diagnosed malignancy in the 
male population of the western world. Small prostatic carcinomas are detected in 
29% of men between 30 and 40 years of age and in 64% of men from 60 to 70 years 
of age (Nelson et al., 2003). In 25% of the affected men this usually indolent disease 
behaves aggressively and progresses to metastasis. In the year 2005 Pca will 
presumably be responsible for 30,350 of deaths in the US, accounting for 10% of all 
male cancer deaths, second only to lung cancer (American cancer society. Cancer 
facts and figures, 2005.). The molecular basis of PCa is still poorly understood, 
particularly due to the extreme heterogeneity of primary tumors and the limited 
number of available stable cell lines. 
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The identification of PCa-specific tumor suppressor genes has been hindered 
by several factors. First, no known syndrome predisposing to PCa has been 
identified, which could serve to identify genetic loci harboring tumor suppressor 
genes. Second, the high prevalence of PCa makes it difficult to identify familial 
clustering and cases of early onset, although a role for genetic predisposition has 
been proposed for ~40% of all PCa cases (Nelson et al., 2003). At least seven 
chromosomal regions have been associated with a predisposition to PCa (reviewed 
in Schulz et al., 2003). However, the candidate genes identified in these regions are 
altered at low frequencies, which suggests that genetic predisposition to PCa 
involves alterations in additional genes. Polymorphisms in detoxifying or repair 
genes, such as GSTT, GSTP1 and MTHFR may also contribute to predisposition for 
PCa (Kimura et al., 2000; Kote-Jarai et al., 2001; Steinhoff et al., 2000).  
The timing and progression of PCa is not understood. Benign prostate 
hyperplasia (BPH), a very common hyperproliferative lesion in the aged prostate, 
does not develop into a malignant tumor. The putative precursor of carcinoma is 
thought to be a lesion called prostate intraepithelial neoplasia or PIN (Figure 5), 
which resembles the carcinoma in situ stage of a breast or cervical cancer. PIN 
displays focal proliferation areas with nuclear heterogeneity and atypia confined 
within epithelial layer. It was proposed, that the stage designated as proliferative 
inflammatory atrophy (PIA) can precede the development of PIN (De Marzo et al., 
1999a) thus representing the earliest pre-cancer lesion in the prostate (Figure 5).   
At the time of diagnosis, prostate-cancer cells contain many somatic mutations, 
gene deletions, gene amplifications, chromosomal rearrangements, and changes in 
DNA methylation (Figure 5). These alterations probably accumulate over a period of 
several decades. The most commonly reported chromosomal abnormalities in PCa 
appear to be gains at 7p, 7q, 8q, and Xq, and losses at 8p, 10q, 13q, and 16q 
(reviewed in Karan et al., 2003). A striking heterogeneity in chromosomal 
abnormalities has been seen in different cases, in different lesions in the same case, 
and in different areas within the same lesion. Additional somatic genomic alterations 
appear to arise in association with the progression of prostate cancer.  
Genetic inactivation of tumor suppressor genes, which are known from other 
types of cancer, is detected at a relatively low frequency in early stage PCa, e.g. 
mutations of p53 are rare (reviewed in Abate-Shen and Shen, 2000; Karan et al., 
2003; Nelson et al., 2003). PTEN may be one of the most consistently affected tumor 
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suppressor genes in PCa. 30% of primary PCa and 63% of metastic PCa display 
mutation or deletion of PTEN (reviewed in Dahia, 2000; Suzuki et al., 1998). The 
NKX3.1 gene, located at 8p21, encodes a prostate-specific homeobox protein that is 
likely to be essential for normal prostate development and is therefore a candidate 
gatekeeper gene. Although genetic studies in mouse models provided support for 
this hypothesis (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999), molecular 
analyses have not yet established NKX3.1 as a somatic target for inactivation during 
prostatic carcinogenesis, as somatic mutations of a remaining allele are not detected 
in tumors with heterozygous deletion of the NKX3.1. 
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cancer
Metastatic and 
androgen-independent
prostate cancer
Blood
vessel
Proliferative inflamatory
atrophy (PIA)
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 Figure 5 The molecular pathogenesis of prostate cancer (adapted from Nelson et al., 
2003) 
AR = androgen receptor gene. For details see text. 
 
Abnormal DNA methylation is commonly found in PCa (reviewed in Li et al., 
2005).  For example, aberrant CpG methylation was found for GSTP1 in ~90%, for 
RASSF1A in ~63% and for RARß2 in ~79% of the analyzed PCa (Kuzmin et al., 
2002; Nakayama et al., 2001; Singal et al., 2001). Other examples of genes 
frequently silenced in PCa are APC, MGMT and MDR1 (Florl et al., 2004; Kang et al., 
2004; Yegnasubramanian et al., 2004). Detection and quantification of specific CpG 
methylation patterns has advantages over protein- and RNA-based diagnostic 
methods (Laird, 2003) and can be performed in different clinical samples including 
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plasma, prostate secretions, voided urine or ejaculates (Li et al., 2005), providing an 
additional tool for noninvasive diagnostics of PCa. The use of a panel of CpG 
methylation markers in combination with standard histologic review of needle 
biopsies was shown to increase the sensitivity of PCa diagnosis (Tokumaru et al., 
2004). 
In spite of the advance in PCa diagnosis attributed to the introduction of serum 
prostate specific antigen (PSA) determination in clinical practice, early detection of 
PCa remains a problem. In general, prostate cancer is diagnosed by needle biopsies 
taken from the patients, in which raised level of serum PSA or lower urinary tract 
symptoms have been revealed. However, serum PSA levels can be increased in 
benign conditions, and biopsies may miss microscopic foci of cancer (Ercole et al., 
1987; Smith and Catalona, 1995). Therefore, the development of a more sensitive 
and specific set of markers that could facilitate the diagnosis of prostate cancer at the 
earliest stages should improve the current standard of care. Moreover, it would be 
useful to identify molecular markers that cannot only sensitively and specifically 
diagnose early-stage prostate cancer but also help identify men that would later 
progress to having symptomatic or metastatic disease. 
The identification of new genes aberrantly methylated in PCa promises a 
better understanding of the etiology and progression mechanisms of this disease. 
Furthermore, this information will aid to establish tumor markers of increasing 
specificity and sensitivity potentially useful for diagnosis and prognosis of PCa.    
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2. Aim of the study 
 
The present study had the following aims:  
 
I. Analysis of the transcriptional program associated with replicative senescence in 
primary human cells in order to identify genes and signaling pathways which may be 
amenable to pharmacologic interference in order to induce cellular senescence in 
cancer cells 
 
II. Analysis of possible mechanisms of down-regulation of 14-3-3σ expression in 
human skin diseases. 
 
III. Identification and functional analysis of genes commonly inactivated by aberrant 
DNA methylation in prostate cancer.  
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3. Materials  
3.1 Chemicals  
Magnesium chloride, sodium dodecyl sulfate (SDS), sodium citrate, sodium bisulfite,  
sodium nitroprusside (SNP), ethylene glycol-bis(ß-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid (EGTA), ethylenediaminetetraacetic acid (EDTA), sodium 
orthovanadate, sodium fluoride, sodium chloride, phenylmethylsulfonylfluoride, 
potassium ferricyanide (K3Fe(CN)6), potassium ferrocyanide (K4Fe(CN)6), ampicillin,  
puromycin, geneticin (G418), doxorubicin (adriamycin), trichostatin A, 5-aza-2’-
deoxycytidine,  crystal violet, propidium iodide, ethidium bromide, hydroquinone, 
paraformaldehyde, polyoxyethylensorbitanmonolaureate (Tween 20), Trizma® base, 
eosin Y solution were from Sigma (Munich, Germany). 
Hydrochloric acid, dimethylsulfoxyde, xylene, Mayer’s hematoxylin solution were from 
Merck (Darmstadt, Germany). 
6-anilino-5,8-quinolinedione (LY 83583) (Calbiochem, Bad Soden, Germany) 
5-brom-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) (Promega, Mannheim, 
Germany) 
Etoposide (Alexis, Lausen, Switzerland) 
Phenol/chloroform/isoamylalcohol mixture (Carl Roth, Karlsruhe, Germany) 
Triton X-100 (Carl Roth)  
Biotin–CTP and biotin-UTP ribonucleotides (Loxo, Dossenheim, Germany) 
α-32p-dCTP (Amersham, Freiburg, Germany) 
Oligonucleotides (Metabion, Martinsried, Germany) 
Glutaraldehyde (Serva, Heidelberg, Germany) 
Agarose for gel electrophoresis (Peqlab, Erlangen, Germany) 
 
3.2 Enzymes and commercial kits 
Platinum Taq DNA polymerase (Invitorgen, Karlsruhe, Germany) 
Proteinase K (Sigma) 
RNAse (Roche, Mannheim, Germany) 
RNAse A (Sigma) 
T4 DNA ligase (NEB) 
T4 DNA polymerase (NEB, Frankfurt, Germany) 
Annexin V-FITC apoptosis detection kit (BD Pharmingen, San Diego, CA, USA).  
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APAAP immunostaining system kit (DAKO, Copenhagen, Denmark) 
BigDye terminator 3.1 sequencing kit (Applera, Darmstadt, Germany) 
Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA) 
BrdU Labelling and Detection Kit I (Roche) 
cGMP immunodetection kit (Sigma) 
ECL kit (PerkinElmer, Cologne, Germany) 
FastStart-DNA Master SYBR Green 1 kit (Roche) 
GalactoLight ß-galactosidase detection kit (Tropix, Bedford, MA, USA) 
Gel extraction kit (Qiagen, Hilden, Germany)  
Lipofectamine™ 2000 transfection reagent (Invitrogen) 
Luciferase Assay System kit (Promega)  
Miniprep kit (Qiagen) 
Nucleotide removal kit (Qiagen) 
PCR purification kit (Qiagen) 
QuickHyb hybridization solution (Stratagene, Amsterdam, The Netherlands) 
Readiprime II random prime labeling system (Amersham) 
RevertAid First Strand cDNA synthesis kit (MBI Fermentas, St. Leon-Rot, Germany) 
Ribomax T7 in vitro transcription kit (Promega) 
RNAgent RNA isolation kit (Promega)  
RNeasy RNA purification kit (Qiagen)  
SuperScript™ III first strand cDNA synthesis kit (Invitrogen) 
SuperScript™ double stranded cDNA synthesis kit (Invitrogen) 
TOPO-TA cloning kit for sequencing (Invitrogen) 
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) 
 
3.3 Antibodies  
3.3.1 Primary antibodies  
Mouse monoclonal anti-ß-catenin (clone 19) (Transduction Laboratories, Lexington, 
KY, USA) 
Mouse monoclonal anti-p63 (4A4) (DAKO, Copenhagen, Denmark) 
Mouse monoclonal anti-p53 (Pab 1801) (Santa Cruz Biotechnology, CA, USA) 
Mouse policlonal anti-p21 (Ab-11) (NeoMarkers, Fremont, CA, USA) 
Rabbit polyclonal anti-p16 (C-20) (Santa Cruz Biotechnology) 
Mouse monoclonal anti-α-tubulin (TU-02) (Santa Cruz Biotechnology) 
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Rabbit anti-14-3-3σ affinity purified serum described in (Chan et al., 1999) 
Mouse monoclonal anti-pRB (BD Pharmingen)  
Rabbit polyclonal anti-phosphor-ERK1/2 (Thr202, Tyr204) (Cell Signaling 
Technology, Frankfurt, Germany) 
Rabbit polyclonal anti- ERK1/2 (Cell Signaling Technology)  
Goat polyclonal anti-SFRP1 (C-19) (Santa Cruz Biotechnology) 
Mouse monoclonal anti-VSV (p5d4) (Sigma) 
 
3.3.2 Secondary antibodies 
Goat anti-rabbit IgG HRP-conjugate (Promega)  
Goat anti-mouse IgG HRP-conjugate (Promega)  
Donkey anti-goat IgG HRP-conjugate (Jackson ImmunoResearch Laboratories, West 
Grove, PA, US)  
Rabbit anti-mouse IgG Cy3-conjugate (Jackson ImmunoResearch Laboratories) 
Horse anti-mouse IgG biotinylated (Vector Laboratories) 
Mouse anti-rabbit IgG (DAKO) 
 
3.4 DNA constructs 
pCMV-ß-gal (BD Clontech), pLXSN (BD Clontech) , TOPO-TA vector (pCR®4-TOPO) 
(Invitrogen), pIRES-EGFP2 (BD Clontech), pEGFP-C1 (BD Clontech), pcDNA3.1-
His-A (Invitrogen) 
Other constructs were described: 
pWWW-Luc p21 promoter luciferase reporter (el-Deiry et al., 1993)  
pcDNA3-His-WNT1  WNT1 expression plasmid (Suzuki et al., 2004) 
pCMV-HA-SFRP1 SFRP1 expression plasmid (Suzuki et al., 2004) 
pGL3-OT and pGL3-OF TCF/LEF reporters (He et al., 1998)  
pSuper vector for short hairpin RNA expression (Brummelkamp et al., 2002b) and 
pRetroSuper self-inactivating retroviral vector for short hairpin RNA expression 
(Brummelkamp et al., 2002a) 
 
3.5 Other materials 
“Human Unigene 1” cDNA microarray (IncyteGenomics, Palo Alto, CA, USA) 
GeneChip® Human Genome U133 A oligonucleotide microarray (Affymetrix, Santa 
Clara, CA) 
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Novex 4-20% pre-cast gradient SDS-polyacrylamide gels (Invitrogen) 
Immobilon-P PVDF membrane (Millipore, Schwalbach Germany) 
Protran nitrocellulose membrane (Schleicher & Schuell BioScience, Dassel, 
Germany) 
Hyperfilm™ X-ray film (Amersham) 
Microcon YM-50 filter columns (Millipore) 
CELLocate glass grids (Eppendorf, Hamburg, Germany) 
ProTaqs IV buffer for IHC (Biocyc, Luckenwalde, Germany) 
 
3.6 Equipment 
Fluorescent microscope Axiovert 200M (Carl Zeiss, Oberkochen, Germany) equipped 
with a CoolSNAP-HQ CCD camera (Photometrics, Tucson, Arizona,USA) and 
Metamorph software (Universal Imaging, Downingtown, PA, USA). 
Axiovert 25 microscope (Carl Zeiss) equipped with a HyperHAD CCD camera (Sony) 
and ImageBase software (Kappa Optoelectronics, Gleichen, Germany) 
MicroBeam laser pressure catapulting system (PALM, Bernried, Germany) coupled to 
an Axovert 200M microscope (Carl Zeiss) equipped with a DXC-390P CCD camera 
(Sony, Tokyo, Japan) and a PALMRobo V2.1.1 software (PALM) 
Phosphoimager BAS-2500 (Fuji, Tokyo, Japan).   
MicroLumatPlus LB96V luminometer (EG&G Berthold, Bad Wildbad, Germany).  
ELISA reader LAMBDA E (MWG-Biotech, Ebersberg, Germany) 
Coulter counter Z1 (Coulter Electronics, Beds, United Kingdom) 
FACScan unit (BD Biosciences, Mountain View, CA, USA) 
PCR thermocycler Perkin Elmer 9700 (ABI) 
LightCycler™ real-time PCR system (Roche) 
Capillary sequencer 3700 (Applera) 
GeneChip® Scanner 3000 (Affymetrix) 
Microarray Suite 4.0 software (Affymetrix) 
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4. Methods 
4.1 Cell culture and treatments 
Neonatal skin HDFs were obtained from Clonetics (San Diego, California, 
USA) and cultivated in DMEM (Invitrogen) supplemented with 10% FBS (Sigma). To 
obtain senescent HDF, the cells were diluted every three days in a ratio of 1:10 
(equal to 1 passage) until they ceased to proliferate. HCT116 cells were cultured in 
McCoy’s medium (Invitrogen) supplemented with 10% FBS. A-375, HeLa, HEK293, 
p16–/– mouse embryo fibroblasts (MEF) and NIH3T3-L1 derivatives were kept in 
DMEM containing 10% FBS. 6-Anilino-5,8-quinolinedione (LY83583, referred to as 
LY hereafter) was dissolved in DMSO at a concentration of 300 µM (< 300× solution). 
As a control, cells were treated with equal volumes of DMSO (<1%). The LY 
concentration was restored at intervals of 24 hours by media exchange. 
The PCa cell lines Du-145, LNCaP, PC3, PPC1 and TSU-PrI were cultured in 
RPMI-1640 supplemented with 10% FBS and antibiotics (Invitrogen). The PCa cell 
line LAPC-4 was kept in RPMI-1640 in the presence of 20% FBS. Human benign 
prostate hyperplasia cells immortalized with SV40 large T-antigene (BPH1) were 
obtained from the German Collection of Microorganisms and Cell Cultures and 
passaged in RPMI-1640 medium supplemented with 20% FBS, 20 ng/ml testosteron, 
50 µg/ml transferrin, 50 ng/ml sodium selenite, 50 µg/ml insulin and a mixture of trace 
elements (Invitrogen). Human primary prostate epithelial cells (PrECs) from an 18-
year old donor (Cambrex Bio Science, Walkersville, MD, USA) were cultured in 
PrEGM according to the supplier’s instructions on Collagen Type I coated dishes 
(BioCoat, BD Falcon). LNCaP, Du-145 and PC3 cells were seeded at low density 24 
hours before de-methylation. Cells were exposed to 1µM of 5Aza-2’dC for 72 hours 
and 300 nM TSA for the last 24 hours or, as a control, to 300 nM TSA for 24 hours. 
 
4.2 Patient material 
Specimens of basal cell carcinoma, squamous cell carcinoma of the skin, 
psoriasis, actinic keratoses and genital warts (condylomata acuminata) were 
obtained from the Department of Dermatology, Ludwig-Maximilians University, 
Munich.  
Archival formalin fixed paraffin-embedded samples of primary prostate carcinoma 
(Gleason Sum 5-10) and cancer free samples of prostate were obtained from the 
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Institute of Pathology, Ludwig-Maximilians University Munich. The specimens were 
taken from consecutive cases of a single year (2001). All patients had undergone 
surgery at the same institution. In all cases, two board-certified pathologists agreed 
on the carcinoma diagnosis. 
 
4.3 Laser-assisted tissue microdissection  
Archival specimens of primary PCa and tumor free prostate tissue were 
deparaffinized in xylene and briefly stained with hematoxylin and eosin. One section 
was covered and used as a reference slide. Microdissection and laser-pressure 
catapulting was performed using a MicroBeam system. Material obtained from 2-3 
parallel sections (~103 cells) was pooled and genomic DNA was isolated by the 
proteinase K/SDS method (see Bisulfite treatment of genomic DNA). Before 
bisulfite-treatment, 1 µg of herring sperm carrier DNA (Promega) was added to each 
sample of microdissected DNA. 
 
4.4 RT-PCR analysis  
Five µg of total RNA was reverse transcribed using an oligo-(dT)18 primer and 
SuperScript™ III cDNA synthesis kit at 50°C for 60 min in a total volume of 20 µl. 
cDNA was diluted two-fold, first tested by qPCR on the LightCycler with EF1α-
specific primers using FastStart-DNA Master SYBR Green 1 kit, then diluted to equal 
concentrations and used for PCR. Two units Platinum Taq polymerase were used 
per 20 µl reaction with 2 µl cDNA .The total reaction volume was analyzed by 
agarose gel electrophoresis. The primer sequences and PCR cycle numbers for each 
of the analysed genes are provided in Table 3.  
 
4.5 Bisulfite treatment of genomic DNA 
Genomic DNA was isolated by overnight incubation in a solution containing 
100 µg/ml proteinase K and 0.1% SDS at 55°C with subsequent phenol/chloroform 
extraction and isopropanol precipitation. 2 µg DNA were denatured in 0.2 M NaOH 
for 10 min at 37°C in 50 µl of volume. After addition of 30 µl of 10 mM hydroquinone 
and 520 µl of 3.5 M sodium bisulfite pH 5.0, the mixture was incubated for 16 hours 
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at 50°C. After column-purification using the PCR purification kit, the DNA was 
incubated in 0.3 M NaOH for 5 min at RT. Converted DNA was ethanol precipitated 
and dissolved in 40 µl TE. 2 µl and 5 µl were used for a single MSP or bisulfite-PCR 
reaction, respectively. 
 
4.6 Genomic bisulfite sequencing 
Converted genomic DNA was used as a template to amplify regions of interest 
(400-1000 bp fragments with a high CpG-content around the transcription start site) 
by PCR using gene specific primers (listed in supplemental Table 1). After 5 min 
incubation at 95°C, 39-41 cycles were performed:  20 s at 95°C, 30 s at annealing 
temperature, 60-90 s at 72°C using 5 units of Platinum Taq polymerase per 100 µl 
reaction. PCR-products were isolated by gel purification and subcloned into a TOPO-
TA vector. At least 6 individual clones for each gene were sequenced in both 
directions using M13 primers and BigDye terminator, and analysed on a 3700 
capillary sequencer. 
 
4.7 Methylation-specific PCR  
MSP was performed in a total volume of 20 µl using 3 units Platinum Taq per 
reaction and gene specific primer sets  listed in Supplemental Table 2, discriminating 
between methylated and unmethylated DNA (Herman et al., 1996). After 5 min 
denaturation at 95°C, 40 PCR-cycles were performed for genomic DNA obtained 
from cell lines and 45 for micro-dissected genomic DNA. Amplified fragments were 
separated by 8% polyacrylamide gel electrophoresis and visualized by ethidium 
bromide staining.  
 
4.8 cDNA microarray analysis of gene expression 
Total RNA was isolated using RNAgents. The poly-A fraction was isolated 
using oligotex beads. The integrity and enrichment was ensured using Northern blot 
analysis. Six hundred nanograms of poly-A mRNA were converted to cDNA with 
incorporation of Cy3- or Cy5-labeled deoxynucleotide-triphosphates (dNTPs). 
Hybridization to arrays coated on glass, quality control, and normalization were 
performed by IncyteGenomics. The “Human Unigene 1” array contained cDNA 
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probes representing 8,392 annotated genes/expressed sequence tag (EST) clusters 
and 74 non-annotated genes/ESTs.  
 
4.9 Oligonucleotide microarray analysis of gene expression 
Total RNA was isolated from cell lines using the RNAgent kit and assessed 
photometrically and by agarose gel electrophoresis. Oligonucleotide microarray 
analyses were performed on the GeneChip Human Genome U133A (the list of genes 
is available at www.affymetrix.com) according to the manufacturer’s protocol. In brief, 
25 µg of total RNA were reverse transcribed using an anchored oligo-dT-T7 primer 
(5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-T24-VN-3’) and the 
double-stranded cDNA synthesis kit. After treatment with RNAse for 30 min at 37°C 
and proteinase K for 30 min at 37°C cDNA was extracted three times with a 
phenol/chloroform/isoamylalcohol mixture and purified by ultrafiltration on Microcon-
YM50 column. Using the in vitro transcription RiboMax T7 kit, biotin-labelled cRNA 
was produced from a double-stranded cDNA template, cleaned up with the RNeasy 
kit, fragmented by incubation in 40mM Tris-acetate pH 8.1, 100mM potassium 
acetate and 30mM magnesium acetate solution for 35 min at 95°C.  The probes were 
hybridized to the U133A oligonucleotide arrays (15 µg of the cRNA per chip) and 
analysed with a GeneChip® Scanner 3000. Genes up-regulated by combined 5Aza-
2’dC plus TSA treatment versus TSA alone were identified by an algorithm provided 
by Affymetrix using the Microarray Suite 4.0 software. 
 
4.10 Quantitative real-time PCR  
Quantitative real-time PCR (qPCR) was performed using the LightCycler and 
the FastStart DNA Master SYBR Green 1 kit as previously described. For qPCR of 
cDNA, primer pairs were designed to generate intron-spanning products of 100–200 
bp. Primer sequences were as follows: GUCY1A3, sense                
5’-TTCAGAGGAGGCAGCAGG-3’ and antisense 5’-GCAACATTCAGCCGTTCAA-3’ 
(annealing temperature, 62°C); and GUCY1B3, sense                
5’-AGGAATCACGCATCAGCC-3’ and antisense 5’-TATGAGGACGAACCAGCGA-3’ 
(annealing temperature, 62°C). cDNA was generated using the RevertAid First Strand 
cDNA synthesis kit. The generation of specific PCR products was confirmed by 
melting-curve analysis and gel electrophoresis. Each primer pair was tested with a 
logarithmic dilution of a cDNA mix to generate a linear standard curve (crossing point 
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[CP] plotted vs. log of template concentration), which was used to calculate the 
primer-pair efficiency (E= 10(–1/slope)). EF1α mRNA was used as an external standard, 
since its expression was not altered significantly in senescent versus early passage 
confluent HDF (data not shown). For data analysis, the second-derivative maximum 
method was applied, and induction of a cDNA species (geneX) was calculated 
according to Pfaffl (Pfaffl, 2001) as follows: 
 
 
4.11 Proliferation assays  
Cells were seeded in equal numbers in six-well plates 24 hours before the 
addition of LY. Cells were treated in triplicates (3 replicas of the same experiment) 
with daily exchange of medium containing drug or drug-free vehicle. For each time 
point, cells were trypsinized and cell proliferation was assessed using Z1 Coulter 
Counter. For the assessment of the net proliferation capacity cells were seeded in 6-
well plates at low density (~2.000/well), cultured for 10 days and stained with crystal 
violet. 
 
4.12 BrdU incorporation assay  
Cells were plated on CELLocate glass grids and labelled for 6 hours using the 
5′-bromo-2′-deoxyuridine Labelling and Detection Kit I. After staining with a FITC-
labelled anti-bromodeoxyuridine (anti-BrdU) antibody, positive cells were detected by 
fluorescence microscopy. 
 
4.13 Measurement of DNA content and apoptosis by flow cytometry  
Cells were trypsinized. Both adherent and floating cells were washed once 
with PBS and fixed on ice in 70% ethanol for more than 2 hours, washed once with 
PBS, and incubated for 30 minutes at room temperature in staining solution 
containing 50 µg/ml propidium iodide (PI), 0.2 mg/ml RNase A, and 0.1 % (v/v) Triton 
X-100 in PBS. Quantification of apoptotic cells was performed using the Annexin V-
FITC apoptosis detection kit. Samples were analyzed with a FACScan unit. 1 x 104 
cells were analyzed for each assay. 
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4.14 Senescence-associated ß-galactosidase staining 
Cells were fixed by incubation in 0.5% glutaraldehyde in PBS for 5 minutes at 
room temperature and stained for senescence-associated ß-galactosidase (SA-ß-gal) 
at pH 6.0 as described (Dimri et al., 1995). 
 
4.15 cGMP assay 
Cells of early and late passages were seeded in equal numbers in six-well 
plates. Twenty-four hours later, sodium nitroprusside (SNP) dissolved in complete 
medium was added at a final concentration of 100 µM. Controls received the same 
volume of drug-free medium. After 2 hours of incubation, the medium was removed 
and cells were lysed by addition of 400 µl of 0.1 M HCl per well for 10 minutes. The 
cGMP concentration in lysates was determined using a competitive immunoassay 
according to the manufacturer’s instructions. The LAMBDA E plate reader was used 
to detect the signal at 405 nm. Experiments were performed in triplicates, with all 
samples measured twice.  
 
4.16 Northern hybridization  
Total RNA was isolated using the RNAgent kit. 15µg of total RNA were 
separated on denaturing 1.5 % formaldehyde agarose gel, transferred to a Protran 
nitrocellulose membrane and cross-linked by exposure to UV.  Probe for the 3’ 
untranslated region of the EF1a mRNA was generated by PCR using EST as a 
template.  p21 probe was generated by excision of the respective open reading 
frame from the p21-EYFP construct. Probes against 14-3-3σ and GSTP1 were 
amplified by PCR from cDNA and subcloned in a TOPO-TA vector. Labelling with 
32p-dCTP was done using the random labelling kit and the product was purified using 
the nucleotide removal kit.  Hybridization was performed in QuickHyb solution 
according to the manufacturer’s protocol.  The signal was detected on a 
phosphoimager.  
 
4.17 Luciferase assay 
HCT116 cells with a knock-out of the p53 gene were co-transfected with the 
p21 promoter reporter construct pWWW-Luc and pCMV–β-gal in triplicates using 
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Lipofectamine™ 2000 reagent. After 24 hours, cells were exposed to 1.5 µM LY or 
an equal volume of DMSO for 12 hours.  
The use of pGL3-OT, a TCF-LEF responsive reporter, pGL3-OF, a negative 
control with a mutated TCF-LEF binding site, and pcDNA3.1 His-WNT1 constructs 
was described previously. LNCaP, PC3, Du-145 and HCT116 cells were plated at 
medium density the day before transfection in 12-well plates in triplicate for each cell 
line. The transfection was performed using Lipofectamin™ 2000 reagent. Three 
constructs were co-transfected in each experiment: (i) 0.5 µg of pGL3-OT or pGL3-
OF; (ii) 0.5 µg of pcDNA3.1-His-WNT1 or pcDNA3.1-His-A; (iii) 50 ng of pCMV-ß-gal. 
After 36 hours, cells were lysed and assayed for luciferase activity.   
Luciferase activity was measured according to the manufacturer’s instructions 
for the Luciferase Assay System kit. β-galactosidase activity was measured in the 
same lysates using Galacto-Light reagents. Luciferase and β-galactosidase 
determination were performed on a MicroLumatPlus LB96V luminometer. 
 
4.18 Western blot analysis 
Exponentially growing cells were lysed in 50 mM HEPES (pH 7.5), 150 mM 
NaCl, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 100 mM NaF, 10 mM Na4P2O7, 1 
µM phenylmethylsulfonylfluoride, and 1 µM Na3VO4. Protein concentration was 
determined using a Bradford assay. Eighty micrograms of protein were mixed with 2x 
Laemmli buffer, separated on Novex 4-20% gradient SDS-polyacrylamide gels, and 
transferred to Immobilon-P membranes or nitrocellulose membranes. Antibodies 
against α-tubulin (TU-02) diluted 1:1000 and affinity purified rabbit 14-3-3σ anti-
serum diluted 1:500 were used in combination with HRP-conjugated secondary 
antibodies diluted 1:10,000. Primary antibodies specific for p21, p53, p16, pRB, 
SFRP1 and VSV tag were used at dilutions 1:500, 1:1000, 1:300, 1:500, 1:200 and 
1:2,000 respectively. Target proteins were visualized after enhanced 
chemiluminescence treatment of membranes and subsequent exposure to 
Hyperfilm™ X-ray film. 
 
4.19 Immunofluorescent staining 
For immunofluorescent staining a mouse anti-ß-catenin antibody was used. 
The cells growing on CELLocate slides were fixed in 3.7 % paraformaldehyde 
solution for 20 min, permeabilized in 0.2 % Triton X in PBS  for 15 min and blocked in 
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FBS for 30 min. Primary antibodies diluted 1:50 in 10% FBS, 0.05% Tween 20 PBS 
were added for 1 hour. After three times washing in Tween20/PBS cells were 
incubated with Cy3-conjugated donkey anti-mouse antibodies diluted 1:200 for 30 
min, then washed again three times and mounted. All steps were performed at room 
temperature.  
 
4.20 Immunohistochemistry 
Skin sections of 4 µm thickness from formalin-fixed, paraffin-embedded tissue 
were deparaffinized in xylene and re-hydrated in a decreasing ethanol series. 
Antigen retrieval was carried out in citrate buffer (0.01 M, pH 6.0) at 98°C for 15 min 
in a pressure cooker. Then, sections were incubated with the 14-3-3σ antibodies 
diluted 1:200 for 25 min at room temperature, rinsed twice in Tris-HCl buffer and 
incubated with linking mouse anti-rabbit antibodies diluted 1:100 for 25 min. For p63 
staining the antigen retrieval was carried out in EDTA buffer (pH 8.0) at 98°C for 20 
min. Anti-p63 antibodies were used at a dilution 1:200 for 25 min at room 
temperature. The APAAP system was used for the visualisation of the signal 
according to the manufacturer’s instructions. 
For the 14-3-3σ staining the same procedure was used in prostate tissue as for skin 
samples. For the detection of SFRP1, deparaffinized and re-hydrated 4 µm sections 
of prostate tissue were subjected to the antigen retrieval procedure by boiling in a 
microwave oven for 30 min in ProTaqs IV buffer. Anti-SFRP1 antibodies diluted 1:25 
were used in combination with the Vectastain Elite kit. After counterstaining with 
hematoxylin, the images were acquired on an Axiovert 200M microscope coupled to 
a DXC-390P CCD camera using a PALMRobo V2.1.1 software.  
 
4.21 Microscopy 
For phase contrast and β-galactosidase staining an Axiovert 25 microscope 
equipped with a HyperHAD CCD camera and ImageBase software was used. In vivo 
expression of histone-H2B–EGFP, ß-catenin immunostaining and BrdU staining were 
documented on an inverted Axiovert 200M microscope equipped with a CCD camera 
CoolSNAP-HQ and Metamorph software. 
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4.21 Generation and analysis of knock–down and transgenic cell lines  
For stable expression of siRNAs, pSUPER-based constructs were used. 
Targeting of three different 19 bp sequences was tested in transient transfection 
experiments by assessing the ability to down-regulate expression of a 14-3-3σ-EYFP 
fusion protein (data not shown). All target sequences did not show any homology to 
other cDNAs in public databases. The most efficient construct targeted the sequence 
GGAGGCCGGGGACGCCGAG of the 14-3-3σ transcript and was used here. For 
vector construction, two oligonucleotides                
(5’-CGGGATCCCCGGAGGCCGGGGACGCCGAGTTCAAGAGTCTCG-3’;              
5’-CGCTCGAGCCAAAAAGGAGGCCGGGGACGCCGAGACTCTTGA-3’) with a 12 
bp overlap were annealed at 37°C and subjected to five PCR cycles resulting in a 
double-stranded fragment, which was digested with BamHI and XhoI and ligated into 
the BglII and XhoI sites of pSUPER. Then the entire H1-promoter-sh14-3-3σ cassette 
was released from pSUPER by restriction with EcoRI and XhoI and inserted into the 
same restriction sites of the self-inactivating retroviral vector pRetroSUPER. The 
resulting construct was transfected into a Phoenix A packaging cell line. pRetroSuper 
was used as a control. PC3 cells were infected by incubation with virus-containing 
supernatant and subjected to puromycin selection for 7 days. Single cell clones were 
established by limiting dilution.  
For the analysis of nuclear aberrations cells growing in 60 mm dishes were 
fixed in methanol and stained with DAPI. Phase contrast and fluorescent images 
were acquired using the Axiovert 200M fluorescent microscope and Metamorph 
software. For the quantification of the total cell number and number of multinuclear 
cells, at least 10 randomly chosen areas were counted per clone. 
For stable expression of DKK3 or SFRP1 the retroviral vector pLXSN, which 
had been modified by insertion of an IRES-EGFP fragment derived from the plasmid 
pIRES-EGFP2, was used. PC3 cells were retrovirally infected using pLXSN-IRES-
EGFP2, pL-DKK3vsv-IRES-EGFP2 or pL-SFRP1-IRES-EGFP2. 72 hours after 
infection GFP positive cells were sorted by FACS and expanded. For the assessment 
of colony formation, cells were seeded at low density in 6-well plates (2000 cells per 
well) and grown for 10 days. Cells were fixed in 1 % formaldehyde and stained with 
crystal violet. Apoptosis was assessed by propidium iodide staining and flow 
cytometry. 
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5. Results  
5.1 Expression profiling of replicative and premature senescence 
5.1.1 Microarray analysis of senescence-specific gene expression  
Microarray analysis of gene expression was used to identify genes and 
pathways involved in the induction and maintenance of replicative senescence. 
Primary HDF were cultivated until all cells were terminally arrested (n 75 population 
doublings) and showed characteristic signs of senescence: cellular enlargement, SA-
ß-gal staining at pH 6, and stable arrest in the presence of high serum concentration. 
Presenescent HDF, which had been arrested in the G1 phase by confluence at 
population doubling 12, were used as a reference. This state was selected to avoid a 
comparison of non-proliferating senescent HDF with proliferating early-passage HDF, 
which would presumably result in the detection of a large number of differences in 
gene expression secondary to growth arrest. mRNA was isolated from senescent and 
control HDF and subjected to analysis using a microarray representing 8,392 
annotated cDNAs. The culturing, analysis and isolation of RNA from early and late 
passage fibroblasts were performed by Dr. Heiko Hermeking. Generation of cDNAs 
and quality control was performed by Dr. Antje Menssen. The Microarray analysis 
was performed by the company Incyte Genomics (USA).  
Table 1 Detection of senescence-specific gene regulation using microarray analysis 
Symbol  Description Differential 
  expression 
PAI1 plasminogen activator inhibitor I +5.9 
PAI2 plasminogen activator inhibitor II +4.7 
MMP10 matrix metalloproteinase 10 +3.1 
p21 cyclin-dependent kinase inhibitor 1A +2.0 
CTGF connective tissue growth factor +3.7 
CCND1 cyclin D1 +5.0 
PK3 pyruvate kinase +5.0 
ID2 inhibitor of DNA binding 2  -2.0 
Gene expression patterns of early-passage confluent HDF were compared to those of senescent HDF using microarrays as 
described in Methods. 
Several genes previously identified as consistently up- or down-regulated 
during senescence of HDF (Ly et al., 2000; Shelton et al., 1999; West et al., 1996) 
were detected as regulated in a similar fashion in the system used  here (Table 1): for 
example, PAI-1 was previously detected as up-regulated in senescent HDF and was 
induced 5.9-fold in senescent HDF in this study (Table 1). Among the genes 
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repressed during senescence were four genes encoding enzymatic components of 
the cGMP pathway (Table 2): soluble guanylate cyclase α3 (sGC- α3), sGC-ß3, and 
cGMP-dependent protein kinase I and II. Differential regulation of sGC-α3 and sGC-
ß3 during senescence was confirmed by qPCR (Table 2). Down-regulation of sGC-ß3 
during senescence was also detected using Northern blot analysis (Figure 6a). sGC-
α3 and sGC-ß3 represent the large and small subunit of soluble guanylate cyclase, 
which converts GTP to 3',5'-cyclic GMP and pyrophosphate (Giuili et al., 1992). 
Interestingly, both genes are located in close proximity on chromosome 4q31.3-q33 
(Giuili et al., 1993), which could provide the basis for the co-regulation observed here.  
Table 2 Repression of genes encoding components of the cGMP signaling pathway
Symbol  Description Differential qPCR 
  expression (SD) 
GUCY1B3 soluble guanylate cyclase-ß3 -7.8 -9.4 (0.7) 
GUCY1A3 soluble guanylate cyclase-α3 -2.5 -2.2 (0.4) 
PRKG2 cGMP-dependent protein kinase II -9.7  
PRKG1 cGMP-dependent protein kinase I -2.5   
Gene expression patterns of early-passage confluent HDF were compared with those of  senescent HDF using microarrays as 
described in Methods. Confirmation of expression data by quantitative real-time PCR is indicated in the column labeled “qPCR” 
including standard deviation in brackets. 
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Figure 6 Modulation of the cGMP pathway in HDF  
(a) Northern blot analysis of GUCY1B3 expression in HDF. Total RNA was isolated from early- ("9.") 
and late-passage ("32.") HDF and HDF ("9. passage") treated with 1 µM LY for 4 days; 2.5 µg of total 
RNA was loaded per lane. GUCY1B3 and, as a control, EF1α mRNA were detected with 32P-labeled 
probes. (b) Response of early-passage and senescent HDF to activation of cGMP synthesis. Cells 
were treated with 100 µM SNP for 2 hours in the absence or presence of LY. Treatments were 
performed in triplicates and measured twice. 
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The coordinated repression of two genes encoding the subunits of soluble 
guanylate cyclase, which generates cGMP in response to signals — for example, 
extracellular nitric oxide (NO) (reviewed in Hofmann et al., 2000) — suggested that 
senescent cells may have an attenuated response to NO donors such as SNP. 
Indeed, exposure to SNP did not result in elevated cGMP levels in senescent HDF, 
whereas early-passage HDF showed a 2.7-fold increase in cGMP levels after the 
addition of SNP (Figure 6b). 
 
5.1.2 Induction of senescence by LY83583 
To specifically inhibit the cGMP signaling pathway, a competitive inhibitor of 
soluble guanylate cyclase, LY, with an IC50 of 2 µM was used (Fleisch et al., 1984). 
Addition of 1 µM LY to HDF significantly inhibited the SNP-induced synthesis of 
cGMP by 50% (Figure 6b), showing that LY had the expected inhibitory effect on 
guanylate cyclase. The effect of LY on the proliferation of early-passage HDF was 
tested at concentrations ranging from 0.25–1.5 µM (Figure 7a). Indeed, treatment of 
early-passage fibroblasts with a concentration of 1 µM of LY was sufficient to 
completely inhibit proliferation, and the presence of 250 nM LY led to a 50% 
reduction in proliferation of HDF after 3 days (Figure 7a). Strikingly, the inhibition of 
proliferation of early-passage HDF by LY was accompanied by morphological 
changes characteristic of senescence and by SA-ß-gal staining at pH 6 (Figure 7c). 
Consistent with the induction of cellular senescence, inhibition of proliferation by LY 
was irreversible after a treatment period of more than 2 days (Figure 7b). Extended 
treatment of HDF with LY for 8 days did not cause significant reduction of cell number 
due to cell death but resulted in stable inhibition of proliferation (Figure 7b). In order to 
characterize the cell-cycle arrest induced by LY, HDF were synchronized in the G1 
phase by confluence (91.2% G1 phase and 2% S phase) and then released by 
splitting (Figure 7d). Untreated cells entered the S phase at a high percentage, 
whereas addition of LY almost completely blocked the entry of HDF into the S phase, 
suggesting that LY acts during the G1 phase of the cell cycle. Furthermore, addition 
of 1 µM LY to synchronized HDF caused complete inhibition of DNA synthesis as 
determined by BrdU incorporation (Figure 7e).  
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 Figure 7 Effect of LY on HDF proliferation 
(a) Inhibition of proliferation by LY. Subconfluent HDF were treated with the indicated concentrations 
of LY for 3 days. Cell numbers were determined in triplicates. (b) Irreversible effect of LY on 
proliferation of HDF. Cells were treated with 1 µM LY for the indicated periods. After trypsinization, cell 
numbers were determined in triplicates. (c) Shown is a comparison of HDF after reaching replicative 
senescence with HDF after LY treatment. The upper panels show morphology (magnification, x100) 
and the lower panels show detection of SA-ß-gal at pH 6 (magnification, x200), using phase-contrast 
microscopy.  (d) FACS analysis of HDF treated with LY. HDF were synchronized by confluence and 
released by trypsinization. After 24 and 36 hours of incubation in media containing 1 µM LY or vehicle, 
cells were collected for FACS analysis. (e) Rate of DNA synthesis after LY treatment. BrdU 
incorporation was determined after incubation of HDF in 10 µM BrdU for 6 hours. For details, see 
Methods. 
 
5.1.3 Microarray analysis of LY-regulated genes  
In order to identify the downstream mediators of the LY-induced cell-cycle 
arrest and senescence, a microarray analysis of LY-treated HDF was performed with 
the same arrays used for the analysis of replicative senescence in HDF described 
above (for details, see Methods). RNA was isolated 36 hours after exposure of early-
passage HDF to LY. The control RNA was isolated from confluent early-passage 
HDF. In HDF that had reached replicative senescence, 216 transcripts were induced 
significantly, whereas 272 mRNAs were induced after LY treatment. Repression was 
observed for 266 mRNAs in HDF undergoing replicative senescence, whereas 294 
mRNAs were repressed after LY treatment. There was a substantial overlap in the 
differentially expressed genes observed during replicative senescence and during LY-
induced senescence, with 114 transcripts differentially regulated in a similar manner 
(Table 3). Among these were genes that had been previously identified as 
differentially regulated during replicative senescence: PAI-1, matrix metalloproteinase 
10, fibrillin, cdc25b, cyclin D1, fibromodulin, and osteoblast specific factor 2 
(Cristofalo et al., 1998; Ly et al., 2000; Shelton et al., 1999). However, most of the 
genes identified here represent new additions to the growing number of genes 
identified as components of the senescence program. Supporting this notion, many of 
the co-regulated genes have functions that may contribute to the phenotype of 
terminally arrested cells. For example, down-regulation of the PDGF receptor α and ß 
chains may contribute to the refractory state of senescent cells, which do not respond 
to mitogenic stimulation with growth factors. The changes in expression observed in 
genes encoding components of the cytoskeleton (e.g., α1-tubulin, ß2-tropomyosin, -
filamin C, α-actinin) may contribute to the flattened and enlarged shape characteristic 
of senescent HDF (Figure 7c). Interestingly, the sGCß3 mRNA was down-regulated 
in LY-treated HDF (Table 3 and Figure 6a).  
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Table 3 Detection of 114 mRNAs coregulated in replicative senescence and LY-treated cells by 
microarray analysis 
 repl.sen. LY  repl.sen. LY 
Gene name (functional class) fold fold Gene name (functional class) fold fold 
Cell cycle    Extracellular Matrix   
wee1+ homolog -4.2 -3.2 fibulin 2 -3.4 -3.4 
cell division cycle 25B -2.3 -3.8 fibrillin 2 -2.2 -4.8 
cyclin G2 -1.7 -1.9 fibromodulin -2.2 -3.8 
checkpoint suppressor 1 -1.8 -2.2 lumican -2.2 -4.8 
cdc-like kinase 1 -2.2 -2.6 matrix metalloproteinase 1  -3.3 -2.6 
cyclin D1 +5.0 +2.0 matrix metalloproteinase 2  -3.9 -2.4 
cyclin-dependent kinase inhibitor 1A (p21, Cip1) +2.0 +3.0 matrix metalloproteinase 10 (stromelysin 2) +2.3 +2.9 
cyclin-dependent kinase 7  +1.7 +1.6 matrix metalloproteinase 15  -8.9 -3.6 
   matrix Gla protein -4.8 -3.1 
Transcription   adducin 3, gamma -4.1 -2.6 
transcription factor 8 -1.8 -2.2 dermatopontin -2.0 -2.9 
Cbp/p300-interacting transactivator (CITED2) +3.0 +2.3 procollagen C-endopeptidase enhancer -2.5 -3.3 
TBP-associated factor, RNA pol II, G, 32kD +1.4 +1.8 cathepsin O -2.0 -3.2 
zinc finger protein 238 -5.5 -5.6 cathepsin F -2.0 -2.7 
SWI/SNF rel., matrix assoc., reg.of chromatin 2 -3.5 -2.8 protein geranylgeranyltransferase type I, b -2.0 +3.2 
ribonuclease, RNase A family, 4 -4.8 -7.6 complement component 1, r subcomponent -15.7 -5.2 
RNA helicase-related protein +3.2 +5.5 complement component 1, s subcomponent -9.8 -5.4 
c-maf -4.8 -2.8 limbic system-associated membrane protein -1.8 -3.9 
microphthalmia-associated transcription factor -2.1 -2.5 protein S, alpha -5.7 -2.7 
   thrombospondin 2 -2.0 -2.6 
Signaling   carboxypeptidase Z -2.4 -2.7 
PDGF receptor-like (PDGFRL) -2.9 -3.0 glypican 3 -32.1 -3.1 
PDGF receptor, alpha -2.0 -2.5 PAI-1 +5.9 +12.6 
PDGF receptor, beta -2.4 -2.7 coagulation factor III  +4.3 +2.3 
guanylate cyclase 1, soluble, beta 3 -7.8 -3.9 metallothionein 1L +2.9 +5.0 
mitogen-activated protein kinase 7 -1.9 -2.2    
B-factor, properdin -2.5 -5.0 Cell shape and motility   
glutamate receptor, ionotropic, AMPA 1 -2.8 -4.3 laminin, alpha 2  -1.9 -2.2 
TGFß receptor III (betaglycan, 300kD) -3.8 -5.1 microfibrillar-associated protein 4 -4.0 -5.6 
purinergic receptor P2X, lig.-gated ion channel, 4 -1.3 -1.8 microfibrillar-associated glycoprotein-2 -3.6 -2.0 
prostaglandin F receptor (FP) -2.1 -2.2 tropomyosin 2, beta +3.7 +2.1 
IGFBP 5 -16.7 -10.1 filamin C, gamma  +1.9 +3.3 
interleukin 1 receptor, type I -4.9 -2.2 tubulin, alpha 1 +1.8 +4.3 
mitogen-activated protein kinase kinase 5 -1.8 -2.0 actin, gamma 1 +2.2 +3.7 
interleukin 11 receptor, alpha -2.9 -2.1 actinin, alpha 1 +3.8 +1.9 
connective tissue growth factor +3.7 +5.0 actin, beta +2.5 +2.8 
fibroblast growth factor 2 (basic) +3.0 +3.0 moesin +2.6 +2.4 
annexin A2 +4.1 +2.3 ARP3 (actin-related protein 3, yeast) +3.1 +2.5 
adenylyl cyclase-associated protein +2.0 +2.0    
regulator of G-protein signaling 4 +1.6 +5.7 Other functions   
neurotrophic tyrosine kinase, receptor, type 1 +2.5 +2.8 cysteine-rich, angiogenic inducer, 61 +4.1 +5.5 
SHC 1 +1.9 +1.8 BRCA1 associated protein +3.8 +4.7 
regulator of G-protein signaling 4 +1.6 +5.7 heat shock 70kD protein 4 +1.9 +1.9 
osteoblast specific factor 2 (fasciclin I-like) -59.9 -3.3 heat shock 70kD protein 8 +1.9 +3.7 
stromal cell-derived factor 1 -19 -2.2 glioma pathogenesis-related protein +2.7 +2.3 
   butyrophilin, subfamily 3, member A2 -2.2 -2.8 
Metabolism   glycoprotein A repetitions predominant -2.1 -3.0 
mannosidase, alpha, class 1A, member 1 -4.2 -4.0 thioredoxin reductase 1 +2.2 +7.8 
alcohol dehydrogenase 1A (class I), a -3.6 -3.6 clusterin -2.3 -3.1 
glucosidase, alpha; acid  -2.6 -2.8 upregulated by 1,25-dihydroxyvitamin D-3 -3.6 -3.3 
superoxide dismutase 2, mitochondrial -2.0 -2.8 selenium binding protein 1 -2.3 -2.9 
phosphatidic acid phosphatase type 2B -7.1 -6.5 arginyl-tRNA synthetase +2.0 +1.8 
short-chain dehydrogenase/reductase 1 -2.1 -3.5 ubiquitin carboxyl-terminal esterase L1 +2.1 +2.0 
prostaglandin I2 (prostacyclin) synthase -2.1 -2.3 Fc fragment of IgG, receptor transporter, alpha -2.6 -2.8 
acid ceramidase -1.9 -2.5 retinoic acid receptor responder 2 +2.0 -2.3 
selenophosphate synthetase -2.4 -2.2 PEG1 -2.1 -2.5 
fucosyltransferase 8  -1.9 -2.6 latent TGFß binding protein 4 -11.2 -2.1 
phospholipid scramblase 1 -2.3 -2.1 matrilin 2 -3,9 -1,9 
pyruvate kinase +5.0 +2.1 carboxypeptidase E -2,4 -2.0 
UDP-N-acetylglucosamine pyrophosphorylase 1 +2.2 +4.1 TGFß inducible early growth response 2 -1,8 -1,9 
prostaglandin-endoperoxide synthase 2 (COX2) +2.1 +1.8 gamma-interferon inducible protein 16 -1,8 -1,8 
sialic acid synthase +2.0 +1.9 poliovirus receptor +2.0 +2.5 
   glypican 1 +2,1 +2.6 
Genes, which showed a similar differential regulation (>1.7 fold induction or repression) in the two microarray analyses, are 
shown after classification according to their function. For each gene, fold differential expression during replicative senescence 
(repl. sen.) or after LY83583 treatment (LY) is shown. For details of the microarray analyses see Methods. 
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5.1.4 Rapid induction of p21WAF1/CIP1/SDI by LY83583 
Among the genes induced by both replicative senescence and LY was 
p21WAF1/CIP1/SDI (Table 3), which encodes an inhibitor of cyclin-dependent kinases 
(CDKs). CDK/cyclin complexes drive cell-cycle progression and proliferation by 
phosphorylation of key substrates. Since induction of p21 could potentially explain the 
antiproliferative effect of LY, the connection between LY and p21 was analyzed in 
more detail. Six hours after treatment with LY, the levels of p21 mRNA in HDF were 
similar to the levels observed 6 hours after addition of a DNA damaging agent 
adriamycin, as shown by Northern blot analysis (Figure 8a). However, after treatment 
with LY, the level of p53 protein, which consistently increases after generation of 
DNA damage and mediates transactivation of p21, did not increase (Figure 8b), 
indicating that LY does not induce DNA damage. The induction of p21 mRNA by 
adriamycin demonstrates, that the signaling pathways necessary for p53 activation 
were still intact in the HDF used (Figure 8a). Induction of p21 protein was detectable 
between 3 and 6 hours after addition of LY, whereas the CDK inhibitor p16INK4A was 
not induced even after 48 hours of treatment with LY (Figure 8b). This result was 
unexpected, since p16INK4A is commonly induced in scenarios that lead to premature 
senescence — for example, ectopic expression of an activated RAS gene (Serrano et 
al., 1997) or suboptimal cell-culture conditions (Ramirez et al., 2001). 
The main cell-cycle–relevant targets of the CDK inhibitor p21 are cyclin-
dependent kinases 2, 4, and 6 (Harper et al., 1993; Harper et al., 1995), which keep 
the pocket-proteins pRB, p107, and p130 in an inactive hyperphosphorylated state 
during cell-cycle progression (reviewed in Grana et al., 1998).  
Therefore, p21-mediated inhibition of G1/S phase–associated CDK/cyclin 
complexes leads to hypophosphorylation of pocket proteins, which allows their 
subsequent binding and inhibition of E2F transcription factors. The association 
between pocket proteins and E2Fs results in inhibition of G1/S progression and 
proliferation (reviewed in Weinberg, 1995). Consistent with the induction of p21 by LY, 
the phosphorylation status of pRB changed rapidly after addition of LY. After only 6 
hours the ratio of phosphorylated to hypophosphorylated, active pRB was clearly 
shifted toward the hypophosphorylated form, and by 19 hours pRB was almost 
completely hypophosphorylated (Figure 8c). Even after extension of the LY treatment 
to 12 days the pRB hypophosphorylation was not reversed (Figure 8c). These results 
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show that LY inhibits proliferation by inducing p21 to levels that are sufficient to 
inhibit CDK activity and to activate the cell-cycle inhibitory function of pRB.  
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Figure 8 Effects of LY on the expression and phosphorylation status of cell cycle 
regulatory proteins  
(a) Northern blot analysis of LY-treated HDF. Total RNA was isolated from HDF treated with 2 µM LY 
or 0.2 µg/ml adriamycin for the indicated periods; 7.5 µg of total RNA was loaded per lane. 
p21WAF1/CIP1/SDI  and, as a control, EF1α mRNA were detected with 32P-labeled probes. (b) Western blot 
analysis of HDF treated with LY. Lysates were obtained from HDF treated with LY for the indicated 
periods; 20 µg of protein was loaded per lane. After separation on 4–20% gradient gels and transfer to 
PVDF membranes, proteins were detected with antibodies against human p21, p53, p16, and — as a 
loading control — α-tubulin. (c) pRB phosphorylation status after treatment with LY. After addition of 
LY for the indicated periods, cell lysates were prepared and proteins were separated by a 7–12% 
gradient SDS-PAGE; ppRB, hyperphosphorylated pRB; pRB, hypophosphorylated pRB. 
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Figure 9 Effects of LY on epithelial cancer cells  
(a) Growth curves of MCF7, A-375, HCT116, and DLD1 cells. Cells were trypsinized at the indicated 
time points and cell numbers were determined. (b) Induction of p21 protein after treatment with LY. 
HCT116 colorectal cancer cells were treated with 1.5 µM LY for the indicated periods. Cell lysates 
were prepared and subjected to Western blot analysis. 
 
 
5.1.5 Effect of LY83583 on cancer cell proliferation  
In order to determine whether LY may be useful to terminate cancer cell 
proliferation, colorectal cancer cell lines (HCT116, DLD1), a breast cancer–derived 
cell line (MCF7), and a melanoma cell line (A-375) were analyzed after addition of 
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LY. All cell lines showed complete cessation of cell proliferation (Figure 9a). 
Consistent with the findings in HDF, HCT116 cells showed induction of p21 at the 
protein level after addition of LY (Figure 9b). Furthermore, p21 mRNA was induced 
by LY in MCF7 cells (data not shown).  
 
5.1.6 Requirement of p21, but not p53, for inhibition of proliferation by LY83583 
To determine whether induction of p21 is essential for the inhibition of 
proliferation by LY, p21-deficient HCT116 cells, generated through homologous 
recombination (Waldman et al., 1996), were analyzed (Figure 10a). p21-deficient 
HCT116 cells were largely resistant to LY, whereas wild-type HCT116 cells showed 
complete cessation of proliferation (Figure 9a). These results show that p21 is 
required for the inhibitory effects of LY on cellular proliferation. Consistent with the 
absence of p53 accumulation in LY-treated HDF, p53-deficient HCT116 cells (Bunz 
et al., 1998) showed a complete block of proliferation after addition of LY (Figure 
10b). The properties of the three different HCT116 cell lines used in this study were 
confirmed by treatment with adriamycin, which induces DNA double-strand breaks 
(Figure 10c). As expected, only wild-type HCT116 cells showed induction of p21 
protein after exposure to adriamycin (Figure 10c). HCT116 cells deficient in p53 and 
transiently transfected with a reporter construct of human p21 promoter fused to the 
luciferase gene showed a more than 10-fold increase in luciferase activity after 12 
hours of LY treatment (Figure 10d). The levels of p21 mRNA and protein of p53–/– 
HCT116 cells after treatment with LY were induced with kinetics similar to those 
observed in HDFs (Figure 10, e and f). These results exclude p53 and thereby 
induction of DNA damage as mediator of the cell-cycle arrest by LY and induction of 
p21 expression. Furthermore, LY treatment did not lead to induction of the CDK 
inhibitors p27 and p15 (data not shown). In addition, proliferation of p16INK4A-deficient 
MEFs (described in Serrano et al., 1996) was inhibited by LY, showing that p16INK4A is 
not required for the effects of LY on the cell cycle (data not shown). Supporting this 
conclusion, the HCT116 colorectal cancer cell lines used in this study do not express 
functional p16INK4A; one p16INK4A allele carries an inactivating point mutation, and the 
other p16INK4A allele is completely silenced by CpG methylation (Myohanen et al., 
1998). Taken together, these results show that the inhibitory effects of LY on 
proliferation are mediated through induction of p21.
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Figure 10 Requirement of p21, but not p53, for inhibition of proliferation by LY 
(a) Response of HCT116 colorectal cancer cells deficient for p21 to LY. Cells were treated with LY or, 
as a control, with vehicle (DMSO), and cell numbers were assessed. Measurements were performed 
in triplicates. (b) Response of p53+/+ and p53–/– HCT116 cells to LY. Cells were treated with LY or, as 
a control, with vehicle (DMSO), and cell numbers were assessed. Measurements were performed in 
triplicates. (c) Analysis of HCT116-derived knock-out cell lines. Shown are the results of a Western 
blot analysis of p53 and p21 protein levels after addition of adriamycin at 0.2 µg/ml for 8 hours. (d) p21 
promoter reporter activity in p53-deficient HCT116 cells after treatment with 1.5 µM LY for 12 hours. 
The experiment was performed in triplicates. For details, see Methods. (e) p53-independent induction 
of p21 mRNA by LY. Shown are the results of a Northern blot analysis with RNA isolated at the 
indicated time points after addition of 1.5 µM LY to p53-deficient HCT116 cells. (f) p53-independent 
induction of p21 protein levels by LY. Shown are the results of a Western blot analysis with lysates 
from p53–/– HCT116 cells treated with 1.5 µM LY. Membranes were probed with antibodies specific for 
p21 and, as a loading control, α-tubulin.  
 
5.1.7 Conversion of LY83583-induced arrest to apoptosis in pRB-negative cells  
Since the antiproliferative effect of p21 is mediated through pocket proteins 
(pRB, p107, p130) (reviewed in Grana et al., 1998), the response of cells with 
nonfunctional pocket proteins to treatment with LY was analyzed. Isogenic NIH3T3-
L1 cell lines (described in Hermeking et al., 1994) stably expressing either SV40 
large T-antigen or an SV40 large T-antigen point mutant (K1) (DeCaprio et al., 1988) 
deficient in binding and inactivating pocket proteins were treated with LY. NIH3T3-L1 
cells expressing the K1-mutant showed inhibition of proliferation, whereas NIH3T3-L1 
cells expressing wild-type SV40 large T antigen underwent apoptosis (Figure 11, a 
and b). Induction of apoptosis by LY was further quantified using annexin V staining 
(Figure 11c).  
In order to extend these observations to human cancer cells, the cell lines 
HeLa and HEK293 were analyzed. The cervical cancer cell line HeLa expresses the 
human papilloma virus (HPV) 18 which codes for the E7 protein. E7 binds to and 
inactivates pocket proteins. In HEK293 cells, the adenoviral E1A protein performs 
analogous functions. HeLa and HEK293 cells did not arrest after treatment with LY 
but instead underwent cell death (Figure 12a, data not shown), which was 
accompanied by cell shrinkage suggesting apoptosis (data not shown). HeLa cells 
expressing a histone H2B-EGFP fusion protein were used to confirm the induction of 
apoptosis by LY (Figure 12b). Treatment with LY led to chromatin condensation, 
which is characteristic of apoptosis. Furthermore, flow cytometry analysis revealed a 
substantial increase of cells with a sub-G1 DNA content after addition of LY (Figure 
12c). 
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Figure 11 Modulation of the effect of LY through the functional status of pRB 
(a) Response of cell lines with lesions in the pRB pathway to LY. NIH3T3-L1 cells expressing SV40 
large T antigen (LT3) and NIH3T3-L1 cells expressing a point mutant of SV40 large T antigen unable 
to bind to pRB-like proteins (K1) were treated with 1.5 µM LY. Cell numbers were determined at the 
indicated time points in triplicates. (b) Morphology of NIH3T3-L1 cells after LY treatment. Phase-
contrast microscopy was performed after incubation of NIH3T3-L1-K1 (K1) and NIH3T3-L1-LT3 (LT3) 
cells in 1.5 µM LY for 3 days (magnification x100). (c) Quantification of early stages of apoptosis. K1 
and LT3 cells (control cells and cells treated with LY for 48 hours) were subjected to double staining 
with anti-annexin V and PI to discriminate living, early apoptotic, and late apoptotic/necrotic 
populations and were analyzed by flow cytometry. The percentage of PI-negative, annexin V–positive 
cells is shown.  
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Figure 12 Effect of LY on HeLa cells 
(a) Growth curves of HeLa cells. Cells were trypsinized at the indicated time points and cell numbers 
were determined. (b) Induction of apoptosis by LY. HeLa cells expressing a histone H2B-EGFP fusion 
protein (kindly provided by G. Wahl) were treated with 2 µM LY for 48 hours, and the chromatin 
morphology in living cells was analyzed at a wavelength of 495 nm. (c) The quantification of apoptosis 
by detection of cells with a sub-G1 DNA content. HeLa cells were treated with LY for the indicated 
period of time. DNA content was determined after PI staining as described in Methods. 
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5.2 Analysis of 14-3-3σ expression in hyperproliferative skin diseases  
5.2.1 Immunohistochemical analysis of hyperproliferative skin diseases  
14-3-3σ antisense expression immortalizes primary keratinocytes. Therefore, 
Dr. Heiko Hermeking established a collaboration with Dr. Thomas Herzinger 
(Dermatologisches Klinikum, LMU, München) to examine the expression of 14-3-3σ 
protein in several benign and neoplastic skin diseases. The specificity of the 
employed antibody was verified using sections of paraffin embedded 14-3-3σ wt (+/+) 
and knock-out (-/-) colon cancer cells (Chan et al., 1999). Unexpectedly, in actinic 
keratoses (Figure 13a), genital warts (condylomata acuminata; Figure 13b), psoriasis 
(Figure 13c) and cutaneous squamous cell carcinoma (SCC; Figure 13d) the level of 
14-3-3σ expression was equal to that of normal epidermis (Figure 13e, arrow) in all 
cases analysed (Table 4). Keratinocytes within the hair follicles and the germinative 
portion of sebaceous glands stained strongly positive for 14-3-3σ (Figure 13g and 
13l). However, 14-3-3σ protein levels were markedly down-regulated in basal cell 
carcinoma (BCC derived from five different patients; Figure 13e-k). As shown in 
Figure 13j and k (higher magnification of the BCC section shown in Figure 11i) the 
basal cells of the epidermis express 14-3-3σ protein. Towards the outer layers of the 
epidermis the level of 14-3-3σ expression increases. Only a few keratinocytes within 
the tumor nests stained positive for 14-3-3σ, particularly in portions of the tumor with 
a more morphoeic (Figure 13h) or squamous differentiation pattern, where 
expression of 14-3-3σ was found around cysts (Figure 13f). In total, 41 BCC were 
analysed for expression of 14-3-3σ: 29 (70.7%) showed no or strongly reduced 
expression of the 14-3-3σ protein (Table 5).  
Different molecular alterations could be responsible for the loss of 14-3-3σ 
expression in BCC. Recently, the p53 homolog p63 was found to be a specific 
marker for keratinocyte stem cells (Pellegrini et al., 2001). The loss of 14-3-3σ 
expression detected in BCC could therefore be due to expression of a dominant-
negative splice variant of p63 ( Np63/CUSP), which is expressed in the epidermal 
stem cell compartment, from which BCC is presumably derived, and may affect 14-3-
3σ expression via the p53-binding sites in the 14-3-3σ promoter (Westfall et al., 
2003). 
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Figure 13 14-3-3σ protein expression in hyperproliferative diseases of human skin 
Paraffin-embedded samples of actinic keratosis (a), genital condyloma (b), psoriasis (c), SCC (d) and 
five different BCCs (e-i) were stained with an affinity-purified, polyclonal antibody specific for 14-3-3σ 
(red). Higher magnifications of the tissue section shown in (i) are provided in (j) and (k). Nuclei (blue) 
were counterstained with haematoxylin (Ep: epidermis; Hf: hair follicle; SCC: squamous cell carcinoma; 
Sg: sebaceous gland). These analyses were performed by Dr. Amir Yazdi and Dr. Thomas Herzinger 
(Department of Dermatology, LMU, Munich) 
 
Therefore, the expression of p63 protein was analyzed. Indeed, all 20 BCC analysed 
were positive for nuclear p63 protein (Figure 14a; Tables 4 and 5). However, seven 
of the 20 BCC tested showed expression of both 14-3-3σ and p63 protein (Table 5). 
Furthermore, cells representing actinic keratoses (7/7) and SCC (6/6), which 
expressed high levels of 14-3-3σ , were also positive for p63 (Figure 14b, e, c, f 
Table 4). Therefore, no direct correlation exists between the absence of 14-3-3σ 
expression and presence of p63 in BCC 
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Figure 14 Analysis of p63 protein expression in 14-3-3σ-positive cases of BCC, 
actinic keratosis and SCC 
Sections of BCC (a, d), actinic keratosis (b, e) and SCC (c, f) were analysed for expression of p63 (a, 
b, c; red nuclear signals). High levels of 14-3-3σ were confirmed in parallel sections of the tissue (d, e, 
f; red cytoplasmic signals). In case of BCC (a), a sample from patient 14 (Table 5) is shown. These 
analyses were performed by Dr. Amir Yazdi and Dr. Thomas Herzinger (Department of Dermatology, 
LMU, Munich) 
 
 
5.2.2 Analysis of 14-3-3σ  CpG methylation in BCC and normal epidermis 
Since it has recently been reported that 14-3-3σ  is silenced by CpG-island 
methylation (Ferguson et al., 2000), this epigenetic mechanism appeared to be one 
possible explanation for down-regulation of 14-3-3σ in BCC. Therefore, I analysed 
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the methylation status of 14-3-3σ in BCC by methylation specific PCR (MSP). The 
specificity of the employed PCR-primers (Figure 15, a and b) and the conditions for 
MSP were confirmed by analysis of the 14-3-3σ methylation status in the breast 
cancer cell line MDA-MB-435S, in which 14-3-3σ undergoes complete methylation 
(Ferguson et al., 2000). As shown in Figure 15b only a 105 bp (base-pair) PCR 
product specific for methylated DNA but no product representing an unmethylated 
14-3-3σ allele was detected in MDA-MB-435S cells with MSP. Furthermore, the 
colorectal cancer cell line HCT116, which expresses 14-3-3σ, did not show 
methylation by MSP, but was positive for the 107 bp MSP product representing an 
unmethylated 14-3-3σ allele (Figure 15b). Laser microdissection was employed to 
isolate BCC tissue samples from paraffin sections obtained from 41 patients. This 
approach allowed the precise separation of BCC from stroma, in which 14-3-3σ is 
silenced by CpG methylation (Umbricht et al., 2001). Consistent with CpG 
methylation of 14-3-3σ in stroma the signal corresponding to methylated 14-3-3σ 
allele was detected in normal human diploid fibroblasts (HDF) passaged in vitro 
(Figure 15b). MSP with genomic DNA extracted from BCC revealed, that 14-3-3σ 
promoter methylation was present in 28 of 41 (68%) of the analyzed BCC samples  
(Figure 15c, Table 5). All samples also demonstrated a signal specific for the 
unmethylated allele of 14-3-3σ (Figure 15c, Table 5). The concomitant presence of 
unmethylated and methylated promoter sequences has also been observed in micro-
dissected tumor-samples obtained from breast cancer lesions (Umbricht et al., 2001). 
Immunohistochemical analysis of adjacent sections from all 38 BCC analyzed by 
MSP shown in Table 1 with the 14-3-3σ-specific  antiserum confirmed strong 
suppression, and in most cases absence, of 14-3-3σ protein expression in BCC (data 
not shown).  
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 Figure 15 Methylation status of the 14-3-3σ and p16INK4A genes in BCC 
(a) Location of the PCR primers employed for MSP analysis of 14-3-3  . (b) Confirmation of 
specific MSP conditions for 14-3-3σ. Paired samples of bisulphite-treated genomic DNA derived from 
the indicated cell lines or primary human diploid fibroblasts (HDF) were subjected to PCR amplification 
with primers specific for unmethylated (U) and methylated (M) 14-3-3σ alleles. (c) Exemplary MSP 
results from eight different BCC patients. (d) Detection of CpG methylation in the 14-3-3σ gene in four 
BCC samples, (e) their corresponding adjacent epidermis and (f) epidermis samples adjacent to 
distant, naevocytic naevi from the same patients. (g) MSP analysis of p16INK4A. Exemplary results are 
shown. Genomic DNA was isolated from six microdissected BCC samples and the colorectal cancer 
cell line HCT116 (positive control for methylated and unmethylated p16INK4A alleles). For the analyses 
shown in (c)-(g) paraffin-embedded 6 µm sections were laser-microdissected. PCR products were 
resolved on 8% polyacrylamide gels and stained with ethidium bromide. 
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Table 4 14-3-3σ and p63 protein expression in different types of hyperproliferative skin diseases 
 14-3-3σ IHC  p63 IHC 
 Cases analy ed s(number) 
14-3-3σ  
(positive) 
Frequency 
(%) 
Cases analy ed s
(number) 
p63 
(positive) 
Actinic keratosis 11 11 100 7 7 
Psoriasis vulgaris 11 11 100 ND ND 
Condylomata acuminata 11 11 100 ND ND 
Squamous cell carcinoma 11 11 100 6 6 
Basal cell carcinoma 41 12 29.3 20 20 
IHC, immunohistochemical analysis. ND, not determined.  
 
Surprisingly, keratinocytes derived from normal epidermis adjacent to the BCC 
lesions also showed methylation of CpG-residues at the 14-3-3σ locus in 7 of 20 
(35%) cases analyzed (Table 5, column 3). The CpG-methylation detected in 
keratinocytes from adjacent, normal epidermis did not coincide with a reduced 
presence of 14-3-3σ protein as detected by immunohistochemistry (data not shown). 
However, epidermis isolated from distant sites adjacent to naevocytic naevi was 
negative for CpG methylation (Figure 15d-f, Table 5, column 4). In order to determine 
whether methylation of 14-3-3σ is a selective event in BCC or whether other genes 
encoding negative cell cycle regulators are also hypermethylated in BCC, the CpG 
methylation status of p16INK4A was analyzed by MSP as described (Herman et al., 
1996) (Figure 15g). In 17 cases of BCC with methylated 14-3-3σ, no CpG 
methylation of p16INK4A was detected (Table 5, column 5). Only in one of 9 cases of 
BCC with un-methylated 14-3-3σ alleles, the p16INK4A promoter was found to be 
methylated (Table 5, column 5).  
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Table 5 Analysis of 14-3-3σ protein expression and promoter methylation in BCC 
 Location / Typ of analysis 
Patient 
number 
BCC 
14-3-3 σ 
MSP (M/U) 
BCC 
14-3-3 σ 
IHC 
Adjacent epidermis 
14-3-3 σ 
MSP (M/U) 
Distant epidermis 
14-3-3 σ 
MSP (M/U) 
BCC 
p16 
MSP (M/U) 
BCC 
p63 
IHC 
1 +/+ + -/+
2 +/+ - -/+
3 +/+ - +/- -/+
4 +/+ -/+ -/+ -/+
5 +/+ -/+ -/+ -/+
6 +/+ -/+ +/+ -/+
7 +/+ -
8 +/+ -/+
9 +/+ + -/+ -/+ +
10 +/+ - +/+ -/+
11 +/+ -/+ -/+
12 +/+ + -/+ +
13 +/+ + -/+ +
14 +/+ + -/+ +
15 +/+ - +
16 +/+ + -/+ -/+ +
17 +/+ -/+
18 +/+ - +/+ -/+
19 +/+ - -/+
20 +/+ - -/+ -/+
21 +/+ -/+ -/+ -/+
22 +/+ - -/+ -/+ +
23 +/+ - +/+ -/+ +
24 +/+ - -/+ -/+ +
25 +/+ - +/+ -/+ +
26 +/+ - -/+ +
27 +/+ - -/+ +
28 +/+ - +/+ +
29 -/+ +
30 -/+ + -/+
31 -/+ + +/+ +
32 -/+ -/+ -/+ +
33 -/+ - -/+ +
34 -/+ + -/+ +
35 -/+ - -/+ -/+ +
36 -/+ -
37 -/+ +
38 -/+ +
39 -/+ -/+ -/+ +
40 -/+ - -/+ +
41 -/+ -/+ -/+ -/+
Keratinocytes representing BCC, adjacent normal epidermis or distant, normal epidermis derived from 41 patients (coded no. 1–
41) were analysed as described in Methods. Parallel sections were stained with a 14-3-3σ-specific antiserum (third column). ‘+’: 
staining similar to normal epidermal keratinocytes; ‘-/+’: staining significantly reduced; -‘: no staining (IHC=immunohistochemical 
analysis). Results obtained by MSP are represented by ‘+/+’: (positive for methylated (M) and unmethylated (U) alleles) or ‘-/+’: 
(negative for methylated and positive for unmethylated alleles). p63 protein expression was analysed in parallel sections 
obtained from BCC. Positive, nuclear p63 staining is indicated as ‘+’ in the right column. Fields with no entries correspond to 
cases that were not analysed. 
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5.3 Identification of genes epigenetically silenced in prostate cancer by 
pharmacological unmasking 
5.3.1 Epigenetic analysis of PCa cell lines 
Expression profiling of PCa cell lines treated with an inhibitor of DNA 
methyltransferases and/or histone deacetylases was exploited to identify genes 
potentially silenced by DNA methylation. Genes up-regulated by combined treatment 
were further validated in a panel of PCa and non-transformed prostate cell lines and 
primary PCa tissues (Figure 16). The imunnohistochemical analysis of primary PCa 
and functional characterization in prostate cells were performed for a subset of 
identified genes.   
5Aza-2’dC/TSA
treatment of PCa cell lines
PC3, LNCaP and Du145
microarray
analysis
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methylation pattern
is unknown
bisulfite sequencing,
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in primary PCa
12 genes positive
for methylation
50 
candidate
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14-3-3σ, SFRP1 and DKK3
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 Figure 16 Epigenetic analysis of PCa: the outline of the experimental procedure  
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Conditions for optimal re-expression after combined treatment with 5Aza-2’dC 
and TSA were determined by methylation-specific PCR of the promoter regions of 
GSTP1, RASSF1A and p16 in several PCa cell lines. Thereby, the metastatic PCa 
cell lines PC3, LNCaP and DU-145 were identified as most suitable for this type of 
analysis (data not shown). For re-expression of silenced genes the cell lines were 
exposed to 1 µM 5Aza-2’dC for 72 hours and to 300 nM TSA for the last 24 hours. 
Treatment with 300 nM TSA alone for 24 hours served as a control. Total RNA was 
isolated, converted to biotinylated cRNA and hybridized to oligonucleotide arrays 
representing ~22,000 individual transcripts. Each microarray analysis was performed 
in duplicates. Efficient demethylation of CpG-dinucleotides was confirmed by MSP 
analysis of several selected promoters (Figure 17a). The microarray analysis 
revealed that several hundred transcripts were induced in the cells exposed to 5Aza-
2’dC and TSA when compared to cells treated with TSA alone (data not shown). 
GSTP1, a gene previously shown to be silenced by CpG methylation in PCa (Singal 
et al., 2001), was induced 1.87 fold in LNCaP cells. Therefore, an induction of at 
least 1.8 fold was chosen as the minimal requirement for further analysis of 
candidate genes. The induction of GSTP1 was confirmed by RT-PCR (Figure 17b) 
and Northern blot analysis (data not shown). Exemplary confirmations of results 
obtained by microarray analysis were performed by RT-PCR for 10 different genes 
(Figure 17b). In addition, the expression of RASSF1A and p16, which are known to 
be induced after demethylation, was analyzed by RT-PCR (Figure 17b). The re-
expression of several imprinted genes (e.g. IGF2) and of genes silenced by CpG 
methylation in somatic tissues (e.g. MAGE) could be detected. Furthermore, 
interferon-responsive genes, which have been previously reported to be activated by 
5Aza-2’dC treatment (Karpf and Jones, 2002), were found to be induced (data not 
shown). Genes belonging to these three classes were excluded from further analysis. 
Re-expressed genes with known putative tumor suppressive functions (e.g. 
involvement in DNA-repair, negative cell cycle regulation, induction of apoptosis, 
detoxification, differentiation, transcriptional regulation) were examined for the 
presence of CpG-islands in their promoters. In total 50 genes met these criteria 
(listed in Table 6).  
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Table 6 Candidate genes for epigenetic silencing identified by microarray analysis 
Methylation detected by 
MSP 
Gene  
  
 Symbol 
  
Chr. 
location
  
Induced  
by 
5Aza2dC
Function 
  
BS-seq. 
in cell 
lines 
in cell 
lines 
in 
primary 
tumors 
14-3-3sigma (stratifin) SFN 1p35 L G2/M transition  yes 41/41 
secreted frizzled-related protein 1 SFRP1 8p12 P Wnt signaling  yes 34/41 
apolipoprotein D APOD 3q26 L, P HDL component  yes n.d. 
tissue factor pathway inhibitor 2 TFPI2 7q22 P, D ECM proteases inhibitor  No   
thrombospondin 1 THBS1 15q15 L, P, D angiogenesis inhibitor  No   
retinoblastoma protein-interacting zinc finger  RIZ1 1p36 P methyltransferase  No   
caspase 7 CASP7 10q25 P, D apoptosis no    
apoptotic protease activating factor APAF1 12q23 P, D apoptosis no    
apoptosis-inducing protein D APPD 19q11 D apoptosis no    
tumor necrosis factor receptor 10b TNFRSF10B 8p22 D apoptosis no    
cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 11p15 L, P cdk inhibitor yes yes 23/41 
cyclin-dependent kinase inhibitor 2D (p19) CDKN2D 19p13 P cdk inhibitor no    
cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 6p21.2 L, P, D cdk inhibitor no    
retinoblastoma-like 2 (p130) RBL2 16q12 D cell cycle no    
glutathione S-transferase M1 GSTM1 1p13 L detoxification yes yes 24§/41 
glutathione peroxidase 3  GPX3 5q23 L, P detoxification yes yes 38/41 
HUS1  HUS1 7p13 D DNA damage response no    
meiotic recombination 11  MRE11A 11q21 D DNA damage response no    
xeroderma pigmentosum, complementation group C XPC 3p25 L DNA repair no    
damage-specific DNA binding protein 2 DDB2 11p12 L DNA repair yes yes 34/41 
postmeiotic segregation increased 2  PMS2 7p22 D DNA repair no    
breast cancer 2, early onset BRCA2 13q12.3 D DNA repair, transcription no    
cylindromatosis (turban tumor syndrome) CYLD 16q11 P deubiquitination no    
bridging integrator 1 BIN1 2q14 D differentiation low n.d. n.d. 
growth arrest and DNA-damage-inducible, alpha GADD45A 1p31.2 P, D growth arrest  low n.d. n.d. 
connective tissue growth factor CTGF 6q23 P, D growth factor no   
nerve growth factor receptor  NGFR 17q21 P, D growth factor receptor no   
interferon regulatory factor 1 IRF1 5q31 P, D  interferon response no    
interferon regulatory factor 7 IRF7 11p15 L, P, D interferon response no    
hydroxyprostaglandin dehydrogenase 15-(NAD) HPGD 4q34 L, P prostaglandin signaling yes yes 30/41 
Prostaglandin E receptor 4 (subtype EP4) PTGER4 5p13 L, P, D prostaglandin signaling no    
cyclooxygenase 2 PTGS2 1q25 L, P prostaglandin signaling yes yes 32/41 
sequestosome 1 SQSTM1 5q35 L, P protein degradation no    
dual specificity phosphatase 1 DUSP1 5q34 P, D signaling no    
jun B proto-oncogene JUNB 14q32 P, D transcription factor no    
cut-like 2  CUTL2 12q24 P transcription factor yes n.d. n.d. 
zinc finger protein 36, C3H type, homolog  ZFP36 19q13 L,  D transcription factor no    
Cbp/p300-interacting transactivator CITED2 6q23 P, D transcriptional control no    
SWI/SNF related regulator of chromatin A1 SMARCA1 Xq25 D transcriptional control no    
inhibitor of DNA binding 3 ID3 1p36 L, P transcriptional control no    
serum-inducible kinase SNK 5q12 L, P signaling no    
serum/glucocorticoid regulated kinase SGK 6q23 L, P, D signaling no    
serine/threonine kinase 38 like STK38L 12p12.3 L signaling no    
growth arrest-specific 2 like 1 GAS2L1 22q12.2 L unknown no    
deleted in liver cancer 1 DLC1 8p22 D unknown no    
ras-induced senescence 1 RIS1 3p.21 D unknown yes yes n.d. 
B-cell translocation gene 1, anti-proliferative BTG1 12q22 D unknown no    
B-cell translocation gene 3, anti-proliferative BTG3 21q21 P, D unknown no    
dickkopf homolog 3  DKK3 11p15 P Wnt signaling yes yes 28/41 
dickkopf homolog 1  DKK1 10q11 D Wnt signaling no    
Experimental results for 50 selected, CpG-island containing genes induced upon treatment with 5Aza-2’dC and TSA in prostate 
carcinoma cell lines are summarized. Bold gene symbols, genes known to be silenced by CpG methylation in other types of 
human cancer (not PCa); underlined chromosomal locations, regions of frequent LOH in PCa; bold cell line abbreviations, 
genomic DNA used for bisulfite sequencing; L, LNCaP; P, PC3; D, Du-145 ; BS-seq., bisulfite sequencing analysis ; MSP, 
methylation sensitive PCR; §, methylation-specific PCR product dominant over PCR product corresponding to unmethylated 
allele. 
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 Figure 17 Analysis of CpG methylation in PCa cell lines 
(a)  Pharmacological reversion of epigenetic silencing in prostate carcinoma cell lines. LNCaP, PC3 
and Du-145 prostate cancer cell lines were treated with 5Aza-2’dC for 72 hours and with TSA for the 
last 24 hours, with TSA only for 24 hours or left untreated. After bisulfite treatment genomic DNA was 
subjected to MSP analysis with primers specific for the indicated genes. The PCR-products labelled 
with “M” were generated by methylation-specific primers, and those labeled with “U” by primers 
specific for unmethylated DNA. (b) mRNA expression of the indicated genes was analyzed by semi-
quantitative RT-PCR. As a loading control and expression standard amplification of the house keeping 
gene EF1α was used. (c) Comparison of GSTM1 and DKK3 CpG methylation pattern in cell lines vs. 
primary tumors. Tumor cells were laser microdissected from paraffin-embedded PCa sections and 
genomic DNA was isolated. Results of sequencing of at least 6 individual subclones for each area are 
shown: grey shaded chart areas represent frequencies of methylated CpG-dinucleotides within the 
respective fragments in PCa cell lines. Results of a parallel MSP-analysis of the genomic DNA 
employed for bisulfite sequencing are depicted.  
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5.3.2 The methylation pattern of candidate promoters 
The CpG methylation pattern of GSTM1 and DKK3 was determined in the cell 
lines LNCaP and PC3 respectively and compared to the pattern found in primary 
PCa cells isolated by laser microdissection of paraffin-embedded prostate sections 
from two patients (Figure 17c). The CpG methylation pattern found in PCa cell lines 
reflected the pattern found in primary tumors and is therefore appropriate for the 
design of MSP primers used in the analysis of primary tumors. In total the promoters 
of 44 induced genes were subjected to analysis by bisulfite sequencing in PCa cell 
lines which have been used for the microarray analysis (Table 6). Extensive CpG 
methylation was detected in the 5’ regions of DDB2, DKK3, GPX3, GSTM1 and 
HPGD, whereas COX2, CUTL2, p57 and RIS1 displayed focal CpG methylation 
(Figure 18). In non-transformed PrECs these genes did not display significant CpG 
methylation (Figure 18). 35 of the 44 genes analyzed by bisulfite sequencing did not 
show detectable CpG methylation, although these genes were significantly up-
regulated after the combined 5Aza-2’dC/TSA treatment (listed in Table 6). 
Presumably, these genes were induced secondary to the up-regulation of other 
genes silenced by CpG methylation or due to non-specific activation of transcriptional 
pathways by the combined 5Aza-2’dC/TSA treatment (Gius et al., 2004; Karpf et al., 
2001). It is possible that the CpG dinucleotides responsible for the silencing of these 
genes were not in the region analyzed by bisulfite sequencing in this study. However, 
as indicated in Figure 18, the analyzed regions covered several hundred base-pairs 
around the transcription start site, which display a high CpG-content and are 
expected to be the main targets for CpG methylation.  
 
 
 
 
Figure 18 Determination of the CpG methylation patterns of candidate genes in PCa 
Bisulfite sequencing was performed with genomic DNA derived from LNCaP (for COX2, DDB2, 
GSTM1 and HPGD), PC3 (CUTL2, DKK3, GPX3, and p57) and Du-145 (RIS1) cells or PrECs (each 
gene). The distribution of CpGs and their methylation status are shown. The depicted areas 
correspond to genomic DNA sequences of 2.5 kbp. Vertical bars represent CpG-dinucleotides. The 
position of the transcription start site is indicated by an arrow. Horizontal, black rectangles indicate 
areas which were amplified and subcloned after bisulfite treatment. Results of sequencing of at least 6 
individual subclones for each area are shown: grey shaded chart areas represent frequencies of 
methylated CpG-dinucleotides within the respective fragments in PCa cell lines. Black shaded areas 
show methylation patterns detected in PrECs. The y-axis corresponds to the relative amount of 
methylation of the CpG-dinucleotide at the indicated relative positions. The exact location of amplified 
fragments and CpG-dinucleotides is given in the supplemental Table 1 
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5.3.3 Validation of candidate genes for epigenetic silencing 
One of the genes induced by demethylation in LNCaP cells was 14-3-3σ. 
Using MSP conditions described in section 5.2.2 it was confirmed that this gene is 
completely methylated in LNCaP cells and underwent partial demethylation upon 
treatment with 5Aza-2’dC resulting in mRNA induction detected by RT-PCR and 
Northern blot analysis (Figure 17, a and b; data not shown). Furthermore, detection 
of methylated cytosines with higher resolution by bisulfite sequencing demonstrated 
a minimal degree of CpG methylation of the 14-3-3σ gene in PrECs, whereas dense 
methylation was evident in the DNA derived from the LNCaP cell line (Figure 19a). 
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 Figure 19 Methylation status and protein expression of 14-3-3σ in PCa cell lines  
(a) The pattern of CpG methylation of the 14-3-3σ locus as determined by bisulfite sequencing. 
Genomic DNA isolated from PrECs and PCa cell line LNCaP was treated with bisulfite and analysed 
as described in Methods. Depicted is a schematic representation of the CpG distribution around 
transcription start site of 14-3-3σ. The detailed description of the graphic features is given in the 
legend for Figure 18.  (b) 14-3-3σ -specific MSP analysis of PrECs, PCa and BPH-1 cell lines. 
Genomic DNA was isolated from exponentially proliferating cells, treated with sodium bisulfite and 
used as a template for MSP analysis with primers specific for the methylated (M) and unmethylated (U) 
14-3-3σ allele. BPH-1: benign prostate hyperplasia cells immortalized with SV40 large T antigen; 
PrECs: human primary prostate epithelial cells. (c) Detection of 14-3-3σ protein expression. Western 
blot analysis was performed with extracts from exponentially growing cells using an affinity-purified 
rabbit 14-3-3σ antiserum. Detection of α-tubulin was employed as a loading control.  
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MSP analysis extended to other cell lines revealed that 14-3-3σ is also 
methylated in the PCa cell lines PPC1 and LAPC4, but not in a cell line established 
from a benign prostate hyperplasia (BPH1) or in primary prostate epithelial cells 
(Figure 19b). By Western blot analysis, an inverse correlation between the degree of 
CpG methylation and protein expression was identified (Figure 19c): LNCaP cells, 
which display complete CpG methylation of 14-3-3σ, were devoid of 14-3-3σ 
expression; PPC1 cells, which have methylated and unmethylated 14-3-3σ alleles, 
showed a significant down-regulation of 14-3-3σ protein expression. The cell lines 
Du-145, PC3 and TSU-Pr1 did not reveal any CpG methylation in the 14-3-3σ gene 
and showed relatively high levels of 14-3-3σ protein expression. The highest level of 
14-3-3σ expression was detected in the PrECs, which lack CpG methylation of the 
14-3-3σ gene. Interestingly, the cell lines Du-145 and PC3 harbor p53 mutations, 
whereas LNCaP cells express wild-type p53. This correlation suggests that silencing 
of 14-3-3σ may potentially alleviate the requirement to inactivate p53 in PCa.  
In order to facilitate detection of aberrant methylation in a larger number of 
specimens the CpG methylation patterns obtained for other candidate genes were 
used to assign the positions of MSP-primers (indicated in Figure 18). The respective 
MSP-primers were tested for their specificity and sensitivity (data not shown). Only 
for CUTL2 reliable MSP-conditions could not be established. For analysis of genes 
previously known to be silenced by CpG methylation in other tumor types, the 
respective published MSP-primers were tested and used for MSP analysis. In total 
14 genes (including 14-3-3σ) which displayed significant CpG methylation as 
determined by bisulfite sequencing or MSP in one of the cell lines PC3, LNCaP or 
Du-145 were examined by MSP in a panel of five prostate cancer cell lines, BPH1, 
PrECs and in the bladder carcinoma cell line TSU-Pr1 (Figure 20, left panel).  
The analysis of candidates revealed, that the genes initially identified in 
selected PCa cell lines also displayed CpG methylation in other PCa cell lines and, 
occasionally in the cell line BPH1. 9 of the 14 analyzed genes did not display CpG 
methylation in primary prostate epithelial cells (PrECs). Therefore, CpG methylation 
of these 9 genes is a specific feature of cancerous prostate epithelial cells. APOD, 
DDB2, GSTM1 and RIS1 displayed partial CpG methylation in PrECs (Figure 20). 
However, the degree of CpG methylation of DDB2, APOD and GSTM1 appeared to 
be significantly elevated in most of the PCa-cell lines when compared to normal 
PrECs (Figure 20), suggesting a PCa-specific increase in CpG methylation of these  
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Figure 20 Comparative analysis of CpG methylation and gene expression 
Left panel: MSP analysis of a series of PCa cell lines and primary prostate epithelial cells (left panel). 
The MSP-analysis was done using two primers sets (M = methlyated; U = unmethlyated) specific for 
the indicated genes. BPH1 = benign prostate hyperplasia cells immortalized with SV40 large T antigen. 
Right panel: RT-PCR analysis of the indicated genes in non-transformed and tumor cells. D1-D4 
samples represent primary prostate epithelial cells (PrECs) from four different donors. ß-actin and γ-
tubulin (TUBG2) were used as additional standards to EF1α.  
 
genes and potential subsequent silencing. CpG methylation of SFRP1, GPX3, 
GSTM1 and APOD was also detected in the bladder carcinoma cell line TSU-Pr1. 
The expression level of 9 genes which showed selective or preferential CpG 
methylation in PCa was analyzed in order to determine whether CpG methylation 
correlates with reduced or absent expression of the respective genes. RT-PCR 
analysis of cDNAs obtained from normal prostate epithelial cells derived from 4 
healthy donors and 4 PCa cell lines revealed several distinct patterns of mRNA 
expression (Figure 20, right panel). The CpG methylation interrogated by the MSP-
primers used here largely correlated with reduced gene expression in the case of 
SFRP1, DKK3, GPX3, COX2, GSTM1, APOD and p57, whereas the detected CpG 
methylation of DDB2 and HPGD was not accompanied by decreased gene 
expression. In the case of HPGD the expression was even induced in 3 PCa samples, 
which clearly showed CpG methylation. These results indicate that CpG methylation 
of a promoter should not be interpreted as proof for its transcriptional repression. 
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5.3.4 Analysis of DNA methylation in primary PCa samples 
The CpG methylation status of the genes showing CpG methylation mediated 
silencing in PCa cell lines was determined in 41 primary PCa samples obtained after 
radical (37 cases) or transurethral (4 cases) prostate resection. In addition, the genes 
DDB2 and HPGD were included in this analysis, although no correlation between 
CpG methylation and down-regulation of mRNA expression for these genes has 
been detected. Nonetheless, the detection of PCa-specific CpG methylation in the 
promoter of these genes may be useful for diagnostic applications. Prostatic tissue 
samples contain several cell–types. Non–neoplastic epithelial cells, stromal cells, 
lymphocytic infiltrates and blood cells are present in close proximity to PCa cells. 
Therefore, laser microdissection was employed to isolate PCa cells. Similarly, non-
neoplastic prostate epithelial cells were isolated from samples obtained from 9 
patients with benign prostate hyperplasia, which did not represent PCa and were in 
the same age group as the 41 PCa patients. Genomic DNA was isolated from these 
samples and subjected to MSP analysis (Figures 21 and 22).  
In the PCa cells, 14-3-3σ  showed CpG methylation at medium to high degrees 
(Figure 21a): in three cases, only the methylated allele was detected and, with the 
exception of one case, the PCR product representing the methylated allele was more 
prominent than the PCR product specific for the unmethylated allele. From prostatic  
paraffin sections of 36 PCa patients, enough adjacent epithelial cells with normal 
appearing morphology could be isolated by laser microdissection to allow MSP 
analysis. The four transurethral and one radical prostatectomy specimens did not 
yield enough DNA for MSP analysis. The adjacent, normal prostate epithelial cells 
did not show methylation of 14-3-3σ in 31 cases (86.1% (31 of 36 cases); Figure 21b). 
Only five cases (pn1, pn19, pn23, pn25, pn30) showed CpG methylation of 14-3-3σ 
in normal prostate epithelium, which may be caused by isolation of PCa-precursor 
cells displaying a normal morphology. In three cases, PCR products with aberrant 
sizes not corresponding to methylated 14-3-3σ were detected (pn6, pn14, pn26). 
CpG methylation of 14-3-3σ was previously detected in histologically normal 
epithelial cells adjacent to cancer cells in other types of cancer and may represent 
precursor lesions (Umbricht et al., 2001). The necessity of laser microdissection for 
epigenetic analysis was underscored by a prominent CpG methylation of 14-3-
3σ detected in stromal cells of the prostate (Figure 21c). Furthermore, 
hyperproliferative prostate epithelial cells obtained from five patients with BPH, which 
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did not present PCa and were in the same age group as the 41 PCa patients, were 
subjected to MSP analysis. The 14-3-3σ promoter was not methylated in prostate 
epithelial cells in four cases of BPH (Figure 21d). In a fifth BPH specimen, a weak 
signal representing methylated 14-3-3σ allele was detected (Figure 21d). 
The other analyzed genes showed CpG methylation at medium to high 
frequencies in PCa cells. CpG methylation was detected for SFRP1 in 34 (83%), 
COX2 in 32 (78%), DKK3 in 28 (68%), GPX3 in 38 (93%), p57 in 23 (56%), HPGD in 
30 (73%) and DDB2 in 34 (83%) of the 41 PCa samples analyzed (Figures 22 and 
23). Predominant methylation of GSTM1 was detected in 24 (58%) of 41 cases. For 
SFRP1 and COX2 no CpG methylation was detected in BPH derived from 9 different 
patients, suggesting that the CpG methylation of these genes is specific for 
neoplastic prostate epithelial cells. CpG methylation was detected for GPX3 in two 
and for DKK3 in one of 9 analyzed BPH samples (Figure 23). For GSTM1 CpG 
methylation was detected in the 5 BPH samples analyzed (Figure 22). However, the 
CpG methylation of GSTM1 was elevated in the majority of PCa samples, whereas in 
the non-neoplastic BPH cells equal signals for the PCR-products representing 
methylated and unmethylated GSTM1 alleles were detected. Furthermore, the 
unmethylated GSTM1 allele was not detected in several samples of PCa. No obvious 
correlation between staging information and CpG methylation was detected by 
cluster analysis (data not shown).   
In order to evaluate the tumor-specificity of the CpG methylation detected in 
PCa, the CpG methylation status was examined in human diploid fibroblasts (HDF) 
derived from neonatal skin, in stroma isolated from 5 cancer-free prostate specimens 
and in peripheral blood mononuclear cells (PBMC) from 6 individuals (Figure 23). 
The p57 gene did not show CpG methylation in stromal cells. Partial CpG 
methylation of SFRP1 and COX2 was evident only in one of five analyzed stroma 
samples. One of six PBMC samples showed partial methylation of SFRP1 and p57 
genes. By contrast, DKK3 and GPX3 displayed CpG methylation in most of the 
stromal samples and blood cells. 
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Figure 21 14-3-3σ -specific MSP analysis of in vivo CpG methylation in prostate 
tissue after laser microdissection.  
Different neoplastic and non-neoplastic cell types were isolated from 5 µm sections of archival 
formalin-fixed, paraffin-embedded samples using laser-pressure catapulting. MSP analysis was 
performed on (a) PCa cells (pc01 - pc41) and (b) normal prostate epithelial cells (pn01 - pn41), (c) 
prostate stromal cells (str1 - str4) and (d) prostate epithelial cells representing BPH (bph1 - bph5) 
obtained from five BPH patients.  
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Figure 22 Detection of CpG methylation after laser microdissection 
Tumor cells or normal prostate epithelial cells were isolated from paraffin-embedded tumor sections 
derived from 41 different patients (pc01-pc41) using laser-pressure catapulting. Representative 
examples of MSP analysis of 5 tumor cell samples and 5 samples derived from normal epithelial cells 
(BPH) for the indicated genes are shown.  
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SFRP1 COX2 GPX3 DKK3 p57 GSTM1 HPGD DDB2 14-3-3σ Gleason pT pN 
pc01
pc02
pc03 7 2a 0
pc04 6 3a 0
pc05 6 2c 0
pc06 7 2c 0
pc07 6 2a 0
pc08 5 2c 0
pc09 6 2a 0
pc10 6 3b 0
pc11 5 2c 0
pc12 5 2c 0
pc13 6 2a 0
pc14 7 2a 0
pc15 7 2a 1
pc16 7 2a 0
pc17 7 3a 0
pc18 9 x x
pc19 7 3a 0
pc20 7 3b 0
pc21 7 2c 0
pc22 7 3a 0
pc23 6 2c 0
pc24 6 2c 0
pc25
pc26 7 2b 0
pc27 6 2c 0
pc28 8 x x
pc29 10 3b 0
pc30 6 2c 0
pc31 6 2c 0
pc32 6 2c 0
pc33 7 3b 0
pc34 6 2c 0
pc35 6 2c 0
pc36 9 x x
pc37 10 x
pc38 7 3b 0
pc39 7 3a 1
pc40 6 2c 0
pc41 7 2c x
bph1
bph2
bph3
bph4
bph5
bph6
bph7
bph8
bph9
str1
str2
str3
str4
str5
HDF
PBMC1
PBMC2
PBMC3
PBMC4
PBMC5
PBMC6
Figure 23 Summary of MSP results in primary PCa 
Gene names are indicated on the top. Each row represents a primary PCa tumor (pc01-41), non-
neoplastic prostate epithelial cells (bph1-9) or prostate stroma samples (str1-5) isolated by laser 
microdissection. Human diploid fibroblasts (HDF) derived from skin and PBMC (peripheral blood 
mononuclear cells) were cultured in vitro. Color coding: white = no significant CpG methylation 
detected; grey = PCR-product representing CpG methylation has a similar intensity as the PCR-
product specific for the unmethylated allele; black = allele with CpG methylation is dominant over the 
unmethylated allele or the unmethylated allele is absent. 
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5.3.5 Analysis of 14-3-3σ and SFRP1 protein expression in PCa  
In order to determine whether CpG methylation of the 14-3-3σ gene affects the 
expression of the corresponding gene product in vivo, the level of 14-3-3σ protein 
expression was determined by immunohistochemistry in tissue sections of the 
prostate. PCa samples from 41 different patients were analysed with an affinity-
purified antibody specific for the 14-3-3σ protein. In normal basal and luminal 
prostate epithelial cells and in prostate epithelial cells representing BPH and atrophic 
lesions, an intense cytoplasmic staining for 14-3-3σ protein was detected (Figure 
24a-f). The expression of 14-3-3σ protein was down-regulated markedly (>50%) in 
neoplastic cells and glands of 26 PCa samples. Representative examples are shown 
in Figure 24a and b. A total of 12 specimens showed a moderate reduction 
(examples in Figure 24, d and e) and four cases showed a minor decrease in 14-3-
3σ protein-specific staining (data not shown). The down-regulation of 14-3-3σ protein 
expression was also detected in PIN (prostatic intraepithelial neoplasia) lesions, 
which represent precursors of PCa (Figure 24, e and f). Loss of 14-3-3σ expression 
was restricted to luminal cells in the PIN lesions, whereas basal cells stained positive 
for 14-3-3σ. At present it is unclear whether the down-regulation of 14-3-3σ 
expression in PIN is due to CpG methylation, since the amount of DNA obtained after 
microdissection of PIN lesions was not sufficient to perform MSP analyses (data not 
shown).  
In order to determine whether the CpG methylation of SFRP1 affects the 
expression of the respective gene product in primary tumors, the level of SFRP1 
protein expression was determined by immunohistochemistry in PCa samples 
derived from 39 different patients (representative example shown in Figure 24, g and 
h). In non-neoplastic prostate glands most of the luminal cells were positive for 
SFRP1 with a characteristic granular cytoplasmic and apical membrane staining, 
whereas PCa cells were devoid of SFRP1 staining. A prominent down-regulation (> 
50% of reduction) or complete loss of SFRP1 protein was detected in 29 of 39 PCa 
samples (data not shown). 
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Figure 24 Analysis of 14-3-3σ and SFRP1 protein expression in primary PCa tissues 
(a-f) Depicted are immunohistochemical detections of 14-3-3σ protein (red color) in paraffin-embedded 
prostate tissue obtained from PCa and BPH patients. (A: atrophic prostate epithelial cells; BC: basal 
PIN cells; BPH: benign prostate hyperplasia; LC: luminal PIN cells; N: non-neoplastic prostate 
epithelial cells; PCa: prostate cancer cells; PIN: prostatic intraepithelial neoplasia). (a, b, d) Sections 
containing normal prostate glands and PCa; (c) section with BPH and an atrophic gland; (e, f) section 
with PIN, PCa and normal prostate glands. The respective magnifications are indicated. (g, h) 
Immunohistochemical detections of SFRP1 (red) in primary PCa. Stainings and their evaluation were 
performed by members of the laboratory of Dr. Joachim Diebold (Institute of Pathology, LMU, Munich)  
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5.3.6 Functional analysis of 14-3-3σ 
In order to assess the functional consequences of down-regulation of 14-3-3σ 
expression in prostate epithelial cells, a retroviral vector expressing a short RNA 
hairpin specifically directed against the open reading frame of 14-3-3σ was generated 
(see Methods for details). Two independent PC3 cell clones (PC3-sh-σ 1 and PC3-
sh-σ 4) stably expressing this construct showed significant down-regulation of 14-3-
3σ protein (Figure 25a). After treatment with etoposide which induces DNA damage 
via inhibition of topoisomerases, PC3-sh-σ 1 and PC3-sh-σ 4 cells were unable to 
stably arrest. By contrast, PC3 cells transfected with the empty vector showed a 
stable arrest in the G2/M phase (Figure 25c). The PC3 cell lines showed a significant 
amount of cells with a >2N DNA content. The peak at 8N observed after DNA 
damage therefore corresponds to tetraploid cells in the G2/M phase (Figure 25c). The 
inability of the PC3-sh-σ 1 and PC3-sh-σ 4 cells to stably arrest was accompanied by 
an increased rate of apoptosis as evidenced by an elevated portion of cells with a 
sub-G1 DNA content (Figure 25b). 
In the absence of DNA-damaging treatment PC3-sh-σ 1 and PC3-sh-σ 4 cells 
have acquired a significant number of cells with an aberrant number of nuclei (Figure 
25d). Two independent clones showed ~14% and ~22% of cells with two or multiple 
nuclei. PC3 cells infected with an empty vector, as well as a parental cell line, 
showed less than 2% of multinuclear cells. These results show that loss of 14-3-3σ is 
sufficient to generate aneuploid cells, which may give rise to alterations in cancer-
relevant genes and promote PCa progression. 
 
 
 
 
 
Figure 25 Effects of 14-3-3σ down-regulation on the DNA damage response.  
(a) Western blot analysis of 14-3-3σ protein expression in PC3 cell lines stably expressing short RNA 
hairpins directed against 14-3-3σ (PC3-sh-σ 1 and PC3-sh- σ 4) and PC3 cells containig a 
pRetroSUPER vector not encoding an shRNA (PC3 mock). (b) Cell cycle distribution of PC3 cell lines 
differing in 14-3-3  expression. PC3 cells treated with the DNA-damaging agent etoposide (20 µM) for 
the indicated periods of time were fixed, stained with propidium iodide and the DNA content was 
determined by FACS. (c) Representation of the sub-G1 (=apoptotic) fraction of PC3 cell lines after 
addition of etoposide for the indicated periods as detected by FACS. (d) Effect of 14-3-3σ loss on 
polyploidization. PC3 cells expressing short hairpin RNA targeting 14-3-3σ and mock infected cells 
were stained with DAPI for visualization of nuclei. Depicted are the phase contrast images overlayed 
with fluorescent pseudocoloured (green) images of nuclei. Representative examples are shown. For 
the vector alone control 12 of 698 (2%), for the PC3 cells with 14-3-3σ down-regulation 85 of 602 
(14%) and for a second clone with 14-3-3σ down-regulation 64 of 285 (22%) evaluated cells were 
multinucleated. 
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5.3.7 Functional analysis of DKK3 and SFRP1 
Epigenetic inactivation of the members of the SFRP gene family presumably 
contributes to activation of WNT signaling in colorectal cancer (Suzuki et al., 2004). 
DKK3 negatively regulates the ß-catenin pathway in osteosarcoma cells (Hoang et 
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al., 2004). Therefore, epigenetic silencing of SFRP1 and/or DKK3 expression in 
prostate carcinoma cells might be associated with constitutive activation of WNT/ß-
catenin signaling. To test this hypothesis the activity of the ß-catenin/TCF pathway in 
PCa cells was investigated. Unexpectedly, ß-catenin was localized at the cell 
membrane and absent from the nucleus in PC3 and Du145 cells (Figure 26a), which 
show significant silencing of DKK3 and SFRP1 (Figure 20). As nuclear ß-catenin is a 
hallmark of an activated WNT/ß-catenin pathway, this pathway is presumably not 
active in PCa. Furthermore, co-transfection with a WNT1 expression construct did not 
result in activation of a TCF-reporter in PC3 and Du145 cells (Figure 26b). In contrast, 
HCT116 colon cancer cell lines, which harbor an activated WNT/APC/TCF4 pathway 
(Morin et al., 1997), showed nuclear ß-catenin localization (data not shown) and 
strong activation of the wild-type but not the mutant TCF reporter by WNT1 co-
expression (Figure 26b).  
Recently it has been reported that WNT1 activates the MAP kinase pathway 
(Civenni et al., 2003). Therefore, the WNT antagonists DKK3 and SFRP1 were 
tested for their ability to inhibit the MAP kinase pathway in PCa. PC3 cells were 
infected with retroviruses containing an expression cassette for DKK3 or SFRP1 
fused to an IRES-EGFP. Expression of the respective protein product in GFP-positive 
pools was verified by immunoblotting (Figure 26c). In exponentially growing PC3 
cells ectopically expressing DKK3 the level of ERK1 and ERK2 phosphorylation, 
which is indicative of MAP kinase activity, was diminished (Figure 26d). Furthermore, 
PC3 cells ectopically expressing DKK3 or SFRP1 showed a significant decrease in 
colony formation (Figure 26e), which was due to a decrease in colony size. The rate 
of spontaneous apoptosis was not affected by ectopic expression of DKK3 or SFRP1 
as determined by flow cytometry (data not shown). Therefore, loss of DKK3 and 
SFRP1 expression by epigenetic silencing presumably promotes the proliferation of 
prostate epithelial cells.  
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Figure 26 Analysis of pathways downstream of DKK3 and SFRP1 in PCa cells  
(a) Detection of ß-catenin in PC3 and Du-145 PCa cells by immunofluorescence. (b) Analysis of 
TCF/LEF reporter activity in PCa (PC3, Du145) and colon (HCT116) cancer cell lines. Cells were 
transfected with a pGL3-OT (OT) TCF/LEF reporter construct, or with pGL3-OF (OF), a negative 
control containing a mutated TCF binding site. A WNT1 expression construct or its backbone construct 
were co-transfected. Luciferase activity was measured 36 hours after transfection. Transfection 
efficiency was normalized by co-transfection of a ß-galactosidase encoding plasmid. The assays were 
performed in triplicates (standard deviation indicated). The values obtained for transfection of the OF-
plasmid alone were set to one to visualize the differences among the three different cell lines. (c)  
Ectopic expression of DKK3 and SFRP1 in prostate carcinoma cells. PC3 cells were infected with 
bicistronic retroviruses encoding EGFP2, DKK3+EGFP2 or SFRP1+EGFP2; GFP-positive cells were 
isolated by flow cytometry and total protein lysates were subjected to Western blot analysis with anti-
VSV or anti-SFRP1 antibodies. Equal loading was confirmed by detection of α-tubulin. (d) Inhibition of 
ERK1/2 phosphorylation in PC3 cells ectopically expressing DKK3. Total protein lysates were 
analyzed using antibodies specific for ERK1 and ERK2 phosphorylated at the Thr202 and Tyr204 
residues or anti-ERK1/2 antibodies. (e) Inhibition of cellular proliferation by DKK3 and SFRP1. The 
equal number of PC3 cells transduced with the indicated constructs was plated at low density in 6-well 
plates, cultured for 10 days and colonies were stained with crystal violet. The analysis was performed 
in duplicates yielding identical results (data not shown).  
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6. Discussion  
 
6.1 Induction of cellular senescence by LY83583 
In the past decades the mainstay of cancer drug development was an 
empirical search for new cytotoxic compounds and their optimization (reviewed in 
Chabner and Roberts, 2005). For most of them the mechanism of action is the 
induction of DNA damage, which however also contributes to carcinogenesis. Apart 
from a limited efficacy, the genotoxic stress exerted by these drugs is also 
responsible for the major side effects of the current chemotherpeutic treatment of 
cancer in normal highly proliferating tissues. A new concept of targeted agent 
development emerged recently aiming to improve specificity and efficiency of cancer 
treatment (reviewed in Sawyers, 2004). The term ‘targeted therapy’ refers to a new 
generation of cancer drugs designed to interfere with a specific molecular target 
(typically a protein) that is believed to have a critical role in tumor growth or 
progression. The identification of appropriate targets is based on a detailed 
understanding of the molecular changes underlying cancer. This study focused on 
cellular senescence as a natural barrier for tumor development and potential target 
for pharmacological intereference. Expression profiling of primary human cells 
undergoing replicative senescence was used to gain insight into underlying molecular 
pathways and to identify a drug-target which can be of use for the inhibition of tumor 
growth.  
Several components of the cGMP signaling pathway were transcriptionally 
suppressed during replicative senescence in HDF. To test whether proliferation of 
early-passage fibroblasts is influenced by cGMP, the activity of the enzyme 
responsible for cGMP generation was pharmacologically modulated. For this purpose, 
LY83583 (LY) was selected, since it specifically inhibits soluble guanylate cyclase 
(Schmidt et al., 1985). LY was first described as an inhibitor of leukotriene release 
(Fleisch et al., 1984). Later, it was found to lower cGMP levels by inhibiting soluble 
guanylate cyclase (Mulsch et al., 1988). In the experiments presented here, LY was 
able to mimic cellular senescence in primary HDF and inhibited proliferation in 
several cancer cell lines. However, it is unclear whether inhibition of cGMP 
generation is the only pathway by which LY achieves its effects. It is possible that LY 
has additional, unknown properties that participate in the induction of cellular 
senescence and cell-cycle arrest. It has been proposed that the quinone structure of 
LY may lead to the generation of superoxide anions (Cherry et al., 1990). A recent 
 76
report that used the colorectal cancer cell line HCT116 and the isogenic p21- or p53-
deficient cells also analyzed in the present study showed that reactive oxygen 
species (ROS) generated by hyperoxic conditions induce expression of p21 in a p53-
dependent manner (Helt et al., 2001). Furthermore, proliferation of HCT116 cells is 
inhibited by hyperoxic conditions in a p21- and p53-independent manner (Helt et al., 
2001). In contrast to induction of p21 by ROS, induction of p21 by LY was not 
mediated by p53. Furthermore, inhibition of proliferation by LY was dependent on 
p21. These results suggest that LY does not act by generating ROS, which in turn 
mediate cell-cycle arrest or senescence.  
The results described here demonstrate that LY induces cellular senescence 
in HDF and cell-cycle arrest in several human and murine cell types. One 
requirement for these effects of LY is the transcriptional induction of the CDK inhibitor 
p21, since p21-deficient cells are resistant to LY-induced arrest. Furthermore, in the 
absence of functional pocket proteins (pRB, p107, p130) which are downstream 
effectors of the p21 cell-cycle the arrest is converted to induction of apoptosis in a 
p53-independent manner. In this case the apoptosis could be a cellular response to 
conflicting signals: negative signals due to LY-induced p21 and resulting CDK 
inhibition versus cell-cycle–driving signals due to the lack of active pocket proteins, 
which allow high levels of active E2F transcription factors. The induction of p21 is not 
mediated through the DNA-damage/p53 pathway, since p53-deficient cells also show 
up-regulation of p21 by LY and subsequent inhibition of cell proliferation. Many tumor 
cells lose pRB function, either through mutation of pRB (Horowitz et al., 1990) or 
through expression of viral proteins. For example, in cervical cancer, expression of 
E7 by HPV16/18 leads to inactivation of pRB (reviewed in zur Hausen, 2001). In 
HPV16/18-infected cells, treatment with LY would presumably induce apoptosis. 
Since LY induces p21, cell-cycle arrest, and apoptosis in a p53-independent manner, 
it may prove useful for the treatment of cancers harboring p53 mutations, which 
represent more than half of all human cancers (reviewed in Hollstein et al., 1999).  
In the future, it will be important to analyze whether LY or derived substances 
can be used to prevent tumor growth in vivo using animal models. The results 
provided in this study may serve as a basis for further characterization and 
optimization of LY derived drugs as therapeutic agents for the treatment of tumors. 
An obvious advantage of LY is its ability to interfere with cellular proliferation and to 
induce apoptosis in pRB-negative cells without inducing DNA damage. These effects 
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of LY are not mediated by the CDK inhibitor p16, which is an advantage given the 
frequent inactivation of p16INK4A in human cancer. On the other hand, the p21 gene, 
which presumably mediates the effects of LY, has not been reported to be inactivated 
in human cancer. Commonly used chemotherapeutic agents, like adriamycin, 
generate DNA damage and thereby induce apoptosis in cancer cells, which lack cell-
cycle checkpoints (reviewed in Hartwell et al., 1997). However, DNA-damaging 
substances have several adverse effects (Batchelor, 2001; Dropcho, 2004) and may 
induce further mutations in precancerous and healthy cells, which lead to secondary 
cancer (Felix, 1998; Travis, 2002).The strategy used in this study — that is, 
identification of pathways that are repressed during senescence and their inhibition in 
tumor cells by synthetic drugs — may also prove useful for the identification of other 
inhibitors of tumor cell proliferation. 
 
 
6.2 Epigenetic inactivation of 14-3-3σ in basal cell carcinoma 
Inactivation of 14-3-3σ in primary human keratinocytes promotes 
immortalization (Dellambra et al., 2000), suggesting that this protein may play a 
tumor suppressive role in human epidermis. Immunohistochemical analysis of benign 
(psoriasis, genital warts and actinic keratoses) and malignant (squamous cell 
carcinoma) hyperproliferative skin diseases revealed no reduction in 14-3-3σ protein 
expression. These results demonstrate that down-regulation of the14-3-3σ protein is 
not a general requirement for hyperproliferation of keratinocytes. They further 
suggest that 14-3-3σ may have additional functions that contribute to the expansion 
of keratinocytes. One function of 14-3-3σ could be the prevention of apoptosis by 
cytoplasmic sequestration of the pro-apoptotic factor BAX, which has been observed 
in colorectal cancer cells (Samuel et al., 2001). 
In contrast to other analyzed pathological conditions, basal cell carcinoma of 
the skin showed a prominent reduction or complete loss of 14-3-3σ in 71% of patients. 
These results suggest, that inactivation of 14-3-3σ may be the preferred mechanism 
to evade senescence in BCC. Further it was demonstrated, that down-regulation of 
the antiproliferative 14-3-3σ protein is a characteristic feature of BCC, which is 
associated with CpG-methylation of the 14-3-3σ promoter. Morphologically normal 
epidermis adjacent to BCC also displayed methylation of this gene in a considerable 
number of cases. However, epidermis isolated from distant sites adjacent to 
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naevocytic naevi from the identical patient was negative for CpG-methylation. Recent 
studies showed that 14-3-3σ is also methylated in epithelial cells derived from 
histologically normal tissue surrounding breast carcinomas (Umbricht et al., 2001) or 
hepatocellular carcinoma (Iwata et al., 2000). However, methylation of 14-3-3σ was 
never detected in breast epithelial tissue derived from cancer-free donors (Umbricht 
et al., 2001). Therefore, it has been suggested that CpG-methylation of 14-3-3σ 
represents a precursor lesion, which precedes any morphological change in tissue 
architecture. Several other genes, which are inactivated during tumor development, 
show CpG-methylation in tissue adjacent to tumor tissue (Ivanova et al., 2002; Li et 
al., 2002; Tokugawa et al., 2002). CpG-methylation of 14-3-3σ in the normal 
epidermis may indicate the presence BCC precursor cells. However, it will be 
necessary to further characterize the relation of these neighboring cells to BCCs to 
conclude that 14-3-3σ methylation is a marker for BCC precursor cells.  
In a fraction of BCC, 14-3-3σ expression was lost in the absence of CpG-
methylation. This could be due to mutational inactivation of 14-3-3σ. However, 
although the 14-3-3σ gene is localized on chromosome 1p35, a region frequently 
deleted in cancer, mutational inactivation of 14-3-3σ has not been observed yet. In 
colorectal cancer, analysis of 40 tumors with LOH at the 14-3-3σ locus revealed no 
mutations in the remaining 14-3-3σ allele (Hermeking et al., unpublished results). 
Similarly, rare cases of LOH at the 14-3-3σ locus have been observed in oral 
squamous cell carcinomas (Gasco et al., 2002). However, the remaining 14-3-3σ 
allele was not mutated. One potential mechanism of 14-3-3σ down-regulation could 
be a ∆Np63α-dependent transcriptional repression. However, it is unlikely to be 
involved in basalioma development, since no direct correlation between the absence 
of 14-3-3σ expression and the presence of ∆Np63α was detected by 
immunohistochemical analysis in BCC and other lesions. Recently, an alternative 
mechanism for loss of 14-3-3σ protein has been identified: the ubiquitin E3-ligase 
EFP targets the 14-3-3σ protein for proteasomal degradation (Urano et al., 2002). 
Therefore, up-regulation of the EFP could potentially account for the loss of 14-3-3σ 
protein in those cases of BCC where no CpG methylation is detected.  
Until now it has been impossible to cultivate BCC cells in vitro. Therefore, the 
functional consequences of 14-3-3σ down-regulation were not amenable to functional 
analysis in this study. In several tumor cell lines, demethylation of 14-3-3σ by 5-aza-
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2'-deoxycytidine leads to re-expression of the 14-3-3σ mRNA (e.g. Ferguson et al., 
2000, see also epigenetic analysis of PCa in this study), showing that CpG-
methylation is causally involved in silencing of 14-3-3σ. In breast cancer cells, 
silencing of 14-3-3σ is associated with a defect in the G2/M checkpoint (Ferguson et 
al., 2000). It is likely that the CpG methylation of 14-3-3σ detected here in BCC has 
similar functional consequences.  
With 750,000 newly diagnosed cases each year, BCC is the most common 
malignancy in the US (Miller, 1991). BCCs rarely metastasize, but may lead to 
significant morbidity because of local tissue destruction (Schubert and Muller, 1997). 
The finding, that 14-3-3σ expression is lost in the majority of BCC, provides an 
opportunity to devise selective therapeutic means, since loss of 14-3-3σ  sensitizes 
epithelial cells to DNA-damaging agents (Chan et al., 1999; Samuel et al., 2001) and 
may explain the effectiveness of radiotherapy for treatment of BCC. 
 
6.3 Functional epigenomic analysis of prostate carcinoma cell lines  
In the present study epigenetic changes characteristic for prostate cancer 
were identified by pharmacological unmasking. This approach takes advantage of the 
fact, that the inhibition of DNA methyltransferase activity by 5-aza-2'-deoxycytidine 
(5-Aza-2’dC) can reverse the silencing of genes hypermethylated in tumor cell lines. 
Genome-wide transcriptional changes exerted by genomic demethylation were 
determined using microarray analysis of gene expression. Several hundred mRNAs 
were up-regulated after combined treatment with 5Aza-2’dC and TSA. Many of these 
transcripts may have been induced secondary to the demethylation or by cellular 
stress evoked by the 5Aza-2’dC. Consistent with this assumption, subsequent 
analysis of CpG methylation by bisulfite sequencing and MSP revealed the presence 
of CpG methylation in the promoters of only about 25% of selected candidate genes. 
This underscores the necessity of the validation of the expression data at the 
genomic level when using this approach. For the majority of genes positive for CpG 
methylation the differential methylation inversely correlated with differential 
expression in tumor/normal cells.  
The sensitivity of the microarray hybridization was not sufficient to detect 
induction of p16 and RASSF1A genes which are known to be hypermethylated in 
PCa cell lines used here, although their up-regulation following genomic 
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demethylation was confirmed by RT-PCR. In addition, the induction of 
uncharacterized ESTs and genes coding for putative proteins was not investigated in 
this study. Thus, it is possible that the analysis presented here has missed some 
hypermethylated genes which are expressed at low levels. 
Nevertheless, the applied strategy resulted in the identification of more than 
ten novel targets for epigenetic silencing in PCa, validating the efficiency of the 
functional epigenomic analysis. The high frequency of CpG methylation observed in 
primary tumors suggests that the differences in CpG methylation which were initially 
detected in PCa cell lines did not occur during in vitro cultivation of PCa cell lines. 
Whether the CpG methylation of distinct genes is the cause or consequence of their 
down-regulation during prostate cancer initiation or progression remains to be shown. 
In addition, the functional relevance of the down-regulation of these genes has to be 
determined in the future. However, the high frequency of the epigenetic silencing 
events identified in this study suggests that these genes may be causally involved in 
prostate cancer development. Potential functional consequences of the epigenetic 
silencing events detected here will be discussed in the following paragraphs. 
 
6.4 Frequent epigenetic silencing of 14-3-3σ in prostate cancer  
The high frequency of CpG methylation (100%) at the 14-3-3σ locus observed 
in primary PCa shows that the CpG methylation initially detected in PCa cell lines did 
not result from prolonged in vitro passaging of PCa cell lines, but reflects a 
carcinoma-specific event. This notion is further supported by the finding that benign 
but hyperproliferative benign prostatic hyperplasia (BPH) shows no significant 14-3-
3σ silencing. The presence of CpG methylation in all PCa samples analysed may 
indicate an absolute requirement of 14-3-3σ down-regulation for PCa formation. The 
strategy used to identify 14-3-3σ as a gene specifically silenced in PCa, that is, 
reversion of CpG methylation-mediated gene repression in PCa cell lines, clearly 
argues for a role of CpG methylation in the down-regulation of 14-3-3σ at the level of 
mRNA and protein expression. Previously, ectopic expression of 14-3-3σ by 
adenoviral infection was shown to cause a G2/M arrest in PrECs (Hermeking et al., 
1997). In line with an involvement of 14-3-3σ in the regulation of G2/M progression, 
RNA interference-mediated down-regulation of 14-3-3σ in the PCa cell line PC3 
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facilitated an escape from a stable G2/M cell cycle arrest after DNA damage. This 
study shows that prostate carcinoma cells with constitutively decreased level of 14-3-
3σ expression spontaneously acquire nuclear aberrations, which presumably arise 
due to aberrant mitosis in the presence of DNA-damage and the subsequent failure 
to complete cytokinesis. Therefore, silencing of 14-3-3σ in pre-neoplastic prostate 
epithelial cells may result in tetra- or polyploidization, which, in turn, allows the loss of 
chromosomal fragments affecting other genes critical for PCa progression. 
During the early phases of PCa progression, a DNA damage signal is 
presumably generated, as telomere shortening has been detected in PIN lesions 
(Meeker et al., 2002). Interestingly, the shortening of telomeres in PIN was restricted 
to luminal cells, which also show down-regulation of 14-3-3σ expression as detected 
here. It is therefore possible that telomere shortening promotes the selection of cells 
that have lost 14-3-3σ expression due to CpG methylation. The silencing of 14-3-3σ 
expression observed here may contribute to PCa formation by promoting the escape 
from the telomere checkpoint. Subsequent cell proliferation with unprotected 
telomeres would contribute to genetic instability and accelerate the inactivation of 
additional tumor suppressive genes or activation of oncogenes (Artandi et al., 2000).  
From other types of cancer, it is known that CpG methylation of 14-3-3σ is 
often an early event during tumor progression. For example, in breast cancer it has 
been shown that CpG methylation of 14-3-3σ occurs during the transition from 
atypical hyperplastic lesions to carcinoma in situ (Umbricht et al., 2001). The loss of 
14-3-3σ protein expression in PIN lesions indicates that 14-3-3σ inactivation is an 
early event during PCa progression.  
The CpG methylation of 14-3-3σ may be used to detect PCa in the future. 
Since 14-3-3σ is also hypermethylated in a number of other carcinomas, a 
combination of this marker with PCa-specific CpG methylation markers may allow the 
development of a highly sensitive and specific diagnostic assay in the future. As 
changes in DNA methylation seem to occur early in carcinogenesis, this assay may 
be suited to detect cells or free DNA released from early PCa lesions in body fluids. 
A potential obstacle to the use of 14-3-3σ CpG methylation as a diagnostic marker 
may be the presence of CpG-methylated 14-3-3σ alleles in stromal cells and 
lymphocytes (Bhatia et al., 2003; Umbricht et al., 2001). However, preliminary studies 
with other CpG marker genes show that these cell types may not interfere with CpG 
methylation-based diagnostic approaches (reviewed in Laird, 2003). 
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6.5 CpG methylation and down-regulation of SFRP1 and DKK3 in prostate 
cancer 
SFRP1 negatively regulates the WNT pathway, which is frequently activated in 
cancer by mutations in the APC and ß-catenin genes (Giles et al., 2003; Kinzler and 
Vogelstein, 1996). Recently, SFRP1 was shown to undergo both genetic and 
epigenetic alterations in colon and bladder cancer (Caldwell et al., 2004; Stoehr et al., 
2004). Frequent hypermethylation of SFRP1 was recently detected in colorectal 
cancer (Suzuki et al., 2002), where the loss of SFRP1 correlated with an increased β-
catenin/TCF4 activity and ectopic expression of SFRP1 led to reduced β-
catenin/TCF4 activity. However, activation of the β-catenin/TCF4 pathway was not 
detected in PCa in this study. Therefore, loss of SFRP1 may contribute to activation 
of other oncogenic signaling pathways in PCa. The SFRP1 gene is located on 
chromosome 8p12, a region which frequently undergoes LOH in PCa. An induction of 
SFRP1 mRNA was detected in human primary fibroblasts undergoing replicative 
senescence (data not shown), suggesting a possible role of SFRP1 in the terminal 
proliferation arrest of senescent cells.  
Dickkopf 3 (DKK3) negatively regulates the WNT-pathway. The zonal 
distribution of DKK3 expression in the adrenal gland suggests that DKK3 is involved 
in zonal differentiation or growth (Suwa et al., 2003). DKK3 was identified as a gene 
which is down-regulated upon immortalization of primary human cells (Tsuji et al., 
2000). Reduced expression of DKK3 was also found in non-small cell lung cancer 
and renal clear cell carcinoma (Kurose et al., 2004; Tsuji et al., 2001). 
Overexpression of DKK3 inhibited growth, invasion and motility of Saos-2 
osteosarcoma cells and non-small cell lung cancer cells by modulating WNT-
signaling (Hoang et al., 2004; Tsuji et al., 2001). Interestingly, the DKK3 transcript 
was shown to be up-regulated in senescent primary prostate epithelial cells 
(Untergasser et al., 2002). The epigenetic silencing of DKK3 by CpG methylation 
observed here might therefore contribute to de-differentiation and immortalization of 
PCa cells.  
The analysis of PCa cell lines suggests that the WNT/ß-catenin pathway is not 
activated in Du-145 and PC3 cells with silenced SFRP1 and DKK3 genes. This is in 
agreement with a recent comprehensive study of 101 cases of primary PCa: none of 
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the tumors showed nuclear ß-catenin staining (Bismar et al., 2004). However, genetic 
alterations of ß-catenin or APC were detected in a subset of advanced PCa and were 
associated with an resistance to apoptosis and hormone-refractory phenotype 
(Chesire et al., 2000; de la Taille et al., 2003). Loss of SFRP1 and DKK3 expression 
may activate alternative signaling pathways (Figure 27). Recently, it was reported 
that transactivation of the EGF receptor by WNT ligands, which results in MAP-
kinase activation, is inhibited by SFRP1 and DKK1 (Civenni et al., 2003). The data of 
this work indicate that DKK3 may also have an inhibitory effect on MAP kinase 
signaling.  
WNT1
ß-catenin/TCF
EGFR
MAPK
DKK3
SFRP1
colon
carcinoma,
osteosarcoma
breast and prostate
carcinoma
Figure 27 Modulation of WNT effects by DKK3 and SFRP1 
In colon cancer epigenetic silencing of SFRP1 contributes to the deregulation of WNT signaling and 
results in the activation of ß-catenin. Similarly, DKK3 antagonizes the ß-catenin/TCF pathway in 
osteosarcoma cells. In breast cancer, and presumably in PCa cells the WNT ligands can transactivate 
the EGF receptor and the downstream MAPK pathway. DKK3 and SFRP1 inhibit this transactivation 
and negatively affect proliferation. Thus, the frequent silencing of DKK3 and SFRP1 in PCa may lead 
to an aberrant activation of MAPK cascade.     
 
6.6 Hypermethylation of p57, GPX3, GSTM1 and COX2 genes in prostate cancer 
p57/KIP2 belongs to a family of conserved CDK inhibitors, which negatively 
regulate the cell cycle. Ectopic expression of p57 suppresses cell transformation, 
whereas cells lacking p57 show increased cell proliferation and decreased 
differentiation (Watanabe et al., 1998; Yan et al., 1997; Zhang et al., 1997). p57 
expression is decreased in PCa cell lines and primary prostate epithelial cells 
immortalized by HPV16 E7 (Schwarze et al., 2001).  Expression of p57 induces a 
senescence-like phenotype in PCa cells (Schwarze et al., 2001), suggesting that 
down-regulation of p57 may be required for immortalization of prostate cells. The p57 
gene is located on chromosome 11p15.5, a region implicated in both sporadic 
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cancers and the Beckwith-Wiedemann cancer syndrome. Mutations of p57 have 
rarely been detected in human tumors (Tokino et al., 1996). Epigenetic silencing of 
p57 was also detected in gastric, hepatocellular, pancreatic carcinomas and acute 
myeloid leukaemia (Kikuchi et al., 2002b; Shin et al., 2000). The down-regulation of 
p57 in bladder cancer involves several mechanisms including LOH and 
hypermethylation (Hoffmann et al., 2004). The p57 gene is located in the vicinity of 
imprinted genes (IGF2 and H19) and itself displays features of an imprinted gene as 
the maternal allele is preferentially expressed. However, the imprinting is not 
absolute, as the paternal allele is also expressed at low levels in most tissues 
(Matsuoka et al., 1996). Furthermore, the relevance of DNA methylation for the 
imprinting of p57 is not clear, as CpG-methylation has not been detected in the 5’ 
region of p57 in normal tissue (Chung et al., 1996; Kikuchi et al., 2002b). Here CpG 
methylation of p57 was not detected in normal PrECs and stromal cells and is 
therefore a specific feature of PCa progression. 
Glutathione peroxidase 3 (GPX3) catalyzes the reduction of peroxides by 
glutathione and protects cells against oxidative damage. The PCa-specific silencing 
of GPX3 may lead to an impaired defence against endogenous and exogenous 
genotoxic compounds, which could potentially result in an increased rate of 
mutations in critical genes. Down-regulation of GPX3 expression upon transition from 
normal to neoplastic prostate tissue was recently detected by microarray analysis of 
microdissected primary PCa (Ashida et al., 2004). Presumably, this down-regulation 
of GPX3 in PCa is caused by the epigenetic silencing of GPX3 detected here.  
Glutathione S-transferase µ 1 (GSTM1) belongs to a family of enzymes that 
catalyze the conjugation of reduced glutathione to a variety of electrophiles. Thereby, 
GSTM1 detoxifies mutagenic substances mainly epoxides formed from common 
carcinogens such as polycyclic aromatic hydrocarbons, and thus may play a 
protective role for the genome, as was proposed for GSTP1 and also for GPX (this 
study). The common null-allele of GSTM1 shows a weak association with lung cancer 
(reviewed in (Mohr et al., 2003). However, no significant association of GSTM1 
polymorphisms or deletion with PCa has been reported. The tumor-specific 
hypermethylation of GSTM1 identified here may explain the decreased expression of 
GSTM1 in PCa detected in three previous studies (Ashida et al., 2004; Chetcuti et al., 
2001; Vanaja et al., 2003). Down-regulation of GSTM1 was also shown in colorectal 
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carcinoma in individuals with GSTM1 positive genotype, but was not associated with 
CpG methylation (Barker et al., 2002). 
Cyclooxygenase 2 (COX2) catalyzes the synthesis of prostaglandin H2, a 
precursor of other prostanoids, and has been implicated in inflammation and 
carcinogenesis (reviewed in Dannenberg and Subbaramaiah, 2003). COX2 
inhibitors, like nonsteroidal anti-inflammatory drugs (NSAIDs), decrease the risk of 
developing PCa (Nelson and Harris, 2000) and inhibit the growth of PCa in a 
xenograft model (Liu et al., 2000). However, the effects of NSAIDs on cancer cells 
may not be caused by inhibition of COX2. The published data on COX2 expression in 
tumors is not uniform: over-expression of COX2 was found in several tumor types 
including PCa (Gupta et al., 2000). However, no consistent over-expression of COX2 
in PCa or high-grade prostatic intraepithelial neoplasia compared to adjacent normal 
prostate tissue was found in another study (Zha et al., 2001). Furthermore, the high 
COX2 levels were detected in areas of proliferative inflammatory atrophy, which 
presumably represents an early precursor of PCa (Nelson et al., 2003). Expression of 
COX2 protein was not detected in the PCa cell lines LNCaP, PC3 and Du-145 (Zha 
et al., 2001), which is consistent with silencing of the COX2 gene by CpG-
methylation reported here. Epigenetic silencing of COX2 was also detected in a 
subset of gastric (Kikuchi et al., 2002a) and colorectal cancers (Toyota et al., 2000). 
While this study was in progress, CpG methylation of the COX2 gene in PCa 
was reported independently (Kang et al., 2004; Yegnasubramanian et al., 2004). In 
the study by Kang et al. the CpG methylation of COX2 was detected in 22 % of 
primary PCa, while Yegnasubramanian et al. detected hypermethylation of COX2 in 
88% of PCa when they applied a quantitative method to analyze a larger collection of 
samples. Interestingly, the hypermethylation of COX2 was associated with a higher 
risk of recurrence of PCa (Yegnasubramanian et al., 2004), proving the prognostic 
potential of methylation markers in PCa. 
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Figure 28 Aberrant DNA methylation in the development of prostate carcinoma  
Since GSTP1, GSTM1 and GPX3 are involved in the protection of the cells from potentially 
carcinogenic substances, their epigenetic inactivation may contribute to an acquisition of oncogenic 
mutations in the prostate at the very beginning of the transformation process. Epigenetic silencing of 
14-3-3σ can compromise genomic stability of aberrantly proliferating cells and occurs already at the 
PIN stage. Epigenetic inactivation of the CDK inhibitor p57 may contribute to abrogation of the 
senescence state and promote the immortalization of prostate cells. A frequent hypermethylation of 
the DKK3 and SFRP1 genes indicates the role of the WNT signaling in prostate carcinogenesis.    
 
The lack of a correlation between CpG methylation and grade or stage of the 
PCa is in agreement with other recent studies (Florl et al., 2004; Kang et al., 2004; 
Yegnasubramanian et al., 2004). Taken together the data suggest that silencing of 
genes by CpG methylation occurs at an early stage of prostate cancer development 
(Figure 28). This may have implications for the use of these CpG methylation events 
for the early diagnostics of PCa lesions. Tumor-specific CpG methylation can be 
detected with high sensitivity and specificity in biopsies and body fluids (Laird, 2003). 
The CpG methylation of SFRP1, COX2 and p57 has the highest specificity for PCa 
and is therefore of higher relevance for potential diagnostic applications. However, 
this conclusion will require validation on larger cohort of patients in the future.  
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7. Summary 
 
Pharmacological induction of the senescence program in tumor cells could be 
of benefit for the treatment of cancer. cDNA microarray analysis of the transcriptional 
changes associated with replicative senescence in primary human diploid fibroblasts 
revealed coordinated down-regulation of the cGMP signaling pathway. A specific 
inhibitor of soluble guanylate cyclase, LY83583 (LY) induced premature senescence 
in HDF and inhibited proliferation of tumor cell lines in a dose-dependent manner. 
Expression profiling of LY-treated fibroblasts revealed a common trend for 114 genes 
differentially expressed upon activation of the replicative and premature senescence 
program. LY treatment resulted in rapid transcriptional induction of the CDK inhibitor 
p21 in the absence of p53 accumulation. Moreover, the inhibitory effect of LY on 
proliferation required the function of p21 but not p53, as shown by analysis of 
isogenic knock-out cell lines. Functional inactivation of pocket proteins converted LY-
induced growth arrest to apoptosis.  
Since the inactivation of 14-3-3σ is sufficient to immortalize primary human 
keratinocytes ex vivo, the expression of 14-3-3σ protein was studied in human skin 
diseases, which display hyperproliferation of the epidermis. Basal cell carcinomas of 
the skin showed prominent reduction or loss of 14-3-3σ expression in 71% of 
analyzed cases. MSP analysis of microdissected BCC tissue showed the presence of 
CpG methylation of 14-3-3σ in 68%, being a likely mechanism of 14-3-3σ silencing. 
CpG methylation of 14-3-3σ may be an early event in BCC formation since it was 
detected in morphologically normal epidermis adjacent to BCC, but not in distant 
epidermis.  
Genes abnormally methylated in cancer may represent tumor-suppressive 
factors or serve as tumor markers, facilitating diagnosis and prognosis. In order to 
identify such genes, global transcriptional changes induced by genomic 
demethylation in three prostate carcinoma cell lines were analyzed using microarrays. 
Several hundred mRNAs were up-regulated upon combined treatment with 5Aza-
2’dC and TSA. Based on their biological function and presence of CpG-island in the 
promoter region, 50 genes were selected for bisulfite sequencing and MSP analysis. 
Seven genes turned out to be epigenetically silenced in PCa cell lines. Interestingly, 
four of those (14-3-3σ, DKK3, SFRP1 and p57) were previously implicated in cellular 
senescence. The frequencies of CpG methylation in 41 microdissected primary PCa 
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were: 14-3-3σ:100%, GPX3: 93%, SFRP1: 83%, COX2: 78%, DKK3: 68%, GSTM1: 
58% and KIP2/p57: 56%. Tumor-specific down-regulation of protein expression in 
primary PCa was confirmed immunohistochemically for 14-3-3σ and SFRP1.  
Depletion of 14-3-3σ by RNA interference in PC3 cells resulted in an impaired G2/M 
arrest after DNA damage and spontaneous acquisition of aberrant nuclei. Ectopic 
expression of DKK3 or SFRP1 inhibited growth of PCa cells. In case of DKK3 this 
effect presumably was mediated through the attenuation of the MAPK signaling. 
Since COX2, SFRP1 and p57 genes showed only a minor methylation in benign 
prostate hyperplasia, prostate stroma and blood cells, detection of CpG methylation 
in those genomic regions may proof useful for the diagnosis of PCa. 
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9. Abbreviations 
5Aza-2’dC – 5-aza-2’-deoxycytidine 
BCC – basal cell carcinoma of the skin 
BPH – benign prostate hyperplasia 
BrdU - 5-bromo-2-deoxyuridine 
cDNA – complementary DNA 
cGMP - 3'5'-cyclic-
guanosinmonophosphate 
CDK – cyclin-dpendent kinase 
CMV – cytomegalovirus (promoter) 
CpG - cytidine-phosphate-guanidin  
DMSO – dimethylsulfoxyde  
EF1α - elongation factor 1 alpha 
EGFP - enhanced green fluorescent 
protein  
EGFR – epidermal growth factor  
receptor  
EYFP - enhanced yellow fluorescent 
protein 
EST - expression sequence tag 
FACS - fluorescence-activated cell 
scanning 
GTP - guanosintriphosphate 
HDACs – histone deacetylases 
HDF - human diploid fibroblasts 
HPV – human papilloma virus  
hTERT – human telomerase reverse 
transcriptase 
IHC – immunohistochemistry 
IRES – internal ribosomal entry site 
MAPK – mitogen-activated protein 
kinases 
MSP – methylation-specific PCR 
PBMC – peripheral blood mononuclear 
cells 
PBS - phosphate buffered saline 
PCa – prostate carcinoma 
PCR – polymerase chain reaction 
PIN – prostate intraepithelial neoplasia 
PrEGM – prostate epithelium growth 
medium 
PrECs – primary prostate epithelial cells 
qPCR - quantitative real-time PCR 
RT-PCR – reverse transcription PCR 
SA-ß-gal – senescence associated beta-
galactosidase 
SAGE – serial analysis of gene 
expression 
SAHF- senescence-associated 
heterochromatic foci  
SCC- squamous cell carcinoma  
SDS- sodium dodecyl sulfate  
SDS-PAGE-sodium dodecyl sulfate 
polyacrylamide gel electrophoresis  
SNP - sodium nitroprusside 
SV40 – simian virus 40 
TSA – trichostatin A 
VSV – vesicular stomatitis virus (tag) 
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10. Supplemental tables  
Supplemental Table 1 Oligonucleotides used for bisulfite sequening 
Gene  forward sequence 5'->3' reverse sequence 5'->3' Product size 
Annealing 
T 
APAF1 genomic sequence ATAGTTCCCCTAGGAGAGGTGGG    CAGCCTGACCCCACAGTCCC
 bisulfite converted ATAGTTTTTTTAGGAGAGGTGGG   
    
   
    
   
   
   
    
    
      
     
    
   
    
   
    
   
   
   
   
   
  
  
    
  
    
   
    
   
  
CAACCTAACCCCACAATCCC 682 60°
APPD genomic sequence GCTGAGGGTGACTGTGCTGTGAGGC CCCAGGCTCCCTGCAGGTTCACCCC
 bisulfite converted GTTGAGGGTGATTGTGTTGTGAGGT CCCAAACTCCCTACAAATTCACCCC 665 60°
BIN1 genomic sequence GGTGAGCCCCTGGAAAAGGAGGGGG CCCTTTACTGCCCATCTCTGCCATC
 bisulfite converted GGTGAGTTTTTGGAAAAGGAGGGGG CCCTTTACTACCCATCTCTACCATC 633
 
60°
BRCA2 genomic sequence TGGCCTGGGACTCTTAAGGGTCAG TTGGCAGAGACAAAAGGGCAAGAAGCC
 bisulfite converted TGGTTTGGGATTTTTAAGGGTTAG TTAACAAAAACAAAAAAACAAAAAACC 517 62°
BTG1 genomic sequence CCCCTAGGGTGGAACAGAAATGGCT ATCTCAATAGCTGCATTTCCAGCTC
upstream bisulfite converted TTTTTAGGGTGGAATAGAAATGGTT ATCTCAATAACTACATTTCCAACTC 771 65°
genomic sequence GAGCTGGAAATGCAGCTATTGAGAT CCACGGCTCCTTTGTCCCCAAATCC 
downstream bisulfite converted GAGTTGGAAATGTAGTTATTGAGAT CCACRACTCCTTTATCCCCAAATCC 771 65°
BTG3 genomic sequence GGTCTAGAGAGCTGGGTCTAGAACT CCCCTGCCCCTCCCCTGTCCCC
 bisulfite converted GGTTTAGAGAGTTGGGTTTAGAATT CCCCTACCCCTCCCCTATCCCC 785 60°
CASP7 genomic sequence GGTACTTCCTTCAAAGCTGAGGGAG CAACCAGGCTCCCCTAGACCAC
 bisulfite converted GGTATTTTTTTTAAAGTTGAGGGAG CAACCAAACTCCCCTAAACCAC 883 65°
CITED2 genomic sequence GAGGCACAAGGGCACTCTGGAGGG CAGCACATAGAGGGGACCTTCCTGGC
 bisulfite converted GAGGTATAAGGGTATTTTGGAGGG CAACACATAAAAAAAACCTTCCTAAC 630 60°
CTGF genomic sequence GTGTAGGACTCCATTCAGCTCATTGG CCGAAGTGACAGAATAGGCCCTTGTGC 
 bisulfite converted GTGTAGGATTTTATTTAGTTTATTGG CCRAAATAACAAAATAAACCCTTATAC 648 60°
CUTL2 genomic sequence GGAGCTGGGGGTAGACAGGTGCAAG CAATGGCTGCACTCAATATCCGGGCTGGAC 
 bisulfite converted GGAGTTGGGGGTAGATAGGTGTAAG CAATAACTACACTCAATATCCRAACTAAAC 548 62°
CYLD genomic sequence GAGGAAGGTCTGTCACAGGGAGG CGCCATTAACAAGGCCAGAACCCC 
 bisulfite converted GAGGAAGGTTTGTTATAGGGAGG CRCCATTAACAAAACCAAAACCCC 806 65°
DDB2 genomic sequence GAAAGGCACTAGCTCTCTACAAAGC GGGCTTGTTCAAACCAGCTTGGAGC
 bisulfite converted GAAAGGTATTAGTTTTTTATAAAGT AAACTTATTCAAACCAACTTAAAAC 665 57°
DKC1 genomic sequence GAAAGCAAAGAAAGAGGTACTGTTTA CTGGCAGCAGCACAGACACTGCCAC
 bisulfite converted GAAAGTAAAGAAAGAGGTATTGTTTA CTAACAACAACACAAACACTACCAC 764 65°
DKK1 genomic sequence AGGCAAGGGCACCCAAGTTCCCAGAGT CTGACTGCAGAGCCTGGGTGCCCC
 bisulfite converted AGGTAAGGGTATTTAAGTTTTTAGAGT
 
CTAACTACAAAACCTAAATACCCC 
 
631 64°
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Supplemental Table 1 (continued)     
    DKK3 genomic sequence GCAGGCAGTGAAGGAGATGGCTG TACCTGGGGTGGACCAAGCACAGGTCA
upstream (a) bisulfite converted GTAGGTAGTGAAGGAGATGGTTG   
       
   
    
  
    
   
    
   
    
   
    
   
    
   
    
   
    
   
    
   
    
   
   
   
   
   
    
   
    
   
    
   
  
TACCTAAAATAAACCAAACACAAATCA 505 64°
genomic sequence TGAGGAGCAGAGCTCAGCTTGTGC CATCTCATTGAGGGTGGCCTCCTCC
downstream (b) bisulfite converted TGAGGAGTAGAGTTTAGTTTGTGT CATCTCATTAAAAATAACCTCCTCC 436 64°
DLC1 genomic sequence GCTCAAGGCACACTAGGGTCCAGGC GCTTCTTTCTGCACATCAAGCAC
 bisulfite converted GTTTAAGGTATATTAGGGTTTAGGT ACTTCTTTCTACACATCAAACAC 759 60°
DUSP1 genomic sequence GGAGGGAGAGAGGGAGGAG CCCACTTCCATGACCATGGC
 bisulfite converted GGAGGGAGAGAGGGAGGAG CCCACTTCCATAACCATAAC 666 61°
GADD45A genomic sequence AAGACATGAAAAGATAATAAGAAAAAAGTG CTTCCTCCCCTGCAAGCCTTCCACAGCCC
 bisulfite converted AAGATATGAAAAGATAATAAGAAAAAAGTG CTTCCTCCCCTACAAACCTTCCACAACCC 813 65°
GAS2L1 genomic sequence TCCCCAGGAGACCAAAGAGGTTGGA TGGGGCTCTGGGCCCAGAGAGGGTG
 bisulfite converted TTTTTAGGAGATTAAAGAGGTTGGA TAAAACTCTAAACCCAAAAAAAATA 549 57°
GPX3 genomic sequence GCCCCCTTGCCCTGGCTGTAATGGAGAC CTGGGAACTTGCACAGCCCACCCAGAC
 bisulfite converted GTTTTTTTGTTTTGGTTGTAATGGAGAT CTAAAAACTTACACAACCCACCCAAAC 860 65°
GSTM1 genomic sequence GTTAGGATCTGGCTGGTGTCTCAAG CCAGGGAAGCCCCCAGTTTACACTGC
 bisulfite converted GTTAGGATTTGGTTGGTGTTTTAAG CCAAAAAAACCCCCAATTTACACTAC 596 60°
HPGD genomic sequence AGCCAGAGGCTGAGGGGAGGCTTTG TGAGGTGTGCTCACAGCCTCAGCTTC
 bisulfite converted AGTTAGAGGTTGAGGGGAGGTTTTG TAAAATATACTCACAACCTCAACTTC 514 66°
HUS1 genomic sequence TTAAAATAACACTTGAAATAGGTGTCA CCTTCATCCCCACAAGTGCCCTCC
 bisulfite converted TTAAAATAATATTTGAAATAGGTGTTA CCTTCATCCCCACAAATACCCTCC 655 60°
ICAM1 genomic sequence GAGGGGCATCCCTCAGTGGAGGGAGC CTACCTAAGCATGCATGACCTGACCC
 bisulfite converted GAGGGGTATTTTTTAGTGGAGGGAGT CTACCTAAACATACATAACCTAACCC 725 64°
ID3 genomic sequence AGTCTGGAGGTCAGACGAACAGCAAATTGG CATCCTTGCCTGGGTGTTCAGCCCTGTC
 bisulfite converted AGTTTGGAGGTTAGAYGAATAGTAAATTGG CATCCTTACCTAAATATTCAACCCTATC 
 
916 65°
IRF1 genomic sequence GAAAAGATGGCCCCAGGAGCCAG CCCCCCACTTCCTGGTGCCC
 bisulfite converted GAAAAGATGGTTTTAGGAGTTAG CCCCCCACTTCCTAATACCC 666
 
61°
IRF7 genomic sequence TGTCCCCTGGGCTGTAGTGGAGTGGC CAGGTGTGGACTGAGGGCTTGTAGCCACC
 bisulfite converted TGTTTTTTGGGTTGTAGTGGAGTGGT CAAATATAAACTAAAAACTTATAACCACC 665 58°
JUNB genomic sequence TGAAACCCCTCACTCATGTGCCTGGG AGGGCTGTTCCATTTTAGTGCACATC
 bisulfite converted TGAAATTTTTTATTTATGTGTTTGGG AAAACTATTCCATTTTAATACACATC 590 60°
MRE11 genomic sequence GGAGGGAGAGGGGATCCAGCTC CCAGGACCCCTCCCCTGCCCACTC
 bisulfite converted GGAGGGAGAGGGGATTTAGTTT CCAAAACCCCTCCCCTACCCACTC 714 64°
NGFR genomic sequence GATGGGTAAGAGAGTGAACCCTGTGG CTCACCCCCAGAAGCAGCAACAGCAGC
 bisulfite converted GATGGGTAAGAGAGTGAATTTTGTGG
 
CTCACCCCCAAAAACAACAACAACAAC 
 
529 64°
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Supplemental Table 1 (continued)     
    p19 (CDKN2D) genomic sequence TTGCCACACTCTGACCAATCAGGAG ACCAGAGAGGAGCTCTGGGGTCTC
 bisulfite converted TTGTTATATTTTGATTAATTAGGAG   
    
   
   
   
    
   
    
  
    
   
    
   
   
   
   
   
    
  
    
    
    
  
    
   
    
  
    
  
    
   
    
   
ACCAAAAAAAAACTCTAAAATCTC 792 58°
p21 (CDKN1A) genomic sequence GGGACCGGCTGGCCTGCTGGAACT CTTCCTGGGCCCCTCCAGGGACAC
 bisulfite converted GGGATTGGTTGGTTTGTTGGAATT CTTCCTAAACCCCTCCAAAAACAC 697 65°
p57 (CDKN1C) genomic sequence GGCTGGGCGTTCCACAGGCCAAGTG CCGGGACACTAGGCAGCTGCTCC 
 bisulfite converted GGTTGGGYGTTTTATAGGTTAAGTG CCRAAACACTAAACAACTACTCC 718 63°
p130 (RBL2) genomic sequence TTCACCCCTGGTGAAACTAGGGGAG CAGAGGAAGTCCCCACCCCTCTC
 bisulfite converted TTTATTTTTGGTGAAATTAGGGGAG CAAAAAAAATCCCCACCCCTCTC 621 65°
PMS2 genomic sequence CATAAAAGTCTGAGTGAGTCCCTGGC GCCATGTTCCCCCCATTTCCAGGG
 bisulfite converted TATAAAAGTTTGAGTGAGTTTTTGGT ACCATATTCCCCCCATTTCCAAAA 749 64°
PTGER4 genomic sequence AGAAAAGTTTGTACAGAGGGTGGAA TCAGTGAAGAATGGTGCTGGATTTC
 bisulfite converted AGAAAAGTTTGTATAGAGGGTGGAA TCAATAAAAAATAATACTAAATTTC 355 53°
PTGS2 b genomic sequence TCAGTCTTATAAAAAGGAAGGTTCT TGCTTGTGGGAAAGCTGGAATATCC
 bisulfite converted TTAGTTTTATAAAAAGGAAGGTTTT TACTTATAAAAAAACTAAAATATCC 413
 
52°
PTGS2 a genomic sequence ATCAGACAGGAGAGTGGGGAC AGCTCCACAGCCAGACGCCCTCAGA
 bisulfite converted ATTAGATAGGAGAGTGGGGAT AACTCCACAACCAAACRCCCTCAAA 331 55°
RIS1 genomic sequence GGGCCCTGGAGCCTCCCTCTGAGAA AGCAGTAGGTCGCACTGGAAGCCCC 
 bisulfite converted GGGTTTTGGAGTTTTTTTTTGAGAA AACAATAAATCRCACTAAAAACCCC 850 64°
SGK genomic sequence TGGGGGCTTGGCTCACTTCCCCAGA GGACTTTCAAAAAATTTCCACTTTG
 bisulfite converted TGGGGGTTTGGTTTATTTTTTTAGA AAACTTTCAAAAAATTTCCACTTTA 855 60°
SMARCA1 genomic sequence AAAGAGCAGATTTAAGGGAAAGAGG CCACCACACACACACCCCCTTCCT
 bisulfite converted AAAGAGTAGATTTAAGGGAAAGAGG CCACCACACACACACCCCCTTCCT 659 64°
SNK genomic sequence TTTAGTACTAGTAACTGTCAAAGGC GGCGGCTGGCTGGTAGGTGATAGT
 bisulfite converted TTTAGTATTAGTAATTGTTAAAGGT AACAACTAACTAATAAATAATAAT 1084 52°
SQSTM1 genomic sequence GGAAGGGGAGAGTAGTGAAGGGG CCTTGGTCACCACTCCAGTCACCA
 bisulfite converted GGAAGGGGAGAGTAGTGAAGGGG CCTTAATCACCACTCCAGTCACCA 593 65°
STK38L genomic sequence CCACTCTCAAGAGAGGCCTGAACAG ACCTAAAATCTCCTCCTGCTCCTGC
 bisulfite converted TTATTTTTAAGAGAGGTTTGAATAG ACCTAAAATCTCCTCCTACTCCTAC 493 60°
TNFRSF10B genomic sequence CCCTGGGAAGGGGAGAAGATCAAGA CCCTCTCTCCCTGCCCTCTCCAGGC
 bisulfite converted TTTTGGGAAGGGGAGAAGATTAAGA CCCTCTCTCCCTACCCTCTCCAAAC 744 65°
XPC genomic sequence GGAAAAAGCAGCCTAGTACAAGAAGCT CTCTTGGCCTTGGATTTCTGGCTGC
 bisulfite converted GGAAAAAGTAGTTTAGTATAAGAAGTT CTCTTAACCTTAAATTTCTAACTAC 445 62°
ZFP36 genomic sequence AGTCTCCAGCTTTGAAAACTGGGCAGG CCTCCAAATCACCAAGCTGGTCTGAGC
 bisulfite converted AGTTTTTAGTTTTGAAAATTGGGTAGG CCTCCAAATCACCAAACTAATCTAAAC 536 65°
Sequence information obtained from the human genome draft sequence (NCBI) is shown for PCR primers specific for DNA sequences converted by bisulfite treatment. Sequence alterations 
caused bisulfite conversion are shown in colour; R = A or G, Y = C or T bases. 
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Supplemental Table 2 Oligonucleotides used for methylation-specific PCR 
Gene  forward sequence 5'->3' reverse sequence 5'->3' Productsize Ta  Reference
SFRP1 MSP (M)     TGTAGTTTTCGGAGTTAGTGTCGCGC      CCTACGATCGAAAACGACGCGAACG 127 65°
  MSP (U) GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT CTCAACCTACAATCAAAAACAACACAAACA 136 65°
Suzuki et al., 2002 Nat Genet 
31(2): 141-9. 
APOD MSP (M) CACACGCGCGAAAACAATAT      TATGTATGTTACGTTCGTCG  59°
  MSP (U)     CACACAAAAACAATATCTCATTTCT  
 
TTTTTTATGTATGTTATGTTTGTTG 55°
Yamashita et al. 2002Cancer 
Cell 2(6): 485-95. 
RASSF1A MSP (M)  GGGTTTTGCGAGAGCGCG      GCTAACAAACGCGAACCG 169 64°
  MSP (U) GGGGTTTTGTGAGAGTGTGTTTAG  
 
TAAACACTAACAAACACAAACCAAAC 175 62°
Liu et al., 2002 Oncogene 21(44): 
6835-40. 
14-3-3σ MSP (M)  TGGTAGTTTTTATGAAAGGCGTC  CCTCTAACCGCCCACCACG 105 65°
  MSP (U) ATGGTAGTTTTTATGAAAGGTGTT 
  
CCCTCTAACCACCCACCACA 107 65°
Ferguson et al., 2000 Proc Natl 
Acad Sci U S A 97(11): 6049-54. 
p16 (CDKN2A) MSP (M) TTATTAGAGGGTGGGGCGGATCGC  GACCCCGAACCGCGACCGTAA 150 65°
  MSP (U) TTATTAGAGGGTGGGGTGGATTGT  
 
CAACCCCAAACCACAACCATAA 151 60°
Herman al., 1996 Proc Natl Acad 
Sci U S A 93(18): 9821-6. 
GSTP1 MSP (M)           *GGTTTTTTCGGTTAGTTGCGCGGCG      CCAACGAAAACCTCGCGACCTCCG 206 60°
  MSP (U) AAAGAGGGAAAGGTTTTTTTGGTTAGTTGTGTGGTG
 
AAACTCCAACAAAAACCTCACAACCTCCA 222 
 
64°
Singal et al., 2001 Cancer Res 
61(12): 4820-6. 
RIZ1 MSP (M) GTGGTGGTTATTGGGCGACGGC GCTATTTCGCCGACCCCGACG 127 68°
  MSP (U)  TGGTGGTTATTGGGTGATGGT  ACTATTTCACCAACCCCAAGA 126 60°
Du et al., 2001 Cancer Res 
61(22): 8094-9. 
THBS1 MSP (M) TGCGAGCGTTTTTTTAAATGC   TAAACTCGCAAACCAACTCG 74 62°
  MSP (U) GTTTGGTTGTTGTTTATTGGTTG CCTAAACTCACAAACCAACTCA 115 62°
Kang et al., 2001 Cancer Res 
61(7): 2847-51. 
TFPI2 MSP (M)     CACAATTTACAACGCGAAAACGACGAA    TTTTGTTTTAGGCGGTTCGGGTGTTC 135 65°
  MSP (U) CTTACACAATTTACAACACAAAAACAACAAA 
     
GTTTTTTGTTTTAGGTGGTTTGGGTGTTT 142 65°
Konduri et al., 2003 Oncogene 
22(29): 4509-16. 
PTGS2 genomic TAAAAAACCCTGCCCCCACCGGGCTTACG AGTCGTATGACAATTGGTCGCTAACCGAG
 MSP (M)    AAAATTTTGTTTTTATCGGGTTTAC    CGTATAACAATTAATCGCTAACCG 165 60°  
  MSP (U)  AAAAAATTTTGTTTTTATTGGGTTTAT 
     
AATCATATAACAATTAATCACTAACCA 170 60°  
GPX3 genomic TGGGGAGCTGAGGGCAAGTCGCGCCCGCC GCTGCCTGATCCCTGGCCACCGTCCGT
 MSP (M)    GGAGTTGAGGGTAAGTCGCGTTC    ACCTAATCCCTAACCACCGTCCG 156 65°  
  MSP (U)  GGGGAGTTGAGGGTAAGTTGTGTTT 
     
 CTACCTAATCCCTAACCACCATCCA 160 65°  
DDB2 genomic GACCCGCAGAGGCCTGGCAGCGCCGCGTT TACAAGCGTACGCCACCACGCCCGGC
 MSP (M)      GTAGAGGTTTGGTAGCGTCGC        GTACGCCACCACGCCCG 175   
   
     
t/d
  MSP (U)   TTTGTAGAGGTTTGGTAGTGTTGT     AACATACACCACCACACCCA 181 t/d
GSTM1 genomic TAGGGAAGCTGGCGAGGCCGAGCCCCGCC CTCGGCCCGCCACAACCCGAAAGGCGCC
 MSP (M)     GAAGTTGGCGAGGTCGAGTTTC     ACCCGCCACAACCCGAAAAACG 157   
   
   
t/d
  MSP (U)   GGGAAGTTGGTGAGGTTGAGTTTT   CAACCCACCACAACCCAAAAAACA 161 t/d
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Supplemental Table 2 (continued)     
     DKK3 genomic GTGAGGTGGCCGGCGCCCCGGCTGGC CCCACCAGGCTCCCTCTCCGCCCCCGCC
upstream (a) MSP (M)    AGGTGGTCGGCGTTTCGGTTGG     CCAAACTCCCTCTCCGCCCCCG 109   
   
     
t/d
 MSP (U)  TGAGGTGGTTGGTGTTTTGGTTGG   CACCAAACTCCTCCTCCACCCCCA 113 t/d
downstream (b) genomic GCCAGGGGCGGGCGGCGGGGCGG CGCTGCATCTCCGCTCTGCGCCCGC
 MSP (M)     GGGGCGGGCGGCGGGGC     ACATCTCCGCTCTACGCCCG 120   
   
   
t/d
  MSP (U)  TTAGGGGTGGGTGGTGGGGT   CTACATCTCCACTCTACACCCA 125 t/d
RIS1 genomic CCCGTCCGCGGCGGGGCCGCGGACGCGCC GGGGCCGCCGAGGCCAGCAGCC      
 MSP (M)      TCGCGGCGGGGTCGCGGACGCG    
    
     
AAAACCRCCRAAACCAACAACC 113 t/d
  MSP (U)    GTTTGTGGTGGGGTTGTGGATGTG AAAACCRCCRAAACCAACAACC 115 t/d
p57 (CDKN1C) genomic GCTGCCCGCGTTTGCGCAGCCCCGGG GGGAAGGTCCCACGGGCGACAAGACGCT
 MSP (M)  TTGTTYGYGTTTGCGTAGTTTC     AAATCCCACRAACGACAAAACG 88 62°  
  MSP (U) GTTGTTYGYGTTTGTGTAGTTTT   AAAAATCCCACRAACAACAAAACA 91 
 
62°  
HPGD genomic GGGGGCATAAAAGCCGCGGCCGCGCGG    GCAGAGAAATTTCCGCGGCTGGGCGCCGGG
 MSP (M)     GTATAAAAGTCGCGGTCGCGC       AAATTTCCGCGACTAAACGCCG 189 65°  
  MSP (U)   GGGTATAAAAGTTGTGGTTGTGT   AAAAAAATTTCCACAACTAAACACCA 195 65°  
Sequence alterations caused bisulfite conversion are shown in colour; R = A or G; Ta = annealing temperature; t/d = touch down PCR with 2 cycles at 68°C, 2 cycles at 66°C, N cycles at 65°C; * = 
error in the reference: one extra T in the M forward primer sequence 
 
Supplemental Table 3 Oligonucleotides used for RT-PCR 
Gene forward sequence 5'->3' reverse sequence 5'->3' Productsize Ta 
Cycle 
number Reference 
14-3-3σ CCAGGCTACTTCTCCCCTC     CTGTCCAGTTCTCAGCCACA 99 60° 31 NM_006142 
APOD AAAAGCTCCAGGTCCCTTC     
    
    
     
     
     
    
    
     
   
     
     
AGGGTTTCTTGCCAAGATCC 498 58° 25 Kao et al., 2002 Endocrinology 143(6): 2119-38. 
DKK3 AAGGCAGAAGGAGCCACGAGTGC GGCCATTTTGGTGCAGTGACCCCA
 
 179 60° 34 NM_013253 
GSTM1 ACTTTCCCAATCTGCCCTAC TTCTGGATTGTAGCAGATCA 191 55° 32 Hurteau et al., 2002 Anal Biochem 307(2): 304-15. 
GSTP1 TCACTCAAAGCCTCCTGCCTAT CAGTGCCTTCACATAGTCATCC 242 60° 33 Singal et al. 2001 Cancer Res 61(12): 4820-6. 
GPX3 CTTCCTACCCTCAAGTATGTCCG GAGGTGGGAGGACAGGAGTTCTT 134 65° 33 NM_002084 
EF1A CACACGGCTCACATTGCAT CACGAACAGCAAAGCGACC 192 60° 18 Menssen and Hermeking,  2002 PNAS 99(9): 6274-9. 
HPGD CTCTGCAAATTAATTTGGTTTCTGT ACAGAAACCAAATTAATTTGCAGAG
 
 149 64° 26 NM_000860 
RASSF1A TGGTGCGACCTCTGTGGCGACTT TCCTGCAAGGAGGGTGGCTTC 239 60° 37 Schagdarsurengin et al., 2003 Oncogene 22(12): 1866-71. 
p57 CTGACCAGCTGCACTCGGGGATTTC
 
GCCGCCGGTTGCTGCTACATGA 341 60° 31 Kikuchi et al.,  2002 Oncogene 21(17): 2741-9. 
p16 AGCCTTCGGCTGACTGGCTGG CTGCCCATCATCATGACCTGGA 139 60° 40 Suzuki et al., 2002 Nat Genet 31(2): 141-9. 
PTGS2 TAAACAGACATTTATTTCCAGAC GAAAGAAATAGTCAATATGCTTG 193 60° 33 Suzuki et al., 2002 Nat Genet 31(2): 141-9. 
SFRP1 TTGTAGTTATCTTAGAAGATAGCATGG ACGGGAATTACTATTAACATAAGCG 532 65° 31 Suzuki et al., 2002 Nat Genet 31(2): 141-9. 
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